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ABSTRACT
IMINOPHOSPHORANES AS USEFUL PRECURSORS TO POTENTIAL TRANSITION
METAL-BASED CANCER CHEMOTHERAPEUTICS
by
Malgorzata Frik

Adviser: Professor Maria Contel

During the past two decades, gold(III), platinum(II), palladium(II) and ruthenium(II)
compounds have been investigated as potential anticancer drugs. Our group at Brooklyn College
reported on the cytotoxic properties of neutral and cationic gold(III), palladium(II) and
platinum(II) complexes with iminophosphoranes (IM) or iminophosphine ligands of the general
formula R3P=NR’. These IM ligands have been very useful to synthesize and stabilize
compounds of d8 transition metals which displayed higher toxicity against leukemia, prostate
cancer and ovarian cancer cells when compared to normal T-lymphocytes. They also seemed to
have a mode of action different from that of cisplatin.
This thesis describes the synthesis of coordination and organometallic, gold(III),
platinum(II), palladium(II) and ruthenium(II) complexes with different iminophosphorane
ligands, the study of their stability in solution by different techniques and of their interaction
with biological targets (mostly DNA and HSA). I have also included data on the biological
activity of these compounds (in vitro and for selected complexes in vivo) to understand their
potential as cancer chemotherapeutics. Most of these compounds have displayed excellent
anticancer properties by a mode of action different from that currently accepted for cisplatin and,
in some cases, have displayed a lower toxicity, better activity or better permeability in vivo.
These results are described in three different chapters as summarized below.
iv

In Chapter III, I describe the synthesis and characterization of a series of coordination
gold(III), palladium(II), and platinum(II) complexes with a luminescent IM ligand derived from
8-aminoquinoline

[Ph3P=N-C9H6N].

The

coordination

palladium(II)

and

platinum(II)

compounds can evolve further, under appropriate conditions, to give stable cyclometalated endo
species [M{κ3-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] (M = Pd, Pt) by C-H activation of the phenyl
group of the PPh3 fragment. The compounds have been evaluated for their antiproliferative
properties in a human ovarian cancer cell line (A2780S), in human lung cancer cells (A-549) and
in a non-tumorigenic human embryonic kidney cell line (HEK-293T). Most compounds have
been more toxic to the ovarian cancer cell line than to the non-tumorigenic cell line. The new
complexes interact with human serum albumin (HSA) faster than cisplatin. Studies of the
interactions of the compounds with DNA indicate that, in some cases, they exert anticancer
effects in vitro based on different mechanisms of action with respect to cisplatin. The stability of
cyclometallated compounds is markedly higher than that of coordination complexes.
In Chapter IV, I describe the synthesis, characterization and stability studies of new
organometallic gold(III) and platinum(II) complexes containing cyclometalated IM ligands. Most
compounds are more cytotoxic to a number of human cancer cell lines than cisplatin. A cationic
Pt(II) derivative ([Pt{κ2-C,N-C6H4(PPh2=N(C6H5)(COD)](PF6)) displays IC50 values in the submicromolar range. Its cell death mechanism is mainly through caspase-dependent apoptosis but it
triggers caspase-independent cell death when apoptosis is blocked. Permeability studies by two
different assays: in vitro caco-2 monolayers and a rat perfusion model have revealed a high
permeability profile for this compound (comparable to that of metoprolol or caffeine) and an
estimated oral fraction absorbed of 100% which potentially makes it a good candidate for oral
administration.
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Lastly in Chapter V, I describe the synthesis, characterization and stability studies of a
series of organometallic ruthenium(II) complexes containing iminophosphorane ligands. These
cationic compounds with chloride as counterion are highly soluble in water (70-100 mg/mL).
Most compounds (especially the highly water-soluble compound- ([(η6-p-cymene)Ru{(Ph3P=NCO-2-N-C5H4)-κ-N,O}Cl]Cl) are more cytotoxic to a number of human cancer cell lines than
cisplatin. Initial mechanistic studies indicate that the cell death type for these compounds is
mainly through canonical or caspase-dependent apoptosis, non-dependent on p53, and that the
compounds do not interact with DNA or inhibit protease cathepsin B. In vivo experiments of
([(η6-p-cymene)Ru{(Ph3P=N-CO-2-N-C5H4)-κ-N,O}Cl]Cl) on MDA-MB-231 xenografts in
NOD.CB17-Prkdc SCID/J mice showed an impressive tumor reduction (shrinkage) of 56% after
28 days of treatment (14 doses of 5 mg/kg every other day) with low systemic toxicity.
Pharmacokinetic studies showed a quick absorption in plasma with preferential accumulation in
the breast tumor tissues when compared to kidney and liver, which may explain its high efficacy
in vivo.
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CHAPTER I

BACKGROUND AND SIGNIFICANCE
_________________________________________________
1.1. Cancer, statistics and current treatment
Cancer is a major public health problem in the United States and all over the world. It is
currently the second leading cause of death in the United Sates, and is expected to surpass heart
disease as the leading cause of death in the nearby future.1 In the U.S. alone, more than one
million people get cancer each year. Although there are many kinds of cancers, cancer starts
when normal cells in a part of the body grow out of control. Cells become cancerous due to DNA
damage. In normal cells when DNA gets damaged, the cells either repair the damage or die. In
cancer cells however, the damaged DNA is not repaired and the cells do not die like the normal
cells. The cells go instead on making new ones that the body does not need. In most cases, the
cancer cells form a tumor and over time the tumors can replace normal tissues, crowd it or push
it aside. Very often cancer cells travel to other parts of the body where they can grow and form
new tumors in a process called metastasis.2
Nevertheless, not every cancer is the same. Some cancers, like leukemia, rarely form
tumors and instead involve the blood and the blood-forming organs and circulate through other
tissues where they grow. Moreover, different cancers can behave very differently. They can grow
at different rates and respond to different treatments. Prostate cancer for instance is the second
leading cause of cancer death among men in the US, whereas breast cancer is more common in
women. At the same time, one particular cancer can differ in how it affects a particular organ.
Lung cancer for example, has three main types, such as non-small cell lung cancer, which is the
most common type of lung cancer accounting for about 85% of all lung cancers; small cell lung
cancer, also called oat cell cancer accounting for about 10-15% of all lung cancers and this type
of cancer tends to spread more quickly; and lung carcinoid tumor which occurs for fewer than
5% of lung cancers. When it comes to breast cancer, different types can be identified depending
how the cancerous cells look under the microscope. Most breast cancers are carcinomas that start
in the cells that line organs and tissues like the breast.2
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Table 1. Ten leading cancer types for the estimated new cancer cases and deaths by sex in the
United States for 2015.1,2

Estimated New Cases
Males
Prostate
Lung & bronchus
Colon & rectum
Urinary bladder
Malenoma of the skin
Non-Hodgkin lymphoma
Kidney & renal pelvis
Oral cavity & pharynx
Leukemia
Liver & intrahepatic bile duct
All sites

Females
220,800
115,610
69,090
56,320
42,670
39,850
38,270
32,670
30,900
25,510
848,200

26%
14%
8%
7%
5%
5%
5%
4%
4%
3%
100%

Breast
Lung & bronchus
Colon & rectum
Uterine corpus
Thyroid
Non-Hodgkin lymphoma
Malenoma of the skin
Pancreas
Leukemia
Kidney & renal pelvis
All sites

231,840
105,590
63,610
54,870
47,230
32,000
31,200
24,120
23,370
23,290
810,170

29%
13%
8%
7%
6%
4%
4%
3%
3%
3%
100%

Lung & bronchus 71,660
Breast 40,290
Colon & rectum 23,600
Pancreatic 19,850
Ovary 14,180
Leukemia 10,240
Uterine corpus 10,170
Non-Hodgkin lymphoma 8,310
Liver & intrahepatic bile duct 7,520
Brain & other nervous system 6,380
All sites 277,280

26%
15%
9%
7%
5%
4%
4%
3%
3%
2%
100%

Estimated Deaths
Males
Lung & bronchus 86,380
Prostate 27,540
Colon & rectum 26,100
Pancreatic 20,710
Liver & intrahepatic bile duct 17,030
Leukemia 14,210
Esophagus 12,600
Urinary bladder 11,510
Non-Hodgkin lymphoma 11,480
Kidney & renal pelvis 9,070
All sites 312,150

Females
28%
9%
8%
7%
5%
5%
4%
4%
4%
3%
100%
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1.1.1. Prostate cancer
According to the latest American Cancer Society (ACS) estimates in the United States for
2015, about 220,800 new cases of prostate cancer will be diagnosed and about 27,540 men will
die of prostate cancer (Table 1).2 The mortality due to prostate cancer has however steadily
declined between 1999 and 2003, which among several factors, may be attributable to earlier
detection and improved treatment of cancer. In the past few years, several targeted therapeutic
agents have been developed and clinically used for the treatment of prostate cancer.3 Current
therapeutic treatments for metastatic castration-resistant prostate cancer includes abiraterone (a,
Zytiga® in Figure 1). Abiraterone was approved by the FDA in April 2011 and by the EMA
since September 2011 for the treatment of metastatic castration-resistant prostate cancer and has
been found to be effective as a second-line treatment with increased survival.2,4
1.1.2. Triple-negative breast cancer
Over the past several years, progress has been made in breast cancer research, including
the discovery of the role of three proteins associated with breast cancer growth. These proteins
include estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth
factor receptor 2 (HER2). Researchers have been successful in creating therapies specifically for
those three proteins, called targeted therapy. Patients diagnosed with triple-negative breast
cancer lack these three proteins on the tumor cells that are responsible for breast cancer growth.
This makes the triple-negative breast cancer difficult to treat. Moreover, triple-negative breast
cancer is more aggressive than other cancers and more likely to recur than any other types of
breast cancer. One of promising chemotherapeutic drugs for triple-negative breast cancer is a
drug called glembatumamab vedotin (CDX-011, b in Figure 1), an antibody-drug conjugate that
targets gpNMB-containing cells, with the goal of killing the cancer cells. gpNMB is a specific
protein over-expressed in breast cancer and other tumor types that is believed to be involved in
cancer growth and the spread of cancer to other parts of the body.5
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Figure 1. Current therapeutic treatments for leukemia, prostate, pancreas, lung, ovarian and
triple-negative breast cancer.

1.1.3. Lung cancer
Lung cancer, both small cell and non-small cell, is the second most common cancer in
both men and women in the United Sates. Lung cancer accounts for about 13% of all new cancer
cases. According to the ACS estimates in the US, in 2015 about 221,200 new cases of lung
cancer will occur and an estimate of 158,040 people will die of lung cancer (Table 1). Lung
cancer mainly occurs in older people, with 2 in 3 diagnosed people being 65 of age or older and
fewer than 2% of all lung cancer cases are found in people younger than 45. The survival
4

statistics in people with lung cancer vary depending on the stage of the cancer when it is
diagnosed. Chemotherapeutics drugs used for small- and non-small cell lung cancer include
cisplatin (c), carboplatin (d, Paraplatin®) and etoposide (e, Toposar®). Paclitaxel (f, Taxol®) is
also used for treatment of non-small cell lung cancer (Figure 1).2 While all the drugs are
administrated intravenously, etoposide can be administrated also orally. Drugs that are
administrated through a vain as an infusion could be irritants that can cause inflammation of the
vein through which it is given. If the medication escapes from the vein it can cause tissue
damage.6 More detailed explanation and description on platinum drugs will be addressed in
section 1.2.
1.1.4. Leukemia
There are four different types of leukemia, depending on the type of cells where they
initiate, how quickly they grow, which people they affect (adults or children) and how they are
treated. The types of leukemia include: acute lymphocytic (or lymphoblastic) leukemia (ALL),
chronic lymphocytic leukemia (CLL), acute myeloid (or myelogenous) leukemia (AML) and
chronic myeloid leukemia (CML). Acute lymphoblastic leukemia is the most common type of
leukemia among children and the risk of developing is highest under the age of 5. According to
the American Cancer Society in the United States, in 2015 there will about 54,270 new cases of
all kinds of leukemia and approximately 24,450 deaths (Table 1). One of the promising drugs for
treatment of chronic lymphocytic leukemia CTT is bendamustine (g, Treanda®) (Figure 1),
while etoposide (e) is used for ALL and sometimes for CLL along with oxaliplatin (h,
Eloxatin®).2,
1.1.5. Ovarian cancer
The ovaries are made up of three main kinds of cells and each type of cell can develop
into a different type of tumor. These tumors include epithelial, germ cell, and stromal tumors.
Most ovarian tumors are epithelial cell tumors. The majority of these tumors are benign (noncancerous) and never spread beyond the ovary and can be treated by removing either the ovary or
the part of the ovary that contains the tumor. Approximately 21,000 women each year are affects
by ovarian cancer in the Unites States (Table 1) and according to the ACS statistics in the United
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States, in 2015 there will about 14,180 women will die of ovarian cancer. Chemotherapeutics
used for ovarian cancer include cisplatin (c), carbolatin (d), etoposide (e) and albumin bound
paclitaxel (f, nab-paclitaxel, Abraxane®).2
1.1.6. Pancreatic cancer
Not all growths in the pancreas are cancerous. Some of them are benign while others
might become cancer over time if left untreated. Since more people are getting imaging tests
such as CT scans more frequently than in the past, these types of pancreatic growths are now
being found more often. Pancreatic cancer involves two types of cells, exocrine and endocrine
cells, which form different types of tumors. These tumors have distinct risk factors and causes,
have different signs and symptoms, are diagnosed using different tests, are treated in different
ways, and have different outlooks. Therefore it is important to distinguish between exocrine and
endocrine cancers of the pancreas in order to address appropriate treatment. Approximately
48,000 people each year are affected by pancreatic cancer in the United States; both male and
female (Table 1) and acccording to the ACS statistics in the United States, in 2015 there will
about 40,560 people will die of pancreas cancer. Chemotherapeutics used for pancreas cancer
include cisplatin (c), oxaliplatin (h), albumin bound paclitaxel and paclitaxel (i).2
1.1.7. Limitations of the current existing chemotherapeutic treatments for the above
described cancers

The preparation of some of the listed chemotherapeutics can be sometimes challenging.
For instance, the current commercial preparation of bendamustine entails at least nine synthetic
steps, involving the use of several hazardous reagents such as thionyl chloride. The treatment
cost for bendamustine is extremely costly as well. Single dose of the drug cost aproximetly
$4.320 and the entire treatment could be as expensive as $80,000.8 The process of preparation of
abiretarone involves multiple steps, including the use of Pd(II) catalysts through Suzuki or
Negashi coupling, and long purification processes. Even though a more recent advancement in
the preparation of abiretarone has been made with a reduced reaction time, it involves multiple
crystallizations in order to enable large-scale synthesis. Furthermore, the process also engages
the use of pyridine in the final step and the excess pyridine, removal of reagents such as acetic
6

anhydride on a rotary evaporator at higher temperature, leading to a laborious work-up with
decrease in the yield and purity of the product.9
In addition, patients who received Zytiga® and prednisone combination have a median
overall survival of 14.8 months, which is only 4 months more from the patients that did not
receive the treatment.10 Clinical trials for Taxol® in advanced ovarian cancer, showed that the
survival impact is an average prolongation of one year in survival, which is a modest dramatic
result for patients with advanced disease. In case of Taxol® for non-small-cell lung cancer, it
prolongs the survival by approximately two months compared to a standard chemotherapy
treatment consisting of cisplatin and etoposide.11
Additionally, the major drawbacks of these drugs are side effects, such as nausea,
vomiting, hair loss or vision problems. Cisplatin and bendamustine can cause major damage to
the kidneys2,12,13 and because of the way etoposide acts on cells in the body, it may increase the
risk of getting a second type of cancer, such as leukemia.2 Paclitaxel can cause allergic reactions
or condition known as hand-foot syndrome, causing pain, numbness or swelling in the hands or
feet, while albumin bound paclitaxel can affect heart rhythm, as well as lung inflammation.2
There is therefore, a real need for new chemotherapeutics that can overcome the major
drawbacks of already existing drugs for the cancers listed above.

1.2. The foundation of platinum-based drugs, as cancer chemotherapeutics - limitations
and resistance

The accidental discovery of cisplatin (cis-diamminedichloroplatinum(II)) over 40 years
ago by Barnett Rosenberg (a Brooklyn College ‘62 alumnus) and its clinical approval in 1978,
revolutionized cancer chemotherapy that represents a major landmark in the history of successful
anticancer drugs.13,14 This discovery led to the synthesis and biological evaluation of hundreds of
cisplatin analogues, such as carboplatin, oxaliplatin, picoplatin, as well as nedaplatin and
lobaplatin (the last two being widely used in Asia) (Figure 2).15 However, only cisplatin and the
follow-on drugs carboplatin (Paraplatin®) and oxaliplatin (Eloxatin®) have been approved
worldwide as anticancer drugs and are still used to treat 40–80% of cancer patients.12,15 At
present, cisplatin is one of the most effective drugs employed to treat testicular and ovarian
cancer. Carboplatin has been approved by the FDA in 1989 to treat ovarian cancer and
7

oxaliplatin has been approved by the FDA in 2002 for treating colorectal cancer. Despite the
precious metal component, cisplatin is actually one of the cheast drugs in the cancer
chemotherapy market. 2

Figure 2. Platinum-based chemotherapeutic agents.

The primary target for cisplatin is DNA (Figure 3). The major mechanism of action is
that cisplatin becomes activated intracellularly by the aquation of one of the two chloride leaving
groups which allows cisplatin to covalently bind to guanines of the DNA, forming a DNA
adduct. This activates various signal-transduction pathways, such as those involved in DNAdamage recognition and repair, cell-cycle arrest and programmed cell death/apoptosis.13
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Figure 3. Binding of cisplatin to guanine bases of the DNA through intrastrand and interstands
crosslink.13

Despite therapeutic success in the treatment of several types of tumors, the high
effectiveness of platinum-derived drugs has faced certain limitations. Since DNA is the primary
target for cisplatin, it can affect both sick and healthy cells. In addition, due to the affinity of
platinum for the sulfur and selenium donor that are present in many proteins in the plasma and in
the cellular environment, cisplatin can interact and disrupt the function of different proteins and
enzymes, as confirmed by the fact that only 1% of the intravenously administrated drug actually
reaches DNA. This produces a variety of side effects such as neurotoxicity, nephrotoxicity,
hepatotoxicity, ototoxicity, gastrointestinal disturbances, bone marrow suppression, hair loss and
anemia.13,15
Another important concern is that cisplatin may induce acquired or intrinsic
resistance.15,16 Cisplatin can bind to DNA through both interstrand and intrastrand cross-linking,
thus hindering RNA transcription and DNA replication which subsequently triggers the cell
death pathway. Unfortunately, its efficacy is frequently lost after several chemotherapeuticcycles due to tumor cells resistance. Platinum drugs such as carboplatin, that bind to DNA in the
same manner and generate the same kind of adduct as cisplatin probably induce cross-resistance
to cisplatin. Another drawback is the fact that cisplatin only reaches DNA in low amounts where
the majority of the complex is dispersed within the plasma and the cells.15
9

A number of platinum analogues have entered clinical trials in the past 30 years with two
(carboplatin and oxaliplatin) having been approved by the FDA. Satraplatin and picoplatin have
emerged after the development of carboplatin. Satraplatin was originally developed as an orally
active version of carboplatin and early clinical trials demonstrated the feasibility of
administrating a platin by the oral route. Satraplatin showed promising clinical activity in a trial
of 50 patients with hormone-refractory prostate cancer. Phase III with this drug, involving 900
patients who had failed previous chemotherapy, showed significant reduction of the risk in
disease progression. The most recent data for Satraplatin has been submitted as a new drug
application to the FDA and awaits approval.13
In addition, picoplatin was designed to provide steric bulk around the platinum centre and
showed to retain activity against a wide range of cisplatin-resistant and oxaliplatin-resistant cells
in vitro. Picoplatin also demonstrated in vivo antitumor activity by both the intravenous and oral
routes, as well as promising antitumor activity in phase II trials of ‘platinum sensitive’ ovarian
cancer and cisplatin-resistant small cell lung cancer. However, it failed in phase III trials for
small-cell lung cancer.17
Overcoming these limitations can be quite challenging in pharmaceutical research.
Development of more active platinum-derived drugs14,18-26 with improved properties and with
less side effects that can address the clinical problems2,12,13,15 related to the use of cisplatin and
their follow-on drugs, carboplatin and oxaliplatin is extremely important. Nanotechnology may
provide several advantages for drug delivery and accumulation of platinum compounds 27 such
as: 1) Control of drug solubility; 2) Modulation of drug distribution; 3) Targeting of specific
cells; and 4) Multidrug delivery and therasnotics. In this context, a few selected Pt(II)
compounds (nanoplatin,28 cisplatin,29 {Pt(NH3)2}2+,30 mitaplatin,31 {di-DAHC-Pt2}4+,32 and
{DACH-Pt}2+,33,34) have been encapsulated into polymer nanoparticles and tested in vitro or in
vivo as potential cancer chemotherapeutics. All these formulations were proven to be beneficial
with better activities in vitro or in vivo and lower nephrotoxicity than cisplatin. The synthetic
strategies involved are nevertheless not straight forward and certainly not cheap. It would also be
desirable to have metallodrugs more selective and effective than cisplatin to be delivered this
way.
A wide range of other transition-metal based drugs emerged as potential candidates and
are currently investigated for future advancement.14,15,35,36,39-43,45-51,53-57 Within this context,
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organometallic compounds with properties bridged somewhat between inorganic and organic
drugs have been recently considered as promising alternatives as cancer chemotherapeutics. One
reason is that these cross-compounds combine the features of a metallic center and organic
scaffolds and may be endowed with versatile stereochemistry having geometries ranging from
linear to octahedral and sometimes even beyond, with a large number of stereoisomers in some
cases. Another reason is that the redox properties of the resulting metal cations in vitro along
with their ability to bind covalently to biological targets can make them good candidates in
medicinal chemistry. Lastly, organometallic species are relatively lipophilic (more permeable)
and can be functionalized with a variety of organic ligands that contain specific reactivity.14
In the following subsections, new coordination and mostly organometallic platinum(II),
gold(III), palladium(II) and ruthenium(II and III) complexes are described as potential cancer
chemotherapeutics.
1.3. Platinum (II), gold(III), palladium(II) and ruthenium (II and III) compounds as
alternatives chemotherapeutic agents
1.3.1. Platinum(II) compounds
From the different strategies employed (trans compounds, platinum(IV) pro-drugs,
multinuclear platinum complexes), organometallic platinum(II) compounds have emerged as
attractive anticancer agents.14 Multiple efforts have been made to synthesize various and
structurally different organoplatinum complexes exhibiting antitumor properties and with
different mechanisms of action. Within this context, novel cyclometalated platinum-based
complexes have been designed, synthesized and studied, with an emphasis on their potential
interaction with DNA and favorable cytotoxicity against different cancer cell lines. 14 The early
development of this type of compounds for anticancer purposes focused on different bidentate CN cycloplatinated complexes having the general formula Pt(C-N)LX. By changing the structure
of C-N ligands and other ancillary ligands, the kinetic, structural and electronic properties of
cycloplatinated compounds can be appropriately tuned to enhance their activity.18,19 One such
example is five coordinated cyclometalated Pt(II) complexes (A, Figure 4) containing chelating
biphosphine ligands, that exhibited more potent anticancer activity in vitro and in vivo than
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cisplatin. Moreover, this compound displayed proteasome inhibitory activity in human breast
cancer cells associated with apoptosis induction.20

Figure 4. Recently developed platinum anticancer agents.14,20-22

Cycloplatinated tridentate C-N-N complexes that are more stable under physiological
conditions than cisplatin and its derivatives have been recently described by Che’s et al. (like B
in Figure 4). This N-heterocyclic carbene platinum complex displayed in vitro cytotoxicity
activity higher than that of cisplatin and inhibited tumor growth in a nude mice model.
Surprisingly, B did not accumulate in the vicinity of DNA but preferentially accumulated in
cytoplasmic structures including sites where active survivin, an inhibitor of apoptosis, is located.
Most importantly, in vivo results showed that injection at 3 mg/kg considerably inhibited NCIH460 tumor growth, did not cause death of mice and induced no significant weight loss.21
Moreover, a rhomboidal Pt(II)-based complex C was recently evaluated in vivo on the
tumor growth rate in a breast cancer (MDA-MB-231) mouse xenograft model. Interestingly,
substantial 64% reduction of the average tumor volume reduction burden was observed on the
last day of the experiment. In addition, the emissive properties of this complex open a possibility
for future development in image-guided drug delivery.22
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1.3.2. Gold(III) compounds
The successful development of antitumor platinum drugs has paved the way for studying
other metal-based chemotherapeutic compounds with potentially improved properties. Gold was
one of the first metals used as a treatment for disease thousands of years ago; however its
exploitation in modern medicine was mainly restricted to the cure of rheumatoid arthritis since
the mid-1930s.15 During the past decade gold complexes have gained increasing attention due to
their strong tumor cell growth inhibiting effects generally achieved by exploiting non-cisplatinlike pharmacodynamic and pharmacokinetic properties and mechanisms of action.31-33 Gold(III)
compounds were initially chosen as an alternative to cisplatin since Au(III) is isoelectronic with
Pt(II) and has a d8 configuration resulting in square-planar tetracoordinate complexes, which in
theory should make them interact with DNA in a similar manner. The ligand exchange kinetics
are relatively slow for both metals although they are slightly faster for Au(III) complexes.
Unfortunately, their relatively poor chemical stability in solution slowed down research in this
field until the mid-1990s when complexes stable in physiologically relevant conditions were
developed.15 Since then, improved classes of gold(III) compounds have been reported with
anticancer activities. They not only display high cytotoxicity against representative human tumor
cell lines in vitro and tumors in vivo, but also show a mode of action different from that of
cisplatin which allows them to be active in specific cell lines resistant to cisplatin. It has been
proposed that the mechanism of action for Au(IIII) complexes is either purely DNA-independent
or that the interaction with DNA in the intercalative mode is partly responsible for the cell death.
Moreover, in most cases, Au(III) compounds display interactions with a variety of target proteins
isolated or inside cells. Thus, they form effective bonds with serum proteins, such as albumin or
with sulfur-containing proteins such as GSH and thioredoxin reductases (TrxR).14,15 The two
main mechanisms known to date that are responsible for the biological activity of gold(III)
compounds include reductive oxygen species (ROS) production and direct metal binding to the
proteasome.34
Among these compounds, gold(III)-dithiocarbamato AuD6 (E) and AuD8 (F) (Figure 5)
were designed as anticancer gold(III)-based peptidomimetics. Both compounds were highly
active against human MDA-MB-231 breast cancer cell lines in vitro, with AuD8 being more
potent than AuD6 (IC50 = 6.5±0.6 µM). In vivo studies showed slightly higher antitumor activity
for AuD8, at a low dose of 1.0 mg/kg/day, with 53% inhibition of xenographt growth after 27
13

days of treatment. In some mice, 85% inhibition after 13 days was observed. AuD68 was also a
more potent proteasome inhibitor both in vitro and in vivo.35

Figure 5. Representative gold(III) dithiocarbamate and cycloaurated complexes.14,35-39

Cinellu, Messori et al. developed a C,N,N-gold(III) complex (G, in Figure 5) that was
stable under pseudo-physiological conditions and was cytotoxic against different ovarian cancer
cell lines.36 Cycloaurated compound G displayed good activity and high selectivity against a
panel of 12 human tumor cell lines while H was considerably more cytotoxic and had a high
degree of selectivity against panel of 36 human tumor cell lines.37 Studies on the inhibitory
effects on TrxR suggested that mitochondrial pathways were directly involved in the apoptotic
process and the cytotoxicity. The interaction of G with Calf Thymus DNA showed to be weak
and reversible in nature. Bovine serum albumin (BSA) studies reveled that Au-protein adduct
was formed, which suggested coordination of the complex at the level of surface histidines.
Interestingly, the gold(III) compounds formed small amounts of metal-protein adducts with
cytochrome c and lysozyme in which gold(III) center and the C-N-N tridentate ligand were
conserved.14,37,38
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In vivo studies in rats bearing HCC orthografts with the dinuclear gold(III) complex I
(Figure 5) reported by Che et al. showed significant inhibition in tumor growth (77%). It was
revealed that the complex inhibited thioredoxin reductase and induced endoplasmic reticulum
(ER) stress. Particularly, I has also been subjected to acute and sub-chronic toxicity evaluation in
nude mice and in beagle dogs, reveling no severe and irreversible side-effects in association with
the consumption of the compound at its effective concentrations in these animal models.
Furthermore, gold(III) complex did not induce obvious genotoxicity.14,38,39
All these results indicate that gold(III) derivatives are therefore good candidates for
further studies and some may be even suitable to enter phase I clinical trials.
1.3.3. Palladium(II) compounds
The coordination chemistry of palladium(II) is very similar to that of platinum(II);
therefore palladium derivatives have been explored as an alternative to platinum-based
compounds due to the structural and thermodynamic similarity between the two metal-based
complexes. One of the features that distinguishes Pd(II) complexes from those of Pt(II) is the
ligand exchange mechanism, which is 105 times higher for Pd(II)-derivatives. This can cause fast
hydrolysis of Pd(II)-based complexes associated with ligand dissociation by generating very
active species that can easily interact with donor groups encountered in the bloodstream and
cellular environment; thus preventing the drug from reaching its target. This makes palladium
complexes generally inactive and somewhat toxic due to their higher reactivity. This process can
be however avoided by using bulky chelating ligands and achieving higher stabilization with
strongly coordinated ligands.14,15 Palladium(II) compounds have been therefore studied as
anticancer agents in the past 15 years with relevant examples found in the family of
organometallic compounds.
The advantage of using Pd(II)-derived complexes over Pt(II) is their higher solubility.15
Moreover, the higher stability of cyclopalladated compounds in physiological media and a lower
toxicity to normal cells are all promising features for their biological applications. 40
Organometallic Pd(II) complexes have been reported to have cytotoxicity activity against human
cervical epitheloid carcinoma, human chronicmyelogenous leukemia, osteogenic sarcoma,
malignant melanoma, breast cancer, lung cancer, glioma, human colorectal adeno-carcinoma,
head and neck squamous cancer, prostate cancer and ovarian cancer.15
15

Figure 6. Representative C,N-palladium(II) complexes.14,41-47

Cyclopalladated complexes are less toxic overall, which makes them very promising as
antitumor compounds. A good example of such cyclopalladated compound is J in Figure 6,
which showed to induce apoptotic cell death in human leukemia cells (HL-60 and Jurkat) by
rapture of lysosomal membranes and release of cathepsin B into the cytoplasm.14,41,42
Travassos et al. reported on the biphosphinic cyclopalladated complex (K, C7a) that
displayed promising antitumor properties against murine and cisplatin-resistant human tumor
cells both in vitro and in vivo. This compound induced the central apoptotic pathway by a strong
effect on mitochondria and interacted with thiol-containing protein groups in the mitochondrial
membrane, by inducing Bax translocation from cytosol, colocalizing with mitochondrial tracker.
Increase in cytosolic calcium concentration, mainly from intracellular compartment was
observed, as well as a significant decrease of adenosine triphosphate (ATP) and
caspse/endonuclease activation. Moreover, in preclinical studies of malenoma model, this
dimeric complex was effective against primary and metastatic tumors, having low toxicity. Thus,
cyclopalladated complex K is a promising tumor chemotherapeutic agent and was selected for
further preclinical studies that include a gene therapy protocols in conjugation with plasmids.43-45
Another study conducted on C7a (K) investigated therapeutic efficacy in patient-derived
xenograft model of adult T-cell leukemia lymphoma (ATLL) and the mechanism of action in the
human T lymphotropic virus type 1-positive and negative-T cell lines (HTLV-1). In vivo survival
studies led to significant increase of survival in the treated mice. Moreover, C7a inhibited more
than 60% of the ex vivo proliferation of PBMC from HTLV-1-infected individuals.46
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Furthermore, this compound was also found to be highly effective to promote cell death in the
K562 human leukemia cells through apoptotic cell death and associated to cytochrome c release
and caspace activation. These results prove that C7a compound is a promising drug in the
chronic myeloid leukemia (CML) antitumor chemotherapy.47

1.3.4. Ruthenium(II and III) compounds
In the 1970s, Clarke et al. reported on a ruthenium complex, [Ru(NH3)5(purine)]3+,
capable of inhibiting DNA and proteins synthesis in human nasopharyngeal carcinoma cells in
vitro.48 This subsequently initiated interest in ruthenium complexes as potential anticancer agents
and without a doubt, ruthenium became the star metal in the present search for chemotherapeutic
alternatives to cisplatin.15 In the 1980s, chloro-ammine-Ru(III) compounds were found to have
anticancer activity against rats, but their poor solubility limited their action. Soon after, a
DMSO-Ru(II) species, cis-[RuCl2(dmso)4] was shown to be active against both primary and
metastatic cancers, though less effective than cisplatin, but with fewer side effects compared
with the platinum-based drugs. Since then a number of active ruthenium compounds in vitro and
in vivo two of which have already entered clinical trials.15
The emergence of ruthenium complexes as some of the most promising candidates for
cancer therapy with metallodrugs can be attributed to their specific characteristics. First of all,
ruthenium compounds can easily access three different oxidation states (II, III and possibly IV)
in physiological solutions.15,49 Ruthenium II and III states can form six-coordinate octahedral
species that can facilitate finer tuning of the steric and electronic properties of the complexes by
intervening with the two “extra” axial ligands. They can also interact with macromolecules in a
different manner that those derived from platinum.49 The rate of ligand exchange in ruthenium
complexes is comparable to that for platinum, ranging from 10-2 to 10-3 per second, which gives
the molecules high kinetic stability and preventing rapid equilibrium reactions. This helps the
molecule to stay intact on its way to the target and it also remains viable throughout its
interaction with the cell.15 And most importantly, ruthenium compounds are able to mimic iron
in binding biologically relevant molecules such as albumin and transferrin, and as a consequence
their toxicity is much lower than that of platinum therapies.15,49
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Figure 7. Selected ruthenium(III) compounds with important antitumor and/or antimetastatic
properties.50-53

A number of ruthenium(III)-arene complexes showed high in vivo antitumor activity and
have successfully completed phase I clinical trials and entered phase II.14 Those compounds
include NAMI-A,50,51 developed by Sava et al., KP1019 and its analogue containing Na+,
KP133950,52 developed by Keppler et al. (Figure 7). KP1019 (indazolium trans[tetrachloridobis(1H-indazole)ruthenate(III)]) was found to be highly active against the rat colon
cancer model, yielded efficacy with up to 95% reduction of tumor volume without any mortality
(0%) and without any considerable weight loss (6%).53 KP1339 was also found to exhibit
cytotoxic activities in various tumor types, such as colon carcinomas.52
NAMI-A

(imidazolium

trans-[tetrachloridobis(1H-imidazole)(S-dimethyl

sulfoxide)ruthenate(III)]) demonstrated to affect the process of metastasizing, rather than acting
against the primary tumors or already established metastases. Its activity is most likely based on
enhanced cell adhesion, inhibition of cancer cell motility and invasiveness, as well as on
inhibition of neoangiogenesis in the tumor tissues.53
I will detail in Chapter V a number of organometallic ruthenium(II) derivatives that have
been subjected to advanced pre-clinical studies.
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1.4. New drug design with iminophosphorane ligands
Iminophosphorane (IM) ligands of the general formula R3P=NR’ are attractive substrates
for coordination (N,N-) or cyclometallation (C,N-). They provide a C,N- or N,N- chelating
backbone that stabilizes the resulting square-planar structure of d8 transition metal complexes
and can also coordinate to d6 metals like Ru(II) (Chart 1). Incorporating phosphines in the
skeleton of the IM pincer ligand is important since the phosphorus atom can serve as a
spectroscopic “marker” for

31

P{1H} NMR spectroscopy in order to study the stability and

oxidation state of the compounds in vitro in different deuterated solvents. Furthermore,
modifications to X ancillary ligands in these metallic compounds permits further functionality by
ligand substitution.

Chart 1. New drug design with iminophosphorane ligands.
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Figure 8. Examples of iminophosphorane ligands.

Iminophosphoranes can be divided into three classes: stabilized, semi-stabilized and nonstabilized (Figure 8), as a function of the carbanionic charge delocalization degree and the ability
to delocalize this charge which is closely related to the nature of the substituents (Figure 9). For
example, the stabilized iminophosphorane ligands are characterized by the presence of the C=O
next to the P=N bond. This results in more stable structures due to the conjugation. The semistabilized and non-stabilized classes lack the C=O and are therefore less stable.54 The main focus
remains on using stabilized and semi-stabilized iminophosphorane ligands avoiding the least
stable third class of IM ligands.

Figure 9. Resonance structures for stabilized iminophosphorane ligands.

There are many different methods in which iminophosphorane ligands can be prepared.
The most common of them is the Staudinger reaction in which a tertiary phosphine reacts with an
20

organic azide in the presence of non-polar solvent, such a dichloromethane, at room temperature,
releasing nitrogen gas and forming semi-stabilized IM (R3P + N3R’

R3P=NR’).54 The second

method is the Pomerantz reaction, in which a tertiary phosphine reacts with a primary amide in
the presence of di-tert-butylazodicarboxylate (tBuDAD) and polar solvent, such a
tetrahydrofuran at 0ºC, forming stabilized IM (R3P + H3NC(O)R’

R3P=NC(O)R’) (Scheme

1).55 A number of our IM were prepared by Pomerantz method which is the method of choice
when amides are used.

Scheme 1. Staudinger and Pomerantz reaction.

1.5. Previous studies using iminophosphorane ligands

Our research group in Brooklyn College has reported that non-toxic iminophosphorane or
iminophosphane compounds serve as stabilizing (C,N- or N,N) chelating ligands in the
preparation of anticancer organometallic and coordination d8 metal complexes (Figure 10).56-60 A
series of neutral and cationic organo-gold(III) iminophosphorane complexes (like 1, in Figure
10) showed higher toxicity against leukemia cells, including cells from patients with chronic
leukemia CCL, while being less toxic to normal T-lymphocytes with IC50 values in the
nanomolar range (60-100 nM). It was found that gold compounds do not interact with Calf
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Thymus DNA and induce intracellular oxidative stress that provokes mitochondrial dysfunction.
Complex 1 induces necrotic cell death and reactive oxygen species (ROS) production at the
mitochondrial level which was a critical step in its antitumor effect.56,57

Figure 10. Selected cytotoxic gold(III), platinum(II) and palladium(II) complexes with IM
ligands (1-6) prepared in our research group.56-60

Another study conducted in our research group involved the coordination of a watersoluble IM ligand PTA=N-C(O)-2-N5H4(N,N-IM) to d8 metals, affording hydrophilic stable
Pd(II) and Pt(II) compounds (like 2, in Figure 10). Compound 2 was highly cytotoxic in vitro
against human T-cell leukemia Jurkat while being less toxic to normal T-lymphocites (PBMC). It
was also 15 times more toxic to Jurkat shBak cell lines than cisplatin, indicating a cell death
pathway that may be different from that of cisplatin. The interactions of compound 2 with Calf
Thymus and plasmid (pBR322) DNA, revealed differences compared to cisplatin and with faster
binding to HSA. It was demonstrated that compound 2 interacted with HSA in a reversible way
which could be potentially beneficial to the antitumor activity in vivo of this compound.58
In another project, a series of water-soluble and highly lipophilic organometallic Pd(II)
complexes including the orthopalladated dimer [Pd(μ-Br){C6H4(C(O)N=TPA-kC,N)-2}]2 (3) and
a mononuclear complex [Pd{C6H4(C(O)N=TPA-kC,N)-2}(acac)] (4) (Figure 10) were
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synthesized. Palladium compounds 3 and 4 displayed high cytotoxicity in vitro against human
Jurkat-T acute lymphoblastic leukemia cells, and DU-145 human prostate cancer cells while
being less toxic to normal T-lymphocytes. Notably 3 and, particularly 4, were very toxic to
cisplatin-resistant Jurkat shBak cells (Bax/Bak-deficient Jurkat cells), indicating a cell death
pathway that may be different from that of cisplatin. The interaction of these Pd(II) complexes
with plasmid (pBR322) DNA was very weak (3) or non-existing at all (4), indicating an
alternative biomolecular target for these cytotoxic compounds.59
The more recent project in our research lab involved the synthesis of Au(III) and Pd(II)
heterometallic complexes with IM ligands derived from ferrocenyl-phosphanes (Figure 10).60
The trimetallic derivatives M2Fe (M = Au, Pd, 5 and 6) exhibited important cytotoxic effects in
the low micromolar range in all the studied cells and being slightly less toxic to non-tumorigenic
human embryonic kidney cell line (HEK-293T). The interaction of Pd(II) derivative 6 with
plasmid (pBR322) DNA showed a strong interaction demonstrating significant retardation of the
faster-running supercoiled form, while Au(III) complex 5 showed no interaction. However,
Au(III) complex showed to be a good inhibitor of the zinc-finger protein PARP-1, while the
Pd(II) complex was noticeably less potent. Our results support the idea of different reactivity of
the complexes with the investigated biomolecules depending on the metal ion and not only on
the ligand set.60
One of the outcomes of our studies with IM ligands was that cyclometallated
monometallic gold(III) and palladium(II) compounds proved to be more stable than coordination
derivatives in physiological media. It seems that the skeleton C,N- is a better alternative to
stabilize mononuclear metal centers than the N,N- backbone when iminophosphorane ligands are
used. However, stable mononuclear Pt(II)58 and trimetallic coordination Fe-Au(III)2 and FePd(II)260 coordination compounds which display important antitumoral effects were prepared.
The successful results of studies with cyclometallated and coordination compounds
conducted in our research group, led us to further explore the synthesis and biological activities
of gold(III), platinum(II), palladium(II) and ruthenim(II) with different IM ligands.
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CHAPTER II

OBJECTIVES
_________________________________________________

2.1. Ultimate goal of the work described in this Thesis

The ultimate goal of my research is to develop effective potential cancer
chemotherapeutics based on metallic complexes with a mode of action different from that of
cisplatin and related compounds in order to overcome some of their drawbacks.

2.2. Hypothesis
Selected iminophosphorane ligands will stabilize d8 and d6 transition metal centers in
physiological media and modifications of these ligands will afford compounds with improved
antitumor properties and/or properties to better understand their mode of action. We envisioned
these modifications in the following way: i) incorporation of water soluble phosphines in the
skeleton to increase the hydrophilicity of the complexes; ii) incorporation of luminescent
molecules in the ligand to ideally be able to track these complexes inside the cells by techniques
like fluorescence microscopy; iii) incorporation of a second different metal in the ligand (like
ferrocene) to prepare heterometallic complexes to improve their activity as anti-tumor agents by
the interaction of

different metals with multiple biological targets or by the improved

chemicophysical properties of the resulting heterometallic compound.
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2.3. Specific Aims of this Thesis

Aim 1: Synthesis and study of the stability in solution of compounds with iminophosphoranecontaining ligands which may behave as potential anticancer agents.
a) Synthesis of water-soluble, ferrocene-based and luminescent iminophosphorane ligands
to use them in the preparation of gold(III), platinum(II), palladium(II) and ruthenium(II)
coordination and organometallic complexes.
b) Study of the stability of the compounds in deuterated solvents or buffers by 31P{1H},1H
NMR and UV-vis spectroscopy.

Aim 2: Study of the mechanism of action of the new iminophosphorane compounds.
Study of the interaction of these compounds with different bimolecular targets like DNA
and HSA by different techniques (gel electrophoresis, circular dichroism, thermal
denaturation experiments and fluorescence spectroscopy).

Since this is an interdisciplinary project while my doctoral work has focused on the specific aims
described above our group, along with the groups of our collaborators, has worked in the
biological and mechanistic evaluation of these compounds in order:
1) To study the antiproliferative properties of the new compounds in different human cancer cell
lines and in non-tumorigenic human cell lines such as a human embryonic kidney cell line
(HEK-293T) or a human renal proximal tubular cell line (RPTC).
2) To investigate the cell death pathway (apoptosis, necrosis, necroptosis) of selected compounds
and explore their mode of action by additional studies (inhibition of capthesin, involvement of
caspases and/or p-53 in the cell death pathway).
In the case of the luminescent compounds, to study (by fluorescence microscopy) their
distribution inside the cancer cells.
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3) To study the in vivo activity in mice (including pharmacokinetic studies) of the most
promising water-soluble ruthenium candidate discovered so far.

I will include in this thesis complete data on the biological evaluation of these compounds as this
is relevant to understand the outcomes and significance of my research but I will detail in every
chapter the contributions of other scientists. My research has consisted on the rational design
and the synthesis and complete characterization of the ligands and metallic compounds
described in this thesis, the study of the stability in solution of the new metallic complexes and
the study of the interactions of these compounds with biomolecular targets like DNA and Human
Serum Albumin as outlined in the specific aims 1 and 2.
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CHAPTER III

SYNTHESIS OF COORDINATION AND ORGANOMETALLIC
GOLD(III), PALLADIUM(II) AND PLATINUM(II)
COMPOUNDS CONTAINING A LUMINESCENT
IMINOPHOSPHORANE LIGAND. IN VITRO EVALUATION
AND PRELIMINARY MECHANISTIC INSIGHTS.
_________________________________________________

3.1. Potential of metal-based theranostics

As explained in the introduction, during the past two decades, a large number of metalbased complexes with promising anticancer activities have been reported.1 In the last five years,
a shift has taken place in the field, with more emphasis being placed on understanding how these
metallodrugs work. Mechanistic approch may be of help to design improved metal-based drugs
by supressing the side effects and clinical problems related to the use of existing platinumderived drugs such as cisplatin.2-5 One approach is to design new active metal-based compounds
that can be tracked in vitro and in vivo in order to “visualize” the cellular location and fate of
these complexes.
Many transition-metal complexes display very interesting photophysical properties that
make them suitable as therapeutics agents for targeting and detection of specific biomolecules.6
These type of compounds are considered to be potential metal-based theranostic, a term which is
defined as the combination of therapy and diagnostic imagining into a single modality.3,6 The
advantage of using this type of approach is that the therapeutic and detection abilities can be
combined within a single metal complex, allowing the progress of any disease to be monitored
without the requirement for an additional labeling or imaging agent.6
Phosphorescent metal complexes have been widely applied for sensing, bio-imaging and
organic light-emitting diode applications. They possess several advantageous features that make
them suitable as sensing or imaging probes. Photophysical properties of metal complexes make
them sensitive to changes in their environment. Moreover, they usually display significant Stokes
shifts which can prevent self quenching and allow for easy resolution of the excitation and
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emission light. In addition, the long phosphorescence lifetime of metal complexes allows their
phosphorescence to be readily distinguished in the presence of endogenous fluorophores likely to
be present in biological environments by the use of fluorescence.6
Within this context, we aimed to explore the anticancer properties of iminophosphorane
d8 transition metal complexes incorporating a luminescent molecule, as well as to determine their
intracellular distribution by using fluorescence microscopy.3,7,8
The following chapter reports on the synthesis, characterization and luminescence studies
of new gold(III), palladium(II) and platinum(II) derivatives containing previously reported9
iminophosphorane ligand derived from 8-aminoquinoline [Ph3P=N-C9H6N] (1). These metalcomplexes were evaluated for their antiproliferative properties in a human ovarian cancer cell
line (A2780S), in human lung cancer cells (A-549) and in a non-tumorigenic human embryonic
kidney cell line (HEK-293T). The compounds were also tested for their possible interactions
with plasmid (pBR322) DNA used as a model nucleic acid, and for their reactivity with the
transport protein human serum albumin (HSA).

3.2. Synthesis and characterization
The iminophosphorane ligand [Ph3P=N-C9H6N] (1) can be prepared by a modification of
a previously reported procedure.8 8-azidoquinoline was obtained by reaction of 8aminoquinoline with trifyl azide9 and subsequently reacted with triphenylphosphine (PPh3) in
CH2Cl2 at room temperature for one hour, using the Staudinger method.10 Upon addition of
ligand 1 to a in situ prepared CH3CN solution of [AuCl2(CH3CN)2]A (A = ClO4-, PF6-), or to
CH2Cl2 solutions/suspensions of PdCl2(COD) and PtCl2, coordination complexes of gold(III) (2,
3) palladium(II) (4) and platinum(II) (5) were obtained in moderate to high yields (Scheme 1).
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Scheme 1. Preparation of the new luminescent metallic complexes 2-7.

All of the complexes were characterized by spectroscopic methods, including 1H,
31

P{1H},

13

C{1H}

and/or

195

Pt{1H} NMR, mass spectrometry, conductivity and elemental

analysis. The crystal structures of the gold(III) (3) and the palladium(II) compound (4) were
determined by an X-ray analysis (Figure 1). Selected bond lengths and angles for both
compounds are collected in Table 1 and described below.
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The geometry about the gold(III) and palladium(II) centers is pseudo-square planar with
the N(2)-M(1)-N(1) angle of 80.5(4)o (3) and 80.5(2)o (4) suggesting a rigid ‘bite’ angle of the
chelating ligand. The Au and Pd centers are on an almost ideal plane with negligible deviations
from the least-squares plane.

Figure 1. Molecular structure of the cation in compound [Au((Ph3P=N-8-C9H6N)-κN,N)Cl2]ClO4 3 and of the compound [Pd((Ph3P=N-8-C9H6N)-κ-N,N)Cl2] 4 with the atomic
numbering scheme.

The main distances M-N(1) or M-N(iminic) and M-N(2) found for the Pd complex 4 are
similar to that in related IM complexes, such as [PdCl2(PTA=N-C(O)-2-NC5H4)],11 [Pd{k2-C,NC6H4(PPh2=NC6H4Me-4’)-2}{µ-OAc)}]2,12

[Pd{k2-C,N-C6H4(PPh2=NC6H4Me-4’)-

2}(tmeda)]ClO4,12 [Pd(C6H4CH2NMe2)(Ph3PNC(O)-2-NC5H4)]ClO4,13 [({Cp-P(Ph2)=N-CH2-2NC5H4}PdCl2)2Fe]14 and [{(Cp-P(Ph2)=N-CH2-2-NC5H4)PdCl2}Fe(Cp)].14 The distances AuN(1), Au-M(2), Au-Cl(1) and Au-Cl(2) in 3 are similar to the ones obtained by X-ray
crystallographic analysis or DFT calculations for [AuCl2(Ph2PyP=NC(O)-Ph)]ClO4,15 [(Ph3P=NCH2-2-NC5H4)AuCl2]ClO4,15 [AuCl2(PTA=N-C(O)-2-NC5H4)]ClO411 [({Cp-P(Ph2)=N-CH2-2-
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NC5H4}AuCl2)2Fe](ClO4)214 and [{(Cp-P(Ph2)=N-CH2-2-NC5H4)AuCl2}Fe(Cp)]ClO4.14 The
distances P=N are shorter than in compounds which incorporate a carbonyl group bonded to the
iminic nitrogen, which is due to a smaller delocalized charge density as compared to the CO
group.11,14-16
Table 1. Selected bond lengths [Å] and angles [o] for complexes 3 and 4.
3

4

Au(1)-N(2)
Au(1)- N(1)
Au(1)-Cl(2)
Au(1)-Cl(1)

1.998(8)
2.045(13)
2.254(3)
2.278(5)

Pd(1)-N(2)
Pd(1)- N(1)
Pd(1)-Cl(2)
Pd(1)-Cl(1)

2.034(5)
2.060(5)
2.2738(15)
2.2903(15)

P(1)-N(1)
N(2)-Au(1)-N(1)

1.656(11)
80.5(4)

P(1)-N(1)
N(2)-Pd(1)-N(1)

1.622(5)
80.5(2)

N(2)-Au(1)-Cl(2)

172.7(3)

N(2)-Pd(1)-Cl(2)

170.63(15)

N(2)-Au(1)-Cl(1)

95.1(3)

N(2)-Pd(1)-Cl(1)

93.62(15)

N(1)-Au(1)-Cl(2)

95.4(3)

N(1)-Pd(1)-Cl(2)

95.51(13)

N(1)-Au(1)-Cl(2)

175.7(3)

N(1)-Pd(1)-Cl(2)

173.73(14)

Cl(2)-Au(1)-Cl(1)

88.88(15)

Cl(2)-Pd(1)-Cl(1)

89.91(6)

The stability of the compounds in different solution was assessed by
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P{1H} NMR

spectroscopy in deuterated solvents. Most compounds are stable for weeks in CD3CN or CD2Cl2
solution. The stability in DMSO-d6 solution was also evaluated for all of the compounds (see
Appendix for more details). Gold(III) compounds 2 and 3 have half-lives of 4 (2) or 6 (3) hours,
after which they decompose to phosphane oxide (Ph3P=O) and the coordination gold(III)
compound based on the deprotonated uninegative bidentate 8-aminoquinoline fragment [Au(N8-C9H7N)-κ-N,N)Cl2]. The poor stability for some monometallic Au(III) iminophosphorane
coordination complexes14,16 and their decomposition to biologically active gold(III) amino
derivatives14 has been described before. The coordination Pd(II) compound 4 in DMSO-d6
solution has a half-life of about 1.5 hours and over time 4 evolves to the endo cyclometalated
species [Pd{κ3-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] (6 in Scheme 1) by activation of the C-H of
one aryl group from the PPh3 fragment of the iminophosphorane ligand. The coordination Pt(II)
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compound 5 evolves to a cyclometalated analogue of 6 to give species [Pt{κ3-C,N,NC6H4(PPh2=N-8-C9H6N}Cl] (7 in Scheme 2) by heating it in DMSO.
The cyclometalated Pd(II) (6) and Pt(II) (7) species have been fully characterized by
spectroscopic methods (including

195

Pt{1H} NMR), mass spectrometry, conductivity and

elemental analysis (see the Experimental Section). These species can also be obtained as pure
compounds in high yields (Scheme 1) by reaction of IM ligand 1 with Pd(AcO)2 in CH2Cl2 at
room temperature, followed by treatment with LiCl in CH3OH (6) or by refluxing the
coordination platinum(II) compound 5 in CH2Cl2 for 3 days (7). The cyclometalated species 6
and 7 are stable in DMSO-d6 solution with half-lives of several weeks. The fact that 6 and 7 are
orthometalated species is clearly inferred from the analysis of their NMR spectra. 6 and 7 display
downfield shifts in their 31P{1H} NMR signals with respect to the coordination compounds 4 and
5, respectively. In the 1H and 13C{1H} NMR spectra of 6 and 7 there are also new signals due to
the presence of 4 protons (a-d) of the cyclometalated aryl ring and six well resolved peaks, for
the carbons of this C6H4- fragment. Moreover, the 2JPt-P coupling constant of 426 Hz is visible
only for the cyclometalated derivative 7 displaying a signal at 44.7 ppm in
195

Pt satellites while the signal in the

195
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P{1H} NMR with

Pt{1H} NMR is a doublet at -2899.7 ppm. A JPt-P

coupling constant is not observable for the coordination iminophosphorane compound 5. This
coupling constant has not been observed for other coordination iminophosphorane platinum
derivatives either.11
The iminophosphorane ligand in compounds 6 and 7 acts as a C,N,N- pincer ligand.
Urriolabeitia et al. have reported on the selective C-H activation by palladium(II) complexes in
iminophosphoranes based on type of IM ligand, solvents that were used and the temperature at
which the cyclometalation reaction takes place giving either endo or exo derivatives.17-20 The
semi-stabilized IM ligand [Ph3P=N-C9H6N] (1) coordinates to a palladium or platinum center (II)
in compounds 4 and 5 affording cyclometalated endo derivatives with the IM acting as a C,N,Npincer ligand in 6 and 7. The only example of a Pt(II) cyclometalated compound containing an
iminophosphorane ligand reported so far is the endo [Pt(C6H4-2-PPh2=N-C(O)-2-NC5H4-κC,N,N)Cl] derivative obtained by reaction of [PtCl2(NCPh)2] with Ph3P=N-C(O)-2-NC5H4 in
refluxing 2-methoxyethanol.20
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3.3. Luminescence studies

These studies were performed by Dr. Josefina Jiménez and Elena Gascón at the University of
Zaragoza, Spain.

The luminescence studies of the metallic complexes 2-7 and of the previously described
IM ligand 18 whose luminescence had not been reported before were carried out. All the
compounds are luminescent in DMSO solution (5 x 10-4 M) at room temperature.
The excitation and emission data as well as the lifetimes for excited states are
summarized in Table 2. The lifetimes are all relatively long (7-12 s), which indicate the
emission transitions are all forbidden and phosphorescent. Ligand 1, non-cyclometalated
complexes 2-4 and cyclometalated palladium complex 6 all show similar optical behavior. The
spectra show a broad band with the emission maximum at around 486-521 nm, upon excitation
between 290-410 nm (see Appendix for more details). Consequently, an intraligand transition
modified by the coordination to metal is probably responsible for the luminescence in all of these
complexes 2-4 and 6. The luminescence profile and features (excitation and emission maxima) of
the cyclometalated platinum complex 7 are different. For this compound, an emission band
showing some evidence of vibrational structure is observed, whose maximum is red-shifted from
521 nm in the free ligand 1 to 677 nm (see also Appendix). This spectral shift suggests a 3MLCT
character in the excited state of 7.21 On the other hand, unlike what we observed for 1 and
complexes 2-6, the absorption spectrum of 7 exhibits a lower-energy band in the 400-500 nm
region (see Appendix) at substantially longer wavelength than the absorption of the free ligand.
This new band leads to the observed emissions and is likely to arise from charge-transfer
transitions involving the metal, as it has been described for other Pt(II) complexes. Thus, a triplet
state of mixed ππ*/MLCT character is probably responsible for the phosphorescence in 7.21-25
Non-cyclometalated platinum complex 5 deserves special attention. A DMSO diluted
solution of this pure compound is brightly emissive yellow under a common UV lamp (ex 365
nm) at room temperature. However, the spectrum shows two emissions, whose intensities depend
on the excitation wavelength and the time of the luminescence measurement (see Figures 20 and
21 in Appendix). At 390 nm, it exhibits two emission bands, a broad one with the maximum at
513 nm (similar to that observed for ligand 1 and complexes 2-4 and 6) and another one with a
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profile and features similar to those observed for the cyclometalated platinum complex 7, with a
maximum at 677 nm. Excitation at a longer wavelength, 450 nm, only gives the emission band at
677 nm. When the luminescence of this solution is measured immediately afterwards the
spectrum only shows the emission band at 677 nm. Under a common UV lamp (ex 365 nm) we
observed an orange-red emission for the irradiated area while the non-irradiated area remained
yellow. This observation seems indicative of the transformation of coordination complex 5 into
cyclometalated 7 upon UV irradiation, which has been demonstrated by
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P{1H} and 1H NMR

spectroscopy. The transformation is not clean, though, and the NMR spectra of the DMSO
solution after irradiation show other signals besides those corresponding to 5 and 7, which have
not been identified.

Table 2. Luminescent spectral data and lifetime measurement for the compounds 1-7.
Compound
1
2
3
4
5
6
7

max, solution (298 K)a
exc
em [ (s)]
296, 336, 370, 407
521[10]
290, 350 sh, 371 sh, 400
513[11]
294, 337, 370, 404
517 [10]
298 sh, 342, 368 sh
496 [7]
306, 343, 377 sh, 390
513 [12]
294, 341 sh, 378, 402
348 sh, 373, 440

486 [10]
645, 677 [8], 702 sh

a

Data of wavelength are given in nm. Data using DMSO as solvent at room temperature, 5 x 10-4
M.

2 and 3 are rare examples of non-cyclometalated gold(III) complexes with chlorido
ligands which emit in a fluid solution at room temperature. Two essential control parameters to
obtain luminescent (square-planar) gold(III) complexes have been highlighted: the ligand field
strength and the rigidity of chelating ligands.26,27 These parameters are also relevant for the
preparation of luminescent platinum(II) complexes.21 The iminophosphorane ligands are strong
-donors, and this is expected to lead to an increase in the ligand field strength, which, in turn,
decreases the probability for the thermal population of non-emissive d-d states. Importantly, for
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all complexes, the energy of the excitation and emission bands are potentially of suitable
wavelengths for cellular distribution studies.7
The luminescence properties of the compounds in DMSO solution was also studied over
time. As expected, the most stable cyclometalated palladium and platinum compounds in DMSO
solution (6, 7) and ligand 1 did not change their luminescence significantly over time. Figure 2
shows the change of the luminescence properties of compound 6 in DSMO solution at room
temperature over 24 hour period time. The other figures are collected in the Appendix.

380
368
402

Intensity (a. u.)

487

t0
t8
t24

341

294

250 300 350 400 450 500 550 600 650 700

Wavelength (nm)

Figure 2. Study of the luminescence of compound 6 in DMSO solution 5 x 10-4 M at RT over
time (24 hours).

In the case of coordination Au(III) complexes, 2 and 3, and coordination Pd(II) complex,
4, the study of the luminescence overtime affords results that are in agreement with the stability
of these compounds in DMSO solution. As mentioned before, 2 and 3 decompose (with halflives of ca. 4 (2) and 6 (3) hours in DMSO-d6) to phosphane oxide (Ph3P=O) and the
coordination Au(III) compound [Au(N-8-C9H7N)-κ-N,N)Cl2]. Compound 2 shows a shift of the
emission band at 513 nm to lower wavelength (473 nm) in concomitance to the appearance of
two new bands of lower intensity at 634 and 683 nm after 3.5 hours.
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The spectrum is identical 24 hours later and therefore it may correspond to that of
decomposition product [Au(N-8-C9H7N)-κ-N,N)Cl2]. Compound 3 is slightly more stable and
the change in intensity and position of the bands to give spectra identical to that of 2 over time
occurs 8 hours later. Coordination Pd(II) complex 4 shows a shift of the emission band at 496 nm
to lower wavelength (486 nm), which corresponds to that of the endo cyclometalated species 6
decomposition product.
The study of the luminescence of compound 7 in a mixture DMSO:H2O (50:50) was
carried out and a broad emission band at 669 nm was observed, which is similar to that obtained
for 7 in DMSO (see Figure 25 in the Appendix). However, the spectrum was completely
different after 6 h, showing two broad emission bands at 430 and 630 nm, which may correspond
to decomposition products. NMR studies of solutions of mixtures of 7 in DMSO:H2O close to
1:1 ratio showed decomposition to different products over time including most plausibly
cyclometalated species 7 with a Cl displaced by DMSO and hydrolysed species. Importantly, the
solutions containing these products are still luminescent after 24 hours and their excitation and
emission bands are of suitable wavelengths for intramolecular cellular distributions studies.
These preliminary luminescence studies support the idea to select the most intense
compounds 3 and 7 as candidates for further intramolecular cellular distribution studies by
fluorescence microscopy.

3.4. Antiproliferative studies

These studies were performed by Dr. Angela Casini and Andreia de Almeida at the University of
Groningen, the Netherlands.

The antiproliferative properties of ligand 1 and metallic complexes 2-7 were assayed by
monitoring their ability to inhibit cell growth using the MTT assay. The cytotoxic activity of the
compounds was determined as described in the Experimental Section in the human ovarian
cancer A2780 cell line, and in the human lung cancer cell line A549, in comparison to cisplatin.
The results are summarized in Table 3. Ligand 1 and its PPh3-based decomposition product
(Ph3P=O) are not cytotoxic in all tested cell lines. The coordination complexes 2 (Au(III)) and 5
(Pt(II)) and cyclometalated monometallic Pt(II) complex 7 are as cytotoxic or more cytotoxic
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than cisplatin toward the A2780 cell line (low micromolar range). However, these compounds
are poorly selective, being very cytotoxic also towards the non-tumorigenic HEK-293T cell line.
The selectivity towards the A2780 cells is more pronounced for the coordination and
cyclometalated Pd(II) compounds 4 and 6. Most compounds are poorly cytotoxic towards the
human lung cancer cell line A459, with the exception of the cyclometalated monometallic Pt(II)
compound 7 which is ca. 3-fold more cytotoxic than cisplatin. However 7 is quite toxic to HEK293T cell lines as well.

Table 3. IC50 (µM) of ligand 1, PPh3 oxide and metal complexes 2-7, and cisplatin in human cell
lines.a
A2780

A549

HEK-293T

Ph3P=O

> 100

> 100

> 100

1

> 100

> 100

> 100

2*

6.35 ± 0.69

25.1 ± 3.8

21.6 ± 5.1

4

11.0 ± 1.5

62.5 ± 3.7

53.5 ± 10.4

5

3.33 ± 0.14

19.5 ± 6.5

10.8 ± 0.8

6

13.2 ± 2.1

86.5 ± 2.5

66.0 ± 5.5

7

3.56 ± 0.70

4.60 ± 0.50

2.64 ± 0.87

Cisplatin

3.90 ± 1.80

8.0 ± 0.5

11.0 ± 2.9

a

MTT assay (see experimental). All compounds were dissolved in 1% of DMSO and diluted with
water before addition to cell culture medium for a 72 h incubation period. Cisplatin was
dissolved in H2O. bSince the biological activity of cationic iminophosphorane gold compounds is
due to the cation, 2 was used to evaluate the biological activity of compounds 2 and 3 with
identical cations.

Studies of intracellular distribution on A2780 cells were attempted with selected
compounds (e.g. 3, and 7) using fluorescence microscopy, but unfortunately, and in spite of the
different conditions tested (different compounds’ concentrations and incubation time with cells),
it was impossible to observe any fluorescence.
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3.5. Interaction with plasmid (pBR322) DNA

The key role of DNA in cell replication makes this biomolecule one of the most
interesting targets in cancer chemotherapy. It is known that most cytotoxic platinum drugs can
form strong covalent bonds with the DNA bases.28 However, a variety of platinum compounds
act as DNA intercalators upon coordination to the appropriate ancillary ligands, while most
gold(III) compounds display reduced affinity for DNA.29,30 There are also reports of palladium
derivatives interacting with DNA in covalent31,32 and non-covalent ways.33,34 Conversely, most
gold-based compounds do not display strong interaction with DNA.35,36 Therefore, agarose gel
electrophoresis studies were performed to unravel the effects of compounds 2-7 on plasmid
(pBR322) DNA (Figure 3).

Figure 3. Electrophoresis mobility shift assays for cisplatin and compounds 2-7 (see
Experimental Section for details). DNA refers to untreated plasmid pBR322. A, B, C and D
correspond to metal/DNAbp ratios of 0.25, 0.5, 1.0 and 2.0 respectively.
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Plasmid (pBR322) DNA has two main forms: OC (open circular or relaxed form, Form
II) and CCC (covalently closed circular or supercoiled form, Form I). Generally, the larger the
retardation of supercoiled DNA (CCC, Form I), the greater the DNA unwinding produced by the
drug.37,38 Changes in electrophoretic mobility of both forms are usually taken as evidence of
direct metal-DNA interactions, such as covalently binding the drug to DNA. Binding of cisplatin
to plasmid DNA, for instance, results in a decrease in mobility of the CCC form and an increase
in mobility if the OC form (lanes A-D for cisplatin, Figure 3).
Treatment of plasmid (pBR322) DNA with increasing amounts of compounds 3-7 do not
affect the mobility of the faster-running supercoiled form (Form I or CCC) at ratios up to 1.0
metal/DNAbp. In the case of the coordination compounds of gold(III) (3) and platinum(II) (5), at
the highest ratio of 2.0 metal/DNAbp, there is retardation of the faster-running supercoiled form
(CCC). It can be, however, concluded that these complexes have no (4, 6, 7) or weak interaction
(3, 5) with plasmid (pBR322) DNA.
On the other hand, the coordination gold(III) compound 2 modifies the electrophoretic
mobility and the retardation of the faster-running supercoiled form (CCC) in the same way as
described previously for other coordination gold(III) compounds containing iminophosphorane
ligands.11 This is due to the poor or lack of stability of these complexes in DMSO/buffer
solutions that causes a cleavage of the P=N from the IM ligand, subsequently decomposing the
Au(III)-IM complex into Ph3P=O and cytotoxic square-planar gold(III) compounds,11 which are
known to intercalate in DNA. Compound 3 is slightly more stable than 2 in solution and
therefore this effect is less noticeable. However, oxidative damage of the DNA produced by the
metal center cannot be ruled out. The rest of compounds which are more stable (coordination and
cyclometalated compounds of palladium(II) and platinum(II) have no or a weak interaction with
plasmid (pBR322) DNA. It has been established to be the case for some coordination and
organometallic compounds of gold(III) and organometallic derivatives of palladium(II)
containing iminophosphorane ligands.11,14,16,39 Moreover, coordination iminophosphorane
complexes of palladium and platinum have displayed interactions with DNA stronger but of a
different nature that those exerted by cisplatin.11,14
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3.6. Interaction with human serum albumin (HSA)

Human serum albumin (HSA) is the most abundant carrier protein in plasma, making
about 60% of the total serum protein concentration. The main function of HSA include
maintaining osmotic blood pressure, serving as a depot protein, and transporting diverse
endogenous and exogenous ligands including fatty acids, bilirubin, drug molecules and metal
ions.40 Furthermore, HSA is able to bind a variety of substrates including metal cations,
hormones and most therapeutic drugs. It has been demonstrated that the distribution, the free
concentration and the metabolism of various drugs can be significantly altered as a result of their
binding to the protein.41 HSA possesses three fluorophores, these being tryptophan (Trp),
tyrosine (Tyr) and phenylalanine (Phe) residues, with Trp214 being the major contributor to the
intrinsic fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding
of substrates, as well as changes in conformation that can result in quenching (either dynamic or
static).
We recorded the fluorescence spectra of HSA in the presence of increasing amounts of
compounds 2-7 and cisplatin in the range of 300-450 nm upon excitation of the tryptophan
residue at 295 nm (Figure 4). The compounds caused a concentration dependent quenching of
fluorescence without changing the emission maximum or shape of the peaks, as seen in Figure 4
(A) for compound 3. Quenching measurements are a valuable source to reveal the accessibility
of fluorophores to quenchers since a decrease in intensity at a specific wavelength is observed in
emission spectra upon quencher addition. However, there are a number of quenching
mechanisms that are available. By the addition of other molecules, excited fluorophores
experience energy loss due to collision between molecules. In the case of collisional (dynamic)
quenching, the quencher must diffuse to the fluorophores and contact the excited fluorophore
physically, which returns to the ground state after the energy of the excitation previously
absorbed is taken away by the quencher. When the quencher binds to a fluorescent molecule,
quenching due to the ground-state complex formation between two molecules occurs. For that
reason, static quenching is a valuable source of information about the binding between the
fluorescence molecule and the quencher.40
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The fluorescence data were analyzed by the Stern-Volmer equation. While a linear SternVolmer plot is indicative of a single quenching mechanism, either dynamic or static, the positive
deviation observed in the plots of F0/F versus [Q] of our compounds (Figure 4) suggests the
presence of different binding sites in the protein.42 Of note, a similar behaviour was observed in
the case of some coordination and organometallic iminophosphorane complexes of d8 metals for
which it was also reported as concentration dependent fluorescence quenching.14,16 In this graph
higher quenching by the iminophosphorane complexes was observed compared to that of
cisplatin under the chosen conditions and without changing the emission maximum or shape of
the peaks.
In the case of [MCl2(PTA=N-C(O)-2-NC5H4)] (M = Pd, Pt) isothermal titration
calorimetry (ITC)16 showed two different binding interactions which explained the lack of
linearity observed in the fluorescence quenching studies, as the Stern-Volmer method assumes
all binding sites to be equivalent. We believe that a similar binding takes place for the
iminophosphorane compounds described here.

Figure 4. (A) Fluorescence titration curve of HSA with compound 3. Arrow indicates the
increase of quencher concentration. (B) Stern-Volmer plot for HSA fluorescence quenching
observed with compounds 2-7 and cisplatin.
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3.7. Conclusions

In conclusion we have prepared a series of luminescent iminophosphorane complexes of
gold(III), palladium(II) and platinum(II) derived from 8-aminoquinoline. The coordination
palladium(II) and platinum(II) compounds can evolve further, under appropriate conditions, to
give stable cyclometalated endo species [M{κ3-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] (M = Pd, Pt)
by C-H activation of the phenyl group of the PPh3 fragment. All the compounds exhibit
important cytotoxic effects in the low micromolar range in a human ovarian cancer cell line
(A2780S), and in particular the Pd(II) derivatives (monometallic coordination 4 and
cyclopaladated 6) show promising selectivity being poorly toxic for the non-tumorigenic human
embryonic kidney cell line (HEK-293T).
Studies of the interactions of the compounds with plasmid (pBR322) DNA indicate that,
unless they lose the IM skeleton in solution, they have none or little interaction with DNA
supporting the idea of different mechanisms of action than cisplatin. The complexes display a
concentration dependent fluorescence quenching of HSA which has been correlated to a faster
binding of our compounds with HSA compared to cisplatin.
Even though the luminescence properties of the compounds did not allow for the
detection inside the cells via fluorescence microscopy, these results will allow us to design new
IM complexes in order to achieve better stability in biological media and to increase the
fluorescence detection limits. More particularly, the focus will be on the synthesis of
cyclometalated IM derivatives containing luminescent phosphines.

3.8. Experimental section

Materials and methods

All manipulations involving air-free syntheses were performed at an nitrogen vacuum manifold
using standard Schlenk-line techniques under an argon atmosphere or in a glove-box MBraun
MOD System. Solvents were purified by use of a PureSolv purification unit from Innovative
Technology, Inc. The phosphine substrate PPh3 was purchased from Sigma-Aldrich, K[AuCl4],
AgClO4, [PdCl2(COD)], Pd(OAc)2 and PtCl2 were purchased from Strem chemicals and used
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without further purification. The purity of the compounds, based on elemental analysis, is
≥99.5%. NMR spectra were recorded in a Bruker AV400 (1H NMR at 400 MHz,
100.6 MHz, 31P NMR at 161.9 MHz,

195

13

C NMR at

Pt NMR at 85.8 MHz). Chemical shifts (δ) are given in

ppm using CD3CN, CDCl3, DMSO-d6 or D2O as solvents. 1H and 13C resonances were measured
relative to solvent peaks considering TMS = 0 ppm. 31P{1H} was externally referenced to H3PO4
(85%) and 195Pt{1H} was referenced to [PtCl6]2-. Infrared spectra (4000-250 cm-1) were recorded
on a Nicolet 6700 FT-IR spectrophotometer from nujol mulls between polyethylene sheets.
Elemental analyses were performed on a Perkin Elmer 2400 CHNS/O Analyzer, Series II. Mass
spectra (ESI) were performed on an Agilent Analyzer and on a Bruker Analyzer. Conductivity
was measured in an OAKTON PC 700 pH/conductivity meter in acetone solution.
Electrophoresis experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal
electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the
gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity
measurements were carried out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham,
NJ) with right angle detection of fluorescence using a 1 cm path length quartz cuvette.

Synthesis of 1
Ph3P=N-8-C9H6N
An alternative method of synthesis was used: a solution of PPh3 (2.59 mmol) in CH2Cl2 was
added dropwise to a solution of 8-Azidoquinoline9 (2.59 mmol) in CH2Cl2 at RT and allowed to
react for 1 h. The solvent was reduced in vacuo to 2 mL and Et2O (10 mL) was added. A paleyellow solid precipitated and was filtered off and dried in vacuo. 1 was used without further
purification. Yield: 0.857 g, 82%.
Synthesis of 2 and 3
[Au(Ph3P=N-8-C9H6N)-κ-N,N)Cl2]X [X = PF6- (2); ClO4- (3)]
To K[AuCl4] (0.076 g, 0.2 mmol) in dry MeCN (10 mL), AgClO4 (0.091 g, 0.44 mmol) for the
obtention of 2 or AgPF6 (0.111 g, 0.44 mmol) for the obtention of 3 in dry CH3CN (5 mL) was
added. The reaction mixture was stirred in the darkness for 30 min and subsequently filtered
through celite (to remove AgCl). 1 (0.081g, 0.2 mmol) in CH2Cl2 (1 mL) was added and the
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yellow solutions became purple instantly. After stirring for 30 min the reaction mixture was
filtered through celite (to remove KClO4) and then the solvent was reduced in vacuo to ~2 mL.
Upon addition of Et2O (10 mL), a purple solid was obtained, which was washed with CH3CN
(<1 mL at a time) and Et2O and dried in vacuo.
2: Yield: 0.1198 g, 73%. Anal. Calcd. for C27H21AuCl2F6N2P2 (817.28): C, 39.68; H, 2.59; N,
3.43. Found: C, 39.21; H, 2.36; N, 3.21. MS(ESI+) [m/z]: 671.0 [M - PF6]+.
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P{1H} NMR

(CD3CN): δ 39.6 (s), -142.5 (sept, PF6-). 1H NMR (CD3CN): δ 6.66 (1H, d, J = 7.8 Hz, H7), 7.15
(1H, t, J = 8.0 Hz, H6), 7.62 (1H, d, J = 8. 2 Hz, H5), 7.62-7.82 (9H, m, Hpara + Hmeta), 8.04 (1H,
dd, J = 8.3, 5.7 Hz, H3), 8.13 (6H, dd, J = 12.6, 7.6 Hz, Hortho), 8.85 (1H, d, J = 8.3 Hz, H4), 9.44
(1H, d, J = 5.6 Hz, H2). 13C{1H} NMR (CD3CN): δ 121.6 (s, C9H6N), 122.6 (s, C9H6N), 122.9
(d, J = 5.0 Hz, C7), 123.6 (s, C5), 123.9 (s, C3), 128.8 (s, C6), 128.9 (d, J = 13.3 Hz, Cmeta), 131.4
(s, Cipso), 134.2 (d, J = 10.6 Hz, Cortho), 135.1 (d, J = 3.0 Hz, Cpara), 144.4 (s, C4), 146.1 (s,
CN=P), 148.4 (s, C2). IR (cm-1):  370 (Au-Cl), 838 (v br, PF6-), 1266 (P=N). Conductivity
(acetone):  = 110 µS/cm.

3: Yield: 0.109 g, 69%. Anal. Calcd. for C27H21AuCl3N2O4P (771.77): C, 42.02; H, 2.74; N,
3.63. Found: C, 42.08; H, 2.96; N, 3.66. MS(ESI+) [m/z]: 671.1 [M - ClO4]+.
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P{1H} NMR

(CD3CN): δ 39.6 (s). 1H NMR (CD3CN): δ 6.48 (1H, d, J = 7.7 Hz, H7), 7.06 (1H, t, J = 8.0 Hz,
H6), 7.49 (1H, d, J = 8.1 Hz, H5), 7.62-7.82 (9H, m, Hpara + Hmeta), 7.93 (1H, dd, J = 8.0, 5.6 Hz,
H3), 8.16 (6H, dd, J = 12.6, 7.6 Hz, Hortho), 8.67 (1H, d, J = 8.3 Hz, H4), 9.41 (1H, d, J = 5.3 Hz,
H2). 13C{1H} NMR (CD3CN): δ 121.5 (s, C9H6N), 122.4 (s, C9H6N), 122.6 (s, C7), 124.1 (s, C5),
124.2 (s, C3), 128.4 (s, C6), 130.2 (d, J = 13.3 Hz, Cmeta), 131.5 (s, Cipso), 134.1 (d, J = 10.5 Hz,
Cortho), 135.1 (d, J = 2.8 Hz, Cpara), 144.0 (s, C4), 145.8 (s, CN=P), 149.0 (s, C2). IR (cm-1):  368
(Au-Cl), 1083 (v, br) and 622 (ClO4-), 1267 (P=N). Conductivity (acetone):  = 128 µS/cm.

Synthesis of 4
[Pd((Ph3P=N-8-C9H6N)-κ-N,N)Cl2]
[PdCl2(COD)] (0.041 g, 0.15 mmol) and 1 (0.042 g, 0.15 mmol) were dissolved in dry and
degassed CH2Cl2 (4 mL) and left to react for 3 h at room temperature after which an orange
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precipitate had formed. The solvent was then reduced to a minimum in vacuo and upon addition
of Et2O a pale orange solid was obtained which was washed twice with CHCl3 and dried in
vacuo. Solution of 1 (0.081 g, 0.2 mmol) in CH2Cl2 was dropwise added to the a solution of
PdCl2(COD) (0.2 mmol) in CH2Cl2 while stirring at RT and allowed to react for 30 min. The
product was then concentrated under vacuum and precipitated with diethyl ether, producing a
light orange solid.

Yield: 0.098 g, 84%. Anal. Calcd. for C27H21Cl2N2PPd (581.77): C, 55.74; H, 3.64; N, 4.82.
Found: C, 55.38; H, 3.65; N, 4.90. MS(ESI+) 509.0 [M-Cl2]2+, 544.4 [M-Cl]+.31P{1H} NMR
(CDCl3): δ 30.0 (s). 1H NMR (CDCl3): δ 6.27 (1H, d, J = 7.8 Hz, H7), 6.88 (1H, t, J = 7.9 Hz,
H6), 7.13 (1H, d, J = 8.0 Hz, H5), 7.47 (1H, dd, J = 8.3, 5.2 Hz, H3), 7.58-7.65 (9H, m, Hpara +
Hmeta), 8.11-8.18 (6H, m, Hortho), 8.22 (1H, d, J = 8.3 Hz, H4), 9.26 (1H, dd, J = 5.2, 1.4 Hz, H2).
13

C{1H} NMR (CDCl3): δ 118.6 (s, C7), 118.7 (s, C5), 121.8 (s, C3), 125.2 (s, C9H6N), 126.2 (s,

C9H6N), 127.2 (s, C6), 129.0 (d, J = 12.9 Hz, Cmeta), 130.0 (s, Cipso), 133.2 (d, J = 3.0 Hz, Cpara),
133.8 (d, J = 9.8 Hz, Cortho), 138.2 (s, C4), 149.7 (s, CN=P), 150.2 (s, C2). IR (cm-1):  342 (PdCl), 1268 (P=N). Conductivity (acetone):  = 3.4 µS/cm.

Synthesis of 5
[Pt(Ph3P=N-8-C9H6N)-κ-N,N)Cl2]
A solution of 1 (0.1616 g, 0.4 mmol) in 20 mL of CH2Cl2 was added to a suspension of PtCl2
(0.1064 g, 0.4 mmol) in 15 mL and refluxed for 3 h. Upon completion a brown side-product was
filtered off and the resulting yellow solution was concentrated under vacuum. Upon addition of
diethyl ether, a bright yellow solid was obtained.

Yield: 0.1662 g, 62%. Anal. Calcd. for C27H21Cl2N2PPt (670.43): C, 48.37; H, 3.16; N, 4.18.
Found: C, 48.18; H, 3.14; N, 4.15. MS(ESI+) [m/z]: 635.1 [M - Cl]+.
31.3 (s).
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P{1H} NMR (CDCl3): δ

Pt{1H} NMR (CDCl3): δ -1930.3 (s). 1H NMR (CDCl3): δ 6.23 (1H, d, J = 7.9 Hz,

H7), 6.83 (1H, t, J = 7.9 Hz, H6), 7.11 (1H, d, J =8.0 Hz, H5), 7.46 (1H, t, J = 8.3 Hz, H3),
7.57-7.67 (9H, m, Hpara + Hmeta), 8.14 (6H, dd, J = 8.0, 8.2 Hz, Hortho), 8.30 (1H, d, J =8.1 Hz,
H4), 9.63 (1H, d, J = 5.0 Hz, H2). 13C{1H} NMR (CDCl3): δ 118.8 (d, J = 5.9 Hz, C7), 119.2 (s,
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C5), 122.1 (s, C3), 125.0 (s, C9H6N), 126.0 (s, C9H6N), 127.0 (s, C6), 129.0 (d, J = 12.6 Hz,
Cmeta), 130.2 (s, Cipso), 133.2 (d, J = 2.9 Hz, Cpara), 133.8 (d, J = 9.9 Hz, Cortho), 137.3 (s, C4),
148.6 (s, C2), 151.0 (s, CN=P). IR (cm-1):  341 (Pt-Cl), 1266 (P=N). Conductivity (acetone): 
= 1.2 µS/cm.

Synthesis of 6
3

[Pd{κ -C,N,N-C6H4(PPh2=N-8-C9H6N}Cl]
A solution of 1 (0.121 g, 0.3 mmol) in 20 mL of CH2Cl2 was added to Pd(OAc)2 (0.067 g, 0.3
mmol) in 10 mL CH2Cl2. The mixture was allowed react overnight (15 h) while stirring at RT.
Excess LiCl (0.020 g, 0.47 mmol) in CH3OH was then added and the mixture was left to react
for 30 min. Concentration under vacuum and precipitation with diethyl ether afforded an orange
solid.

Yield: 0.133 g, 81%. Anal. Calcd. for C27H20ClN2PPd (545.31): C, 59.47; H, 3.70; N, 5.14.
Found: C, 58.98; H, 3.72; N, 5.20. MS(ESI+) [m/z]: 544.4 [M], 509.3 [M - Cl]+. 31P{1H} NMR
(CDCl3): δ 43.4 (s). 1H NMR (CDCl3): δ 6.73 (1H, dd, J = 6.6, 1.7 Hz, H7), 6.90 (1H, ddd, J =
11.3, 7.7, 1.4 Hz, Hd), 7.05 (1H, ddd, J = 12.8, 7.4, 1.1 Hz, Hc), 7.14-7.20 (2H, m, H5 + H6), 7.26
(1H, t, J = 7.7 Hz, Hb), 7.45 (1H, dd, J = 8.3, 4.8 Hz, H3), 7.53-7.61 (4H, m, Hmeta), 7.65-7.61
(2H, m, Hpara), 7.91-7.99 (4H, m, Hortho), 8.17 (1H, dd, J = 8.3, 1.5 Hz, H4), 8.24 (1H, dd, J = 7.9,
1.6 Hz, Ha), 9.19 (1H, dd, J = 4.7, 1.6 Hz, H2). 13C{1H} NMR (CDCl3): δ 115.7 (d, J = 7.9 Hz,
C7), 117.2 (s, C5 + C6), 121.9 (s, C3), 124.6 (d, J = 15.6 Hz, Cd), 125.5 (s, C9H6N), 126.4 (s,
C9H6N), 127.4 (s, C5 + C6), 128.8 (d, J = 4.7 Hz, Cc), 129.4 (d, J = 11.9 Hz, Cmeta), 130.7 (s,
Cipso), 131.3 (d, J = 3.1 Hz, Cb), 133.1 (d, J = 10.4 Hz, Cortho), 133.6 (d, J = 2.8 Hz, Cpara), 137.7
(s, C4), 138. 6 (d, J = 14.7 Hz, Ca), 143.5 (d, J = 144.7 Hz, Ce, C-P), 147.2 (s, CN=P), 148.4 (s,
C2), 154.5 (d, J = 19.1 Hz, Cf, C-Pd). IR (cm-1):  307 (Pd-Cl), 1285 (P=N). Conductivity
(acetone):  = 30.5 µS/cm
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Synthesis of 7
[Pt{κ3-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl]
The coordination platinum(II) complex 5 (0.167 g, 0.25 mmol) was dissolved in CH2Cl2 and the
resulting solution refluxed for 3 days. After cooling at RT, the solution was concentrated under
vacuum and 20 mL of diethyl ether were added. A yellow solid precipitated (7) which was
filtered off, dried in vacuo and used without further purification.
Yield: 0.1353 g, 87%. Anal. Calcd. for C27H20ClN2PPt  H2O (651.08): C, 49.74; H, 3.40; N,
4.30. Found: C, 49.77; H, 3.37; N, 4.20. MS (ESI+) [m/z]: 634.08 [M+H]+.
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P{1H} NMR

(CDCl3): δ 44.7 (s, 2JPt-P = 426 Hz). 195Pt{1H} NMR (CDCl3): δ -2899.69 (d, 2JP-Pt = 419 Hz). 1H
NMR (CDCl3): δ 6.74 (1H, t, J = 4.3 Hz, H7), 6.93 (1H, dd, J = 11.7, 7.6 Hz, Hd), 7.06 (1H, dd, J
= 13.4, 6.9 Hz, Hc), 7.14-7.20 (2H, m, H5 + H6), 7.31 (1H, dd, J = 7.6 Hz, Hb), 7.51 (1H, dd, J =
8.3, 4.8 Hz, H3), 7.55-7.60 (4H, m, Hmeta), 7.69 (2H, t, J = 7.2 Hz, Hpara), 7.95 (4H, dd, J = 12.3,
7.6 Hz, Hortho), 8.23-8.29 (2H, m, H4+Ha), 9.47 (1H, d, J = 4.3 Hz, H2). 13C{1H} NMR (CDCl3):
δ 116.1 (s, C7), 117.8 (s, C5 + C6), 122.1 (s, C3), 124.0 (d, J = 15.6 Hz, Cc), 125.2 (s, C9H6N),
126.0 (s, C9H6N), 127.5 (s, C5 + C6), 129.1 (d, J = 4.7 Hz, Cd), 129.5 (d, J = 12.2 Hz, Cmeta),
131.1 (d, J = 3.2 Hz, Cb), 131.3 (s, Cipso), 133.2 (d, J = 10.5 Hz, Cortho), 133.7 (d, J = 2.8 Hz,
Cpara), 137.1 (d, J = 13.8Hz, Ca), 137.6 (s, C4), 142.7 (d, J = 138.4 Hz, Ce, C-P), 147.4 (s, CN=P),
147.7 (s, C2), signal corresponding to C-Pt (Cf) not observable. IR (cm-1):  319 (Pt-Cl), 1286
(P=N). Conductivity (acetone):  = 5.7 µS/cm.

Luminescence Studies

Absorption spectra in solution were recorded with a Unicam UV-4 spectrophotometer. Steadystate photoluminescence spectra were recorded with a Jobin-Yvon Horiba Fluorolog FL-3-11
spectrofluorimeter using band pathways of 3 nm for both excitation and emission.
Phosphorescence lifetimes were recorded with a Fluoromax phosphorimeter accessory
containing a UV xenon flash tube at a flash rate between 0.05 and 25 Hz. The lifetime data were
fit using the Jobin-Yvon software package and the Origin 7.0 program.
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Cell culture and inhibition of cell growth

The human lung cancer cell line A549 and the human ovarian cancer cell line A2780 and the
human (obtained from the European Centre of Cell Cultures ECACC, Salisbury, UK) were
cultured in DMEM (Dulbecco’s Modified Eagle Medium) and RPMI, respectively, containing
GlutaMaxI supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen), at
37°C in a humidified atmosphere of 95% of air and 5% CO2 (Heraeus, Germany). Non-tumoral
human embryonic kidney cells HEK293 were kindly provided by Dr. Maria Pia Rigobello
(CNRS, Padova, Italy), and were cultivated in DMEM medium, added with GlutaMaxI
(containing 10% FBS and 1% penicillin/streptomycin (all from Invitrogen) and incubated at
37°C and 5% CO2. For evaluation of growth inhibition, cells were seeded in 96-well plates
(Costar, Integra Biosciences, Cambridge, MA) and grown for 24 h in complete medium.
Solutions of the compounds were prepared by diluting a freshly prepared stock solution (in
DMSO) of the corresponding compound in aqueous media. Afterwards, the intermediate
dilutions of the compounds were added to the wells (100 L) to obtain a final concentration
ranging from 0 to 150 M, and the cells were incubated for 72 h. DMSO at comparable
concentrations did not show any effects on cell cytotoxicity. Following 72 h drug exposure, 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to the cells at a
final concentration of 0.25 mg ml-1 incubated for 2 h, then the culture medium was removed and
the violet formazan (artificial chromogenic precipitate of the reduction of tetrazolium salts by
dehydrogenases and reductases) dissolved in DMSO. The optical density of each well (96-well
plates) was quantified three times in tetraplicates at 540 nm using a multiwell plate reader, and
the percentage of surviving cells was calculated from the ratio of absorbance of treated to
untreated cells. The IC50 value was calculated as the concentration reducing the proliferation of
the cells by 50% and is presented as a mean (± SE) of at least three independent experiments.
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Interaction of of compounds 2-7 and cisplatin with plasmid (pBR322) DNA by
Electrophoresis
(Shift Mobility Assay)

10 µL aliquots of pBR322 plasmid DNA (20 µg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO4,
pH = 7.39) were incubated with molar ratios between 0.25 and 2.0 of the compounds at 37 oC for
20 h in the darkness. Samples of free DNA and cisplatin-DNA adduct were prepared also as
controls. After the incubation period, 2 µL of loading dye were added to the samples and of these
mixtures, only 7 µL were finally loaded into the gel. The samples were separated by
electrophoresis in 1%(w/v) agarose gel for 1.5 h at 84 V in Tris-acetate/EDTA buffer (TAE).
Afterwards, the gel was dyed for 30 min with a solution of GelRed Nucleic Acid stain.

Interaction of metal complexes with HSA by Fluorescence Spectroscopy

The excitation wavelength was adjusted at 295 nm, and the emission spectra were recorded at
room temperature in the range of 300 to 450 nm. The fluorescence intensities of the new
compounds, the buffer and the DMSO are negligible under these conditions, and so is the effect
of additions of pure DMSO to the fluorescence of HSA. An 8 mM solution of each compound in
DMSO was prepared and ten aliquots of 2.5 µL were added successively to a solution of HSA
(10 µM) in phosphate buffer (pH = 7.39), the fluorescence being measured after each addition.
The data was analyzed using the classical Stern-Volmer equation
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3.9. Appendix

Table with the crystal data and structure refinement for complexes 3 and 4, luminescence
profiles and studies of the luminescence overtime in solution for ligand 1 and compounds 27; Stability of compounds 2-7 in DMSO-d6 solution overtime by 31P{1H} NMR spectroscopy.

3.9.1. Crystallographic Data for Compounds 3 and 4.

Single crystals of 3a and 3d (see details below) were mounted on a glass fiber in a random
orientation. Data collection was performed at room temperature on a Kappa CCD diffractometer
using graphite monochromated Mo-Ka radiation (l=0.71073 Å). Space group assignments were
based on systematic absences, E statistics and successful refinement of the structures. The
structures were solved by direct methods with the aid of successive difference Fourier maps and
were refined using the SHELXTL 6.1 software package. All non-hydrogen atoms were refined
anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding
model. Details of the crystallographic data are given in Table S1 (below). These data can be
obtained

free

of

charge

from

The

Cambridge

Crystallographic

Data

Center

via

www.ccdc.cam.ac.uk/data_request/cif. (CCDC 977990 for compound 3, and 977991 for
compound 4).

3: Crystals of 3 (purple prisms with approximate dimensions 0.25 x 0.23 x 0.23mm) were
obtained from a solution of 3 in CH3CN by slow diffusion of Et2O at RT. 4: Crystals of 4 (orange
prisms with approximate dimensions 0.25 x 0.24 x 0.22mm) were obtained from a solution of 4
in CH2Cl2 by slow diffusion of Et2O at RT.
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Table 4. Crystal Data and Structure Refinement for Complexes 3 and 4.
Compound
formula

3
C27H20Cl2N2PAu. CH3COCH3. ClO4-

4
C27H21Cl2N2PPd.3CHCl3

fw

828.81

939.83

T [K]

293(2)

293(2)

0.71073

0.71073

crystal system

Triclinic

Orthorombic

space group

P-1

P2(1)2(1)2(1)

a [Å]

7.894(5)

19.497(4)

b [Å]

15.290(5)

10.517(2)

c [Å]

25.892(5)

18.232(4)

α [o]

90.028(5)

90

β [o]

90.039(5)

90

γ [o]

90.581(5)

90

V [Å]3

3125(2)

3738.5(13)

Z

4

4

Dcalcd (g cm-3)

1.762

1.670

µ (mm-1)

5.057

1.351

GOF

1.053

1.060

R1[I>2σ]

0.0512

0.0483

wR2(all data)

0.1509

0.1343



(MoKα)[Å]
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3.9.2. Luminescence Studies for Ligand 1 and compounds 2-7.

Ph3P=N-8-C9H6N (1)
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258
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Figure 5. Absorption spectra of ligand 1 and gold compounds 2 and 3 in DMSO solution (5 x 104
M) at RT.
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Figure 6. Absorption spectra of ligand 1 and palladium compounds 4 and 6 in DMSO solution (5
x 10-4 M) at RT.
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Ph3P=N-8-C9H6N (1)
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Figure 7. Absorption spectra of ligand 1 and platinum compounds 5 and 7 in DMSO solution (5
x 10-4 M) at RT.
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Figure 8. Excitation (blue) and emission (red) spectra of compound 1 in DMSO solution (5 x
10-4 M) at RT.

59

336 368 407

t0
t3
t8
t24

Intensity (a. u.)

296

521

250 300 350 400 450 500 550 600 650 700 750 800

Wavelength (nm)

Figure 9. Luminescence of compound 1 in DMSO solution (5 x 10-4 M) at RT over time (24 h).
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Figure 10. Excitation (blue) and emission (red) spectra of compound 2 in DMSO solution (5 x
10-4 M) at RT.
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Figure 11. Luminescence of compound 2 in DMSO solution (5 x 10-4 M) at RT over time (24 h).
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Figure 12. Excitation (blue) and emission (red) spectra of compound 3 in DMSO solution (5 x
10-4 M) at RT.

61

371
345
332
289

t0
t3
t8
t24

402

Intensity (a. u.)

522

398

296

471

632 682

250 300 350 400 450 500 550 600 650 700 750 800

Wavelength (nm)

Figure 13. Luminescence of compound 3 in DMSO solution (5 x 10-4 M) at RT over time (24 h).
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Figure 14. Excitation (blue) and emission (red) spectra of compound 4 in DMSO solution (5 x
10-4 M) at RT.
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Figure 15. Luminescence of compound 4 in DMSO solution (5 x 10-4 M) at RT over time (24 h).
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Figure 16. Excitation (blue and green) and emission (red) spectra of compound 5 in DMSO
solution (5 x 10-4 M) at RT.
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Figure 17. Excitation (blue) and emission (red) spectra of compound 5 in DMSO solution (5 x
10-4 M) at RT immediately after the first measurement of luminescence.
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Figure 18. Excitation (blue) and emission (red) spectra of compound 6 in DMSO solution (5 x
10-4 M) at RT.
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Figure 19. Luminescence of compound 6 in DMSO solution (5 x 10-4 M) at RT over time (24 h).

373

1,0

440

645

677

348

702

Intensity (a. u.)

0,8
0,6
0,4
0,2
0,0
300 350 400 450 500 550 600 650 700 750 800 850

Wavelength (nm)

Figure 20. Excitation (blue) and emission (red) spectra of compound 7 in DMSO solution (5 x
10-4 M) at RT.
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Figure 21. Luminescence of compound 7 in DMSO solution (5 x 10-4 M) at RT over time (24 h).
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Figure 22. Excitation (blue) and emission (red) spectra of compound 7 in DMSO:H2O (50:50)
solution (5 x 10-4 M) at RT.
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Figure 23. Luminescence of compound 7 in DMSO:H2O (50:50) solution (5 x 10-4 M) at RT
over time (24h).

3.9.3. Stability of compounds 2-7 in DMSO-d6 solution overtime assessed by 31P{1H} NMR
spectroscopy. Selected 31P{1H} NMR spectra for compounds 4 and 7.

Compound

Time (DMSO-d6)
4h

1d

2d

4d

1w

2w

Half life (50%)

2

53%

13%

0%

4h

3

73%

31%

0%

6h

4

4%

0%

5

41%

9%

6

>99%

>99% >99% >99%

>99%

>99%

weeks

7

>99%

>99% >99% >99%

>99%

>99%

weeks

1.5 h
9%

9%

2h

% of decomposition of initial compound determined by integration of all the signals appearing in
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Figure 24. Conversion of coordination palladium compound [Pd((Ph3P=N-8-C9H6N)-κ-N,N)Cl2]
4 (δ = 30.0 ppm) into cyclometalated [Pd{κ3-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl] 6 (δ = 44.6
ppm) in DMSO-d6 solution over time. Small peak at δ = 29.4 ppm corresponds to Ph3P=O.

Figure 25. Study of the stability of cycloplatinated compound [Pt{κ3-C,N,N-C6H4(PPh2=N-8C9H6N}Cl] 7 ((δ = 45.2 ppm) by 31P{1H} NMR spectroscopy in DMSO-d6 solution over time.
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CHAPTER IV

SYNTHESIS OF CYCLOMETALLATED IMINOPHOSPHORANE
GOLD(III) AND PLATINUM(II) COMPLEXES. IN VITRO
EVALUATION. PERMEABILITY AND PRELIMINARY
MECHANISTIC STUDIES.
_________________________________________________

4.1. Cyclometallated gold(III) and platinum(II) compounds as potential anticancer agents

From the various strategies and approaches that have been employed in the search of
more effective and selective potential anticancer metallodrugs,1 organometallic compounds have
emerged as attractive candidates.2 It has been reported that organometallic platinum compounds
perform better than non-organometallic derivatives.3 Overall, organometallic compounds are
more stable in physiological environments and more lipophilic than coordination metal
complexes, which allows for the design of anticancer metallodrugs with improved properties.2 In
the last five years, several reviews on the anticancer activity of organometallic compounds of
different transition metals have appeared in the literature.2,4-15
In particular, gold(III)1,5 and platinum(II)1,3,16-18 organometallic compounds have been
studied as potential anticancer agents. A number of complexes containing the [Pt(COD)]
fragment and different ligands, such as alkyls, alkynyls, an nucleosides have been recently
described.19-21 Platinum COD alkynyl compounds showed high toxicity against HT-29 colon
carcinoma and MCF-7 breast adenocarcinoma cell lines22,23 while [PtMe(R-COD)L]
compounds24 with different ligands (halides, alkyl, aryl, alkynyl) revealed higher toxicity to
HeLa cells in comparison to that of cisplatin. In the case of gold(III), it is well known that pincer
ligands containing carbon- and nitrogen-ligands stabilize the metal center against reduction to
gold(I) and gold(0) species in physiological media.25 Some cyclometallated gold(III)
complexes26-28 based on C-N-N and C-N-C pincer complexes have displayed notable anticancer
activity in vitro and in vivo by a mode of action different than that of cisplatin. The presence of
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the σ(M-C) bond in these complexes, potentially increases the stability allowing the
organometallic fragment to reach the cell unaltered. Additionally, for platinum-based compounds
the presence of aromatic groups in the cyclometallated ligand might favor intercalative binding
to DNA (π-π stacking), while the labile positions in the coordination sphere of the metal may
favor covalent coordination to DNA (similar to that for cisplatin). Very recently, a luminescent
DNA

intercalator

cyclometallated

platinum(II)

complex,

[Pt(C^N^N)(C-NtBu)]ClO4

(HC^N^N=6-phenyl-2,2’-bipyridyl) with a potent inhibitory effect in human cancer cells in vitro
and in a xenograft model in mice has been described.29 The stabilization of the topoisomerase I–
DNA complex with resulting DNA damage by the cyclometallated compound is suggested to
contribute to its anticancer activity.

Chart 1. Possible cyclometallation positions in organometallic iminophosphorane derivatives.

Iminophosphorane ligands can be cyclometallated at different positions generating stable
organometallic compounds containing pincer C,N- and C,N,N- ligands.30-32 Urriolabeitia and coworkers described cyclometallation processes for palladium(II) compounds for which exo or
endo products could be obtained depending on the ligand, the solvent and the temperature
employed. Endo derivatives are those generated by C-H activation of an aryl group (H in ortho to
the phosphorous atom) in the phosphine fragment of the R3P=NR iminophosphorane moiety (see
74

Chart 1). Exo derivatives are those generated by C-H activation on an aryl group contained in the
imino or amido fragment of the IM ligand. Additionally, organometallic exo compounds can be
prepared by exchange of a bromine or chlorine atom by a metal in the imino or amido fragment
of the iminophosphorane. By modification of synthetic conditions and choice of appropriate
ligands we can potentially prepare exo or endo cyclometallated complexes. Most endo
derivatives involve the use of semi-stabilized IM ligands (Chart 1). This synthetic route limits
the use of phosphines to those containing at least one aryl group. This becomes important if we
want to use alternative phosphines in order to improve the hydrophilicity of the final product or
to tune electronic/steric properties. On the other hand, the preparation of exo derivatives allows
for the use of a variety of different phosphines. The best substrates for this purpose are stabilized
iminophosphoranes containing CO or -CH2- between the aryl group to be metallated in the ortho
position and the N=PR3 fragment31 (Chart 1).

Chart 2. Endo gold(III) and exo palladium(II) complexes previously prepared in our group.33,34

As mentioned in the introduction, our group prepared endo cyclometallated compounds
of gold(III) with the IM ligand Ph3P=NPh.33,35 In the previous chapter we also described
cyclometallation processes happening at high or room temperature in polar solvents with the
ligand PPh3=N-8-C9H6N to afford endo derivatives of palladium(II) and platinum(II) in which
75

the iminophosphorane moiety behaved as a C,N,N- pincer ligand.31 In order to obtain
organometallic compounds of palladium(II) in water, we synthesized an iminophosphorane
ligand (PTA=N-C(O)-2BrC6H4 (C,N-IM)) containing PTA. Exo palladium(II) complexes were
obtained by oxidative addition of a palladium(0) derivative on the C-Br bond (Chart 2).34 All our
studies with iminophosphorane metal compounds indicated that in most cases the
cyclometallated compounds were more stable in physiological media than coordination N,Ncompounds, and that they displayed relevant anticancer properties (especially cationic
compounds).33,35

Within this frame work, we aimed to prepare exo cyclometallated IM

compounds of gold(III) and platinum(II) in a systematic way in order to expand the range of
phosphines incorporated into the final molecule to tune the hydrophilicity and/or electronic/steric
properties of the resulting complexes.
This chapter reports on the synthesis of novel exo cyclometallated C,N-IM compounds of
gold(III) and platinum(II) containing the water-soluble phosphine PTA (1,3,5-Triaza-7phosphaadamantane) and the synthesis of endo C,N-IM compounds of platinum(II) derivatives
never described before. These metal-complexes along with previously described exo derivative
[Au(2-C6H4C(O)N=PPh3)Cl2] (1)36 and cisplatin have been evaluated against a number of human
cancer cell lines in vitro. We studied the interaction of these complexes with plasmid (pBR322)
DNA and HSA and the interaction of the platinum(II) compounds with Calf Thymus DNA by
circular dichroism. Initial cell death mechanistic insights of the most active compounds in cancer
cells are also described in this chapter. Additionally, the permeability of selected platinum(II)
compounds was evaluated by two different assays: in vitro caco-2 monolayers and rat perfusion
assay, in order to make comparisons with cisplatin and drugs or compounds that can be orally
administered.

4.2. Synthesis and characterization

The synthesis of the exo cyclometallated gold(III) and platinum(II) compounds was based
on the preparation of [Hg(Ph3P=N-CO-2-C6H4)Cl] by Nicholson et al.36 The C-H activation at
the N-CO-Ph fragments takes place at a manganese center and by transmetallation of the
resulting

cyclometallated

iminophosphorane

manganese

compounds

to

HgCl2,

the

organomercury derivatives with PPh3, [Hg(Ph3P=N-CO-2-C6H4)Cl],36 or water soluble
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phosphine PTA, [Hg(PTA=N-CO-2-C6H4)Cl]37 (whose synthesis and characterization will be
described in Chapter V) are obtained in high yields (Scheme 1).

Scheme 1. Previously described synthesis of organomercury compounds containing the semistabilized IM ligands PPh3=N-CO-2-C6H438 and PTA=N-CO-2-C6H437 which will be described
in Chapter V of this Thesis.

Transmetallation reactions of [Hg(PR3=N-CO-2-C6H4)Cl] (PR3 = PPh336; PTA37) with
NMe4[AuCl4]

or

[PtCl2(COD)]

afforded

previously

described

compound

[Au(2-

C6H4C(O)N=PPh3)Cl2] (1)36 and new cyclometallated exo iminophosphorane complexes of
gold(III) and platinum(II) of the type

[Au(2-C6H4C(O)N=PTA)Cl2] (2) and [Pt(2-

C6H4C(O)N=PTA)(COD)]2[Hg4Cl10] (3) (Scheme 2) in moderate to high yields.

Scheme 2. Synthesis of gold(III) and platinum (II) cyclometallated exo iminophosphorane
complexes. Compound [Au(2-C6H4C(O)N=PPh3)Cl2] (1) had been previously reported.36
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The reaction of [Hg(PPh3=N-CO-2-C6H4)Cl] with [PtCl2(COD)] did not afford a pure
cycloplatinated compound. Different synthetic conditions were tried and in most cases abundant
Pt(0) decomposition took place while unreacted [Hg(PPh3=N-CO-2-C6H4)Cl] and Ph3P=O were
the observed products along with free COD. Longer refluxing times in polar solvents afforded
small amounts (4-10%) of a possible cyclometallated product along with [Hg(PPh3=N-CO-2C6H4)Cl] and Ph3P=O.
New compounds 2 and 3 are obtained as air-stable yellow and white solids, respectively.
Compound 2 is neutral whereas the Pt(II) derivative 3 is cationic (2:1 ions) as confirmed by
conductivity measurements (see Experimental Section). Compound 3 is only soluble in solvents
such as DMSO or DMF. We found that the COD ligand in 3 is immediately exchanged by
DMSO molecules in DMSO-d6 solution at room temperature and that the new IM-cyloplatinated
species did not change in DMSO-d6 over time (see Appendix, Figure 18). This was surprising
since a COD ligand is not easily replaceable and usually requires thermal activation. The
structures of these compounds have been proposed on the basis of elemental analysis, NMR and
IR spectroscopy and MS spectrometry. Both compounds are soluble in mixtures 1:99
DMSO:H2O at micromolar concentrations, relevant for biological studies.

Figure 1. Molecular structure of compound 2.
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The structure of 2 has been determined by an X-ray analysis and it is very similar to that
of previously reported36 compound [Au(2-C6H4C(O)N=PPh3)Cl2] (1)36 with very close distances
and angles. The molecular structure of 2 is depicted in Figure 1 while selected structural
parameters are collected in Table 1. The analysis confirms the square-planar arrangement around
the gold(III) center with a bite angle of

81.68(8)o. Like in other C,N-IM cycloaurated

complexes32,33,36,39 the Au-Cl(1) bond trans to the carbon is longer (2.3834(5) Å) than the AuCl(2) trans to the nitrogen (2.2798(5) Å) due to the higher trans influence of the C donor atom.
As observed in compound 1, upon coordination to the gold there is an increase in both the P-N
and N–C bond lengths when compared to the uncoordinated ligand40 (P-N: 1.626(3) Å in ligand,
1.6658 (18) Å in 2; N–C:1.353(5) Å in ligand, 1.401(3) Å in 2). This effect is also observed in
the IR spectra of compound 2 for which band corresponding to the P-N bond appears at a lower
frequency than that for the free ligand (1,289 cm-1 versus 1,374 cm-1). As described in the
structure of compound 1, a decrease of the C=O bond length was observed (from 1.245(5) Å in
the ligand to 1.213(3) Å in the cycloaurated complex).

Table 1. Selected Structural Parameters of complex 2 obtained from X-ray single crystal
diffraction studies. Bond lengths in [Å] and angles in [].

Au(1)-Cl(1)
Au(1)-Cl(2)

2.3834(5)
2.2798(5)

N(1)-Au(1)-Cl(2)
N(1)-Au(1)-Cl(1)

173.33(5)
97.32(5)

Au(1)-C(1)

2.020(2)

Cl(2)-Au(1)-Cl(1)

88.62(2)

Au(1)-N(1)
P(1)-N(1)

2.0497(18)
1.6658(18)

P(1)-N(1)-Au(1)
P(1)-N(1)-C(7)

126.07(10)
119.25(15)

N(1)-C(7)
C(7)-O(1)

1.404(3)
1.213(3)

N(1)-C(7)-C(6)
N(1)-C(7)-O(1)

112.16(19)
123.72(19)

C(7)-C(6)
C(6)-C(1)

1.478(3)
1.385(3)

C(7)-N(1)-Au(1)
C(7)-C(6)-C(1)
C(6)-C(1)-Au(1)

114.68(14)
118.0(2)
113.24(16)

C(1)-Au(1)-N(1)

81.68(8)

N(1)-P(1)-C(10)

113.99(10)

C(1)-Au(1)-Cl(2)

92.44(6)

N(1)-P(1)-C(8)

116.45(10)

C(1)-Au(1)-Cl(1)

178.28(6)

N(1)-P(1)-C(13)

117.81(10)
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The biological activity of the endo iminophosphorane compound [Au{κ2-C,NC6H4(PPh2=N(C6H5)-2}Cl2]32 and some of its cationic derivatives like [Au{κ2-C,NC6H4(PPh2=N(C6H5)-2}(S2CN(CH3)2)]PF633 had been described by our research group at
Brooklyn College.33,35 We had never synthesized Pt(II) endo compounds with the IM Ph-N=PPh3
ligand or evaluated their biological activity. The reaction of [Hg{C6H4(PPh2=N(C6H5)-2}Cl]32,39
with [PtCl2(COD)] was carried out and a cationic species (4) was obtained. Compound 4 (as for
the exo compound 3) has a mercury chloride containing anion (in this case [Hg2Cl6]2-). In order
to avoid the use of organomercury compounds and the presence of mercury in the resulting
compound, a “greener” synthetic approach41 based of the transmetallation with an
organogold(I)phosphine compound [Au{C6H4(PPh2=N(C6H5))-2}(PPh3)] described previously32
was employed (Scheme 3).

Scheme 3. Synthesis of the new platinum(II) cyclometallated endo iminophosphorane complexes
4 and 5.

This mercury-free approach had been used to obtain the endo gold(III) cyclometallated
compound [Au{κ2-C,N-C6H4(PPh2=N(C6H5)-2}Cl2].32 The reaction described here with
[PtCl2(COD)] proceeds much faster and in much milder conditions than that for the synthesis of
4 (25 min at RT in CH2Cl2 instead of 5 days in refluxing acetone). Compound 5 is obtained in
moderate yield (58%). In order to avoid the formation of a neutral platinum(II) dimer with
chloride bridges [Pt{C6H4(PPh2=N(C6H5))-2}Cl]2 observed while performing this reaction,
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NH4PF6 was added. In this way, we obtained compound 5, an analogue of cationic compound 4
with a mercury-free anion (PF6-). The structures of these compounds have been confirmed by
elemental analysis, NMR (including

195

Pt NMR) and IR spectroscopy, and MS spectrometry

studies. In this case the compounds do not exchange the COD ligand for DMSO molecules at RT
in DMSO-d6 solution as in the case of compound 3 which may have some implications for the
biological activity of the compounds. Compounds 4 and 5 are also soluble in mixtures 1:99
DMSO:H2O solutions at micromolar concentrations which are relevant for biological studies. A
mercury-free analogue of compound 3 could not be obtained since the preparation of the
appropriate Au(I) transmetallation agent from the organomanganese compound (Scheme 1) was
not successful so far.

Figure 2. Molecular structure of the cation in compound 4. The anion [Hg2Cl6]2- is omitted for
clarity.

The number of cycloplatinated iminophosphorane compounds described previously is
limited to two examples of endo neutral derivatives [Pt(C6H4-2-PPh2=N-C(O)-2-NC5H4-κC,N,N)Cl]42 and [Pt{κ3-C,N,N-C6H4(PPh2=N-8-C9H6N}Cl]43 in which the iminophosphorane
fragment acts as a C,N,N- pincer ligand. In compounds 3-5 the IM ligand is cyclometallated in
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either an exo (3) or endo (4, 5) position acting as a C,N-pincer ligand. The other two
coordination positions for the Pt(II) center are occupied by the COD ligand. The molecular
structure for compound 4 was determined by X-ray crystollagraphy confirming the proposed
structure. The molecular structure of the cation in 4 is depicted in Figure 2 while selected
structural parameters are collected in Table 2. A complete drawing of the crystal structure of 4
including the [Hg2Cl6]2- anion and crystallization molecules along with a more complete Table of
distances and angles are provided in the Appendix, section 4.8.1, Tables 7-9.
The coordination geometry around the platinum atom is slightly distorted from squareplanarity, with the C(1)-Pt(1)-N(1) angle of 85.31(9)o suggesting a rigid ‘bite’ angle. The X(1)Pt(1)-N(1) also deviates (94.14(9)o). The distance Pt-N(1) 2.039(2) Å is shorter than that for
other C,N- cyclometallated Pt(II) derivatives such as dmba (dimethylbenzylamine) compounds
(ca. 2.1230-2.1340 Å).e.g. 17,44,45 The distances Pt-N(1) and Pt-C(1) both of 2.039(2) Å are almost
identical to those found for Au-N(1) and Au-C(1) (both 2.035(4) Å) in a cyclometallated
compound with the same IM ligand such as [Au{C6H4(PPh2=N(C6H5))-2}(PPh3)].32 The
distances Pt-X(1) and Pt-X(2) to the centroids of the COD ligand are 2.169(3) and 2.039(3) Å,
respectively, which reflects the higher trans-influence of C versus N (longer Pt-X(1) distance).

Table 2. Selected Structural Parameters of the cation in complex 4 obtained from X-ray single
crystal diffraction studies. Bond lengths in [Å] and angles in [º].
Pt(1)-C(1)
Pt(1)-N(1)

2.039(2)
2.039(2)

N(1)-Pt(1)-C(1)
C(1)-Pt(1)-X(1)

Pt(1)-X(1)
Pt(1)-X(2)
P(1)-N(1)

2.169(3)
2.039(2)
1.622(2)

C(1)-Pt(1)-X(2)
N(1)-Pt(1)-X(1)
N(1)-Pt(1)-X(2)

P(1)-C(2)
P(1)-C(7)

1.773(2)
1.797(3)

X(1)-Pt(1)-X(2)
C(19)-N(1)-Pt(1)

85.78(10)
125.82(16)

P(1)-C(13)

1.797(3)

C(19)-N(1)-P(1)

116.21(16)

N(1)-C(19)

1.444(3)

C(19)-N(1)-P(1)

116.21(16)

C(1)-C(2)

1.409(3)
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85.31(9)
178.95(9)
94.79(10)
94.14(9)
179.01(9)

The stability of 1 and of the new compounds 2-5 was evaluated in DMSO-d6 solution by
31

P{1H} and 1H NMR spectroscopy. All the complexes are stable for months in DMSO-d6

solution (see spectra and stability table in the Appendix, sections 4.8.2 and 4.8.3). As mentioned
before, compound 3 exchanges the COD ligand by DMSO immediately when dissolved in
DMSO-d6 (free COD is clearly visible along with coordinated DMSO). In the case of
compounds 4 and 5, this exchange is extremely slow and after one week the percentage of free
uncoordinated COD observed is around 6%. Compounds 4 and 5 are stable in DMSO and
mixtures 1:99 DMSO:PBS for 24 hours as established by UV-Vis spectroscopy. The UV-Vis
band shifts from 262 nm in DMSO to 225 nm in 1:99 DMSO:PBS for compound 4, and from
264 nm in DMSO to 225 nm in 1:99 DMSO:PBS for compound 5. The UV-Vis band observed
for the free iminophosphrane ligand Ph3P=NPh in DMSO appears at 257 nm, while in
DMSO:PBS there are two visible bands, a major band at 230 nm and a minor band at 265 nm.
This might explain the shift observed for compounds 4 and 5 in the UV-VIS spectra in
DMSO:PBS solution when compared to DMSO solution (see Addpendix).

4.3. Biological activity in vitro

These studies were performed by Dr. Isabel Marzo, Oscar Gonzalo and Alfonso Serrano del
Valle at the University of Zaragoza, Spain. The studies on non-carcinogenic RPTC cell lines
were performed by PhD student Benelita T. Elie in our laboratory.
4.3.1. Antiproliferative studies in vitro

The antiproliferative properties of the gold(III) and platinum(II) complexes 1-5 and
ligand COD were assessed by monitoring their ability to inhibit cell growth using the MTT assay
(see Experimental Section). The cytotoxicity activity of the compounds was determined in
several human cancer cell lines: leukemia Jurkat-T, lung A549, prostate DU-145, pancreas
MiaPaca2, and triple negative breast MDA-MB-231, in comparison to cisplatin. The results are
summarized in Table 3. The COD ligand is poorly cytotoxic in all tested cell lines (IC 50 >125
µM). The IM ligands are known to be poorly cytotoxic (IC50 in different cell lines >100-500
µM).34,43,46,47
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Cyclometallated neutral gold(III) compound showed similar cytotoxicity to cisplatin
while compound 2 was less cytotoxic for all the studied cell lines with the exception of the
leukemia Jurkat cell line. We have found previously that the replacement of PPh3 by PTA in IMcyclometallated complexes decreases the cytotoxicity.37 The IC50 value for Jurkat for compound
1 is very similar to that obtained for the neutral iminophosphorane endo derivative [Au{κ2-C,NC6H4(PPh2=N(C6H5)-2}Cl2].32 Cationic gold(III) complexes containing IM ligands are more
cytotoxic than neutral derivatives.33,35 The cationic cyclometallated platinum compounds
described here 3 and especially 4 and 5 were considerably more cytotoxic than cisplatin in all the
cell lines studied. 4 and 5 (same cation) display almost identical IC50 values with the exception
of A549 and MDA-MB-231 for which compound 4 containing the Hg2Cl62- anion is twice as
active than 5. The data indicates that cytotoxicity for these compounds comes mainly from the
cationic platinum fragment.

Table 3. IC50 (µM) of metal complexes 1-5, ligand COD and cisplatin in human cell lines.a All
compounds were dissolved in 1% of DMSO and diluted with water before addition to cell culture
medium for a 24 h incubation period. Cisplatin was dissolved in H2O.
Jurkat

A549

DU-145

MiaPaca2

MDA-MB231

HEK-293T

1

3.4 ± 0.5

85.3 ± 5.9

40 ± 8.1

81.8 ± 2.6

101.8 ± 16

14.6 ± 1.4

2

9.5 ± 0.07

>125

> 125

> 125

> 125

> 125

3

2.13 ± 0.24

20.8 ± 1.7

22.5 ± 4.2

7.53 ± 5.0

14.6 ± 3.7

4.0 ± 0.42

4

0.43 ± 0.06

0.85 ± 0.29

0.93 ± 0.43

0.79 ± 0.09

0.39 ± 0.05

1.25 ± 0.25

5

0.53 ± 0.13

2.01 ± 0.89

0.81 ± 0.07

1.03 ± 0.06

0.84 ± 0.29

0.94 ± 0.07

COD

> 125

> 125

> 125

> 125

> 125

> 125

Cisplatin

10.8 ± 1.2

114.2 ± 9.1

112.5 ± 33

76.5 ± 7.4

131.2 ± 18

69.0 ± 6.7

a

Data are expressed as mean ± SD (n =4).

In order to assess the compounds’ selectivity for cancerous cells with respect to normal
cell lines, they were also screened for their antiproliferative effects on the non-tumorigenic
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human embryonic kidney cells HEK293T. In most cases the cytotoxicity is comparable for the
cancerous and HEK293T cells. All compounds are more toxic to leukemia than to HEK293T cell
lines (2 to 12 times) and compound 4 is more toxic to all the cell lines than to the HEK293T cell
lines. The toxicity of mercury-free compound 5 to HEK293T is comparable to that in the human
cancer cell lines. As HEK293T cell lines (immortalized cells) can display a higher sensitivity to
chemicals we measured the effect of compound 5 on human renal proximal tubular cells (RPTC).
Renal proximal tubular cells in primary culture have been described as an in vitro model to study
nephrotoxicity.37 The IC50 value (XTT assay 24 hours see SI for details) for 5 in this cell line was
2.77±0.83 µM making 5 more sensitive to cancerous cell lines than to RPTCs. In addition, we
will describe in chapter V an IM ruthenium compound [(η6-p-cymene)Ru{(Ph3P=N-CO-2-NC5H4)-κ-N,O}Cl]Cl which displayed similar IC50 values in vitro for all the human cancer cell
lines described above and HEK293T but which was very effective in vivo on MDA-MB-231
xenografts in NOD.CB17-Prkdc SCID/J mice while having low toxicity.37
4.3.2. Mechanism of cell death for compound 5

The mechanism of cell death induced by mercury-free cytotoxic cycloplatinated
compound 5 was analyzed in two cell lines of different origin: A549 lung carcinoma and Jurkat
T-cell leukemia. Phosphatidyl serine exposure, plasma membrane damage and nuclear
morphology were assessed in both cell lines after treatment with 5. Caspase implication in the
toxicity of 5 was studied using the general caspase inhibitor z-VAD-fmk. In A549 cells we found
that z-VAD-fmk protected cells from 5 at doses up to 0.5 µM (Figure 3) inhibiting both
phosphatidylserine exposure (annexin V binding) and plasma membrane permeabilization (7ADD uptake). As expected, phosphatidylserine exposure was more dependent on caspase
activity. At higher concentrations 7-AAD staining, but not annexin V binding, increased,
suggesting that cell death was necrotic.
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Figure 3. Role of caspases on cell death induced by compound 5 in A595 cells. Cells were
cultured for 24 h in the presence of 5 at the indicated concentrations, alone (solid lines) or
combined with the general caspase inhibitor z-VAD-fmk (dashed lines). Subsequent,
phosphatidylserine exposure (triangles) and cell membrane permeabilization (squares) were
analyzed by flow cytometry after staining with annexin V-DY634 and 7-AAD respectively.
Results are mean+/-SD of two independent experiments with duplicates.

The apparent decrease in the percentage of annexinV positive cells could reflect cell
disintegration caused by necrosis. Consistently, z-VAD-fmk did not inhibit cell death at 1 µM
(Figure 3). When an early event of apoptosis, loss of mitochondrial transmembrane potential,
was analyzed we also observed that caspase inhibition by z-VAD-fmk only partially reduced
∆Ψm loss caused by 5 (Figure 4), further suggesting that compound 5 can induce caspasedependent and caspase-independent cell death in A549 cells.
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Figure 4. Caspase implication in mitochondrial effects of compound 5 in A549 cells. Cells were
cultured for 24 h in the presence of compound 5 at the indicated concentrations, alone (solid line)
or combined with the general caspase inhibitor z-VAD-fmk (dashed line). Then, transmembrane
mitochondrial potential was analyzed by flow cytometry after staining with the probe DiOC6(3).
Results are mean+/-SD of two independent experiments with duplicates.

Jurkat cells were more sensitive to 5 than A549 cells, with an IC50 of 0.6 µM, even
though this cell line does not express functional p53, discarding an essential role of this protein
in the activity of compound 5. In these cells the percentage of 7-AAD (Figure 5) and that of
Annexin V-positive (data not shown) cells were the same in every assay. High sensitivity of
Jurkat cells was confirmed in short-term experiments as we observed that 5 at 0.5 µM induced
cell death in almost 100% of cells even at 6 h. Caspase inhibition by z-VAD-fmk completely
avoided cell death at 6 h. However, longer treatment with 5 induced both caspase-dependent and
caspase-independent cell death (Figure 5).
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Figure 5. Implication of caspases in cell death induced by compound 5 in Jurkat cells. Cells
were treated with compound 5 for 6 or 24 h in the presence or in the absence of the general
caspase inhibitor z-VAD-fmk. Membrane integrity was analyzed by flow cytometry after
staining with 7-AAD, respectively, as indicated in the Experimental Section. Results are
mean±SD of two independent experiments.

Mitochondrial damage was also analyzed in Jurkat cells (Figure 6). At 24 h treatment
with 5 caused a decrease in ∆Ψm in 80% of cells, compared to 32% in cells treated with 5 in the
presence of the general caspase inhibitor z-VAD-fmk. In order to determine whether
mitochondrial damage caused by 5 was irreversible and committed cells to death, cells were
washed and re-suspended in fresh medium. After a further 24 h incubation in fresh medium ∆Ψm
collapse was observed in nearly 100% of cells (Figure 6). These results indicate that caspase
inhibition only delays cell death in Jurkat cells and 5 induces cell damage leading to cell death
independently of caspase activation. Thus, these experiments confirm that alternative caspaseindependent cell death mechanisms are activated by this compound, as observed in A549 cells.
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Figure 6. Jurkat cells were treated with 5 or 5+z-VAD for 24 h and then harvested, washed and
seeded in fresh medium. After further 24 h in fresh medium mitochondrial transmembrane
potential (∆Ψm) was analyzed as indicated in the Experimental Section. Results are mean+/-SD
of three independent experiments.
On the other hand analysis of nuclear morphology indicated that 5 induced typical
apoptotic features (chromatin condensation and fragmentation) that were prevented by z-VADfmk in both cell lines (Figure 7). However, some nuclei of cells treated with 5 + zVAD displayed
an altered morphology when compared to controls. This morphology could be caused by
necroptosis48 or AIF-mediated cell death.49

Figure 7. Compound 5 induces apoptosis in Jurkat (upper panels) and A549 cells (bottom
panels). Cells were cultured for 24 h in the presence of compound 5 (0.5 µM), alone or combined
with the general caspase inhibitor z-VAD-fmk or left untreated (Control). Nuclei were stained
with Hoechst 33342 (10 μg/ml) and cells were photographed under UV light. Magnification
x400.

89

Finally, the implication of mitochondria in the toxicity of compound 5 was analyzed.
Jurkat-shBak cells, obtained by RNAi of Bak49 were employed. Since Jurkat cells do not express
Bax, Jurkat-shBak cell line constitutes a model of human leukemia cells deficient in the intrinsic
(mitochondrial) pathway of apoptosis. A cell line transfected with a non-specific shRNA was
used as a control (Jurkat pLVTHM). As shown in Figure 8, Jurkat-shBak cells were less
sensitive to 5 than control cells. However, high concentrations of 5 induced Bax/Bak
independent cell death in Jurkat-shBak cells, suggesting that this compound could be useful in
the treatment of tumors with alterations in the intrinsic pathway of apoptosis.

Figure 8. Jurkat-pLVTHM (control) and Jurkat-shBak cells were treated with compound 5 for
24 h. Mitochondrial transmembrane potential was analyzed as indicated in the Experimental
Section. Results are mean±SD of three independent experiments.

To summarize, from these initial mechanistic studies it seems clear that the cell death
type for compound 5 is mainly through caspase-dependent apoptosis but that it triggers caspaseindependent cell death when apoptosis is blocked pointing out to a mode of action different from
that of cisplatin.
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4.3.3. Lipophilicity and permeability assays

These studies were performed by Víctor Mangas-Sanjuán, Dr. Marta González-Alvarez, Dr.
Isabel González-Alvarez and Prof. Marival Bermejo at the University Miguel Hernández, Spain.

The lipophilicity of the most active cycloplatinated 4 and 5 was determined by
calculation the partition coefficients (see Table 4 and Experimental Section) between n-octanol
and phosphate buffer (pH 7.00). Partition coefficients have been used to predict the permeability
of drugs since there is a good correlation between intestinal permeability and physicochemical
parameters such as lipophilicity.

Table 4. Partition Coefficients (ratio n-octanol: phosphate buffer) of Compounds 4 and 5 and
reference Metoprolol.
Compound

P

logP

Metoprolol

0.20 ± 0.02

-0.68

4

0.54 ± 0.03

-0.26

5

1.05 ± 0.05

0.02

Metoprolol was chosen as the reference compound for permeability since 95% of the
drug is known to be absorbed from the gastrointestinal tract. Thus, drugs that exhibit partition
coefficients and human intestinal permeability values greater than or equal to the corresponding
value for metoprolol are considered high-permeability drugs. Drugs with estimated partition
coefficients and human intestinal permeability values less than the corresponding value for
metoprolol are classified as low-permeability drugs. This type of correlation is a suitable source
of information on the passive and also possible carrier mediated absorption mechanism. From
this data we can state that compound 5 is more lipophilic than 4 and metropolol.
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Figure 9. Permeability values obtained from apical to basal (Pab) and from basal to apical (Pba)
of Cisplatin (at different concentrations), cycloplatinated 4, 5 and permeability reference
compounds (Metoprolol, Cimetidine and Lucifer Yellow) at 20 µM in Caco-2 cells. Data
correspond to the averaged values for three independent experiments.

Subsequently, the permeability of cisplatin as commercialized parent compound,
cycloplatinated 4 and 5 as test compounds and Metoprolol, Cimetidine and Atenolol/Lucifer
Yellow as reference compounds of high, intermediate and low permeability respectively, were
determined using an in vitro cell model based on the measurement of the permeability of the
compounds through Caco-2 monolayers50,51 and an in situ method by performing a rat perfusion
assay.52,53 Results from the in vitro cell assay are shown in Figure 9 and data collected in Table 5
while the results in the rat model are depicted in Figure 10 and data collected in Table 6.
Pab is the value corresponding to the permeability from apical to basolateral chamber that
simulates the permeability in the physiological sense from intestine to plasma. The Pba value
corresponds to the permeability form basolateral to apical chamber. This Pba value would be the
hypothetical value for the permeability “from plasma to intestine”. Despite Pba value has not
physiological sense, this parameter and the ratio Pab/Pba can help to elucidate the mechanism of
drug transport across the intestinal barrier.54
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Table 5. Permeability values obtained by the Caco-2 cell monolayers assay. Metoprolol,
Cimetidine and Lucifer Yellow were used as model compounds of high, medium and low oral
permeability. Data correspond to the averaged values for three independent experiments.

Compound (20 µM)

P (cm/s)

SD

Cisplatin

5.44·10-07

4.66·10-07

4

4.62·10-06

3.54·10-06

5

2.71·10-05

5.00·10-06

Metoprolol

2.32·10-05

1.75·10-06

Cimetidine

1.86·10-06

3.71·10-07

Lucifer Yellow

1.90·10-07

4.98·10-08

Cell transport assays reveal that cisplatin is a compound with very low permeability. This
permeability value (5.44·10-07cm/s) indicates that cisplatin is not a drug suitable for oral route
administration if the objective is to obtain therapeutic plasma values. However, organoplatinum
compounds 4 and 5 show higher permeability values than cisplatin. In fact, the permeability
value of compound 4 is ten-fold higher than that of cisplatin at the same concentration and the
permeability of compound 5 is fifty-fold higher. The permeability of compound 4 is higher than
Lucifer Yellow and Cimetidine but lower than Metoprolol. 4 can be considered a compound of
medium oral permeability. However, the permeability of compound 5 is higher than that of
compound 4 and even higher than Metoprolol (in accordance with the lipophilicity data)
indicating that it can be considered a highly permeable compound. The high permeability of
active principles is a crucial condition for oral administration.
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Figure 10. Absorption rate coefficients in rats.

Results from the in situ rat model assays confirm those obtained by the in vitro cell
experiments. The permeability of compound 4 is higher than that of Atenolol, slightly higher that
the permeability of Cimetidine but lower than that of Metoprolol. Compound 4 can be
considered a compound of intermediate permeability. Compound 5 exhibits higher permeability
than compound 4 and slightly higher than Metoprolol indicating that 5 is a highly permeable
compound. Both compounds 4 and 5 display a much better absorption profile than cisplatin.

Table 6. Absorption rate coefficients, Ka, and permeability values obtained from in situ rat
assays. Metoprolol, Cimetidine and Atenolol were used as model compounds of high, medium
and low oral permeability. Data correspond to values of six independent experiments.
Compound
Cisplatina
4a
5a
Metoprololb
Cimetidineb
Atenololb
a
20 µM.
b
100 µM.

Ka(h1)
Non
detectable
2.00
2.12
2.30
1.68
0.22

SD
±
±
±
±
±
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0.11
0.22
0.15
0.12
0.02

Peff (cm/s)
Non
detectable
4.72·10-05
5.50·10-05
5.40·10-05
3.97·10-05
5.19·10-06

SD
±
±
±
±
±

2.60·10-06
5.40·10-06
3.54·10-06
3.04·10-06
4.72·10-07

In addition, the relationship between caco-2 cells permeability and oral fraction absorbed
in the experimental system (represented in Figure 11) had been validated and previously used for
fraction absorbed predictions.54 The permeabilities of cisplatin and derivatives 4 and 5 were
included in this correlation. The oral fraction absorbed predicted is more than 60% for compound
4 and almost 100% for compound 5 demonstrating its improved absorbability properties with
respect to cisplatin. In the absence of solubility or dissolution limitations the absorption of these
compounds would be almost complete, thus with the adequate formulation strategy they
represent promising candidates for oral administration

Figure 11. Correlation between oral fractions absorbed vs permeability values obtained from
Caco-2 cell monolayers transport assay in apical to basal direction (Pab). Gray diamonds
correspond to the internally validated correlation (IVC).54 Triangles correspond to permeability
reference compounds (metoprolol/caffeine for high permeability, Cimetidine for intermediate
permeability and Lucifer Yellow for low permeability). Light grey squares correspond on tested
compounds 4 and 5.
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4.4. Interactions with DNA

Since DNA replication is the key event for cell division, it is among critically important
targets in cancer chemotherapy. Most cytotoxic platinum drugs form strong covalent bonds with
DNA bases.55 However, a variety of platinum compounds act as DNA intercalators upon
coordination to the appropriate ancillary ligands.56 It has been reported that most gold(III)
compounds display reduced affinity for DNA33 although there are a number of Au(III) porphyrin
complexes5,25,57 and cyclometallated species with C-N-C pincer ligands5,25,58 that act as DNA
intercalators and, in some cases as DNA topoisomerase inhibitors. We investigated the
interaction of the gold(III) and platinum(II) complexes with plasmid (pB322) DNA and with Calf
Thymus DNA and directly compared to that of cisplatin.

4.4.1. Interaction of complexes 1-5 with plasmid (pBR322) DNA

To gain insight into the nature of the compound-DNA interactions, gel electrophoresis
studies were performed with gold(III) (1 and 2) and platinum(II) (3-5) complexes on plasmid
(pBR322) DNA (Figure 12). Plasmid (pBR322) presents two main forms, OC (open circular or
relaxed) and CCC (covalently closed circle or supercoiled), which display different
electrophoretic mobility. Changes in the electrophoretic mobility of any of the forms upon
incubation of the plasmid DNA with a compound are usually interpreted as evidence of drugDNA interaction. Generally, a drug that induces unwinding of the CCC form will produce a
retardation of the electrophoretic mobility, while coiling of the OC form will result in increased
mobility. Figure 12 shows the effect of cisplatin and compounds 1-5 on plasmid (pBR322) DNA
after incubation at 37ºC for 20 h in Tris/HCl buffer at different drug/DNA ratios. As previously
reported, cisplatin is able to both increase and decrease the mobility of the OC and the CCC
forms, respectively.59 Treatment with increasing amounts of compounds 1, 2, 4 and 5 do not
cause any shift for either form, consistent with no unwinding or other changes in topology under
the chosen conditions. Treatment with increasing amounts of 3 retards the mobility of the fasterrunning supercoiled form (Form I) especially at higher molar ratios. In order to understand the
interaction of 3 with DNA, platinum compounds 3-5 were incubated with Calf Thymus DNA and
analyzed by circular dichroism
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Figure 12. Electrophoresis mobility shift assays for cisplatin and compounds 1-5 (see
Experimental Section for details). DNA refers to untreated plasmid pBR322. A, B, C and D
correspond to metal/DNAbp ratios of 0.25, 0.5, 1.0 and 2.0 respectively.

4.4.2. Interaction with Calf Thymus DNA

More detailed DNA conformational changes can be detected by means of Circular
Dichroism (CD) spectroscopy. CD spectral technique is very sensitive to diagnose alteration of
the secondary structure of DNA that results from DNA-drug interactions. A typical CD spectrum
of Calf Thymus DNA shows a positive band with a maximum at 273 nm due to base stacking,
and negative band with a minimum at 242 nm due to helipticity, characteristic of the B
conformation of DNA.60 Therefore, changes in the CD signals can be assigned to corresponding
changes in DNA secondary structures. In addition, it is known that simple groove binding or
electrostatic interaction of small molecules causes little or no alteration to any of the CD bands
when compared to major perturbation induced by covalent binding or intercalation. The most
dramatic changes in the CD spectrum of CT DNA can be observed with compound 3 (Figure
13A). Upon addition of increasing amounts of the complex, the intensity of the positive band
diminishes and a new negative band at 287 nm and a positive band at 251 nm appears. This type
of modification in CD spectrum of CT DNA is characteristic of conformational changes in DNA
from B, usual right-handed form of DNA, to Z, left-handed form of DNA.61 The formation of
left-handed helix of Z-form DNA structure is similar to the transition seen in purely electrostatic
environments such as those provided by HgCl262 and Hg(ClO4)2.63 Thus, the presence of
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[Hg4Cl10]2- anion in compound 3 seems to lead to the conformational change from B form to Z
form.
Cycloplatinated endo compound 4 leads to minor changes of the B-type CD spectrum
(Figure 13B), with slight decrease of the intensities of the positive bands and with no
modification in the negative region. This points out that the DNA binding of complex 4 induces
conformational changes including conversion from a more B-like to a more C-like structure
within the DNA molecule.64 This conformational change is indicative of a non-intercalative
mode of binding of the complex and offers support for either groove binding or electrostatic in
nature65,66 and it might be due to the lower concentration of Hg2+ released by compound 4,
[Hg2Cl6]2- (compared to that released by compound 3, with a [Hg4Cl10]2- anion) although the
influence of the more lipophilic Pt(II) cation could not be completely ruled out.

Figure 13. CD spectra of CT DNA (195 µM) and CT DNA incubated with 0.1, 0.25, 0.5 and 1.0
equivalents of compounds 3 (A), 4 (B), 5 (C) and cisplatin (D) for 20 h at 37ºC.
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Finally, as shown in Figure 13C, compound 5 leads to no modification of the DNA bands
with respect to untreated CT DNA, suggesting that the interaction of compound 5 with CT DNA
is almost non-existent. This is in good agreement with our findings described above about the
influence of the mercury anion in compounds 3 and 4 in their interaction with CT DNA since the
anion in compound 5 is PF6-.
In conclusion, the experiments of DNA-drug interactions have shown that compound 3
induces the formation of left-handed helix of Z-form DNA through strong electrostatic
interactions and compound 4 appears to be either groove binding or electrostatic in nature. This
is supported by two main facts: 1) retardation of the plasmid (pBR322) DNA electrophoretic
mobility is observed only for compound 3; and 2) results obtained by CD spectroscopy.
Importantly, the mercury-free cationic organoplatinum compound 5 does not seem to interact
with DNA indicating that as for other transition-metal IM complexes,33-35,37,43,46,47 its antitumor
properties are due to non-DNA related mechanisms/factors.

4.5. Interaction with HSA

As mentioned in Chapter III, human serum albumin (HSA) is the most abundant carrier
protein in plasma and is able to bind a variety of substrates including metal cations, hormones
and most therapeutic drugs. It has been demonstrated that the distribution, the free concentration
and the metabolism of various drugs can be significantly altered as a result of their binding to
this protein.67 HSA possesses three fluorophores, namely tryptophan (Trp), tyrosine (Tyr) and
phenylalanine (Phe) residues, with Trp214 being the major contributor to the intrinsic
fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding of
substrates, as well as changes in conformation that can result in quenching (either dynamic or
static).
Thus, the fluorescence spectra of HSA in the presence of increasing amounts of the
compounds 1-5 and cisplatin were recorded in the 300-450 nm range upon excitation of the
tryptophan residue at 295 nm. The compounds caused a concentration dependent quenching of
fluorescence without changing the emission maximum or the shape of the peak, as seen on
Figure 14A for compound 3. All these data indicate an interaction of the compounds with HSA.
The fluorescence data was analyzed by the Stern-Volmer equation (Figure 14B). While a linear
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Stern-Volmer plot is indicative of a single quenching mechanism, either dynamic or static, the
positive deviation observed in the plots of F0/F versus [Q] of compounds 2-4 (Figure 14C)
suggests the presence of different binding sites in the protein with different binding affinities.68
Of note, a similar behavior was observed in the case of coordination iminophosphorane
complexes of d8 metals for which we also reported a concentration dependent fluorescence
quenching.34,37,43,46,47 On the other hand, the Stern-Volmer plot for complexes 1 and 5 shows a
linear relationship (Figure 14D), suggesting the existence of a single quenching mechanism,
most likely dynamic, and a single binding affinity. The Stern-Volmer constants for complexes 1
and 5 are 4.58x106 and 3.67x106 M-1, respectively.
In general, higher quenching by the iminophosphorane complexes was observed
compared to that of cisplatin under the chosen conditions, most likely due to the faster binding of
our compounds with HSA, as compared to cisplatin.

Figure 14. (A) Fluorescence titration curve of HSA for compound 3. Arrow indicates the
increase of quencher concentration. Stern-Volmer plot for HSA fluorescence quenching
observed with compounds 1-5 and cisplatin (B), 2-4 and cisplatin (C) and 1, 5 and cisplatin(D).
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4.6. Conclusions

We have shown in this chapter a systematic way to synthesize novel exo cyclometallated
C,N-IM compounds of gold(III) and platinum(II) containing the water-soluble phosphine PTA.
This synthetic method could be expanded to incorporate different phosphines in the IM ligand to
tune the hydrophilicity and/or electronic/steric properties of the resulting metal complexes. I also
prepared an endo C,N-IM compound of platinum(II) for comparison purposes. These complexes
resulted stable in solution of DMSO-d6 and in DMSO:PBS buffer (1:99) overtime as
demonstrated by NMR and UV-vis spectroscopic studies. The compounds, along with exo
derivative [Au(2-C6H4C(O)N=PPh3)Cl2], were evaluated against a number of human cancer cell
lines in vitro. The platinum compounds 3 and particularly, 4 and 5 were significantly more
cytotoxic than cisplatin in all the cell lines studied; indicating that cytotoxicity of 4 and 5 comes
mainly from the cationic fragment. The interaction of complexes 3-5 with plasmid (pBR322) and
calf thymus DNA by circular dichroism demonstrated different modes of action. Compound 3
induces the formation of left-handed helix of Z-form DNA through strong electrostatic
interactions, while compound 4 appears to be either grove binding or electrostatic in nature. In
addition, higher quenching of has fluorescence was observed compared to that of cisplatin under
the chosen conditions, most likely due to the faster reactivity of the complexes with HSA, as
compared to cisplatin.
All the above metioned results have helped us to identify a mercury-free lipophilic
cationic cycloplatinated iminophosphorane compound (5) as a good candidate for subsequent
advanced precilinical studies. This compound is not only active against a number of cisplatin
resistant cell lines, but also less toxic on human renal proximal tubular cell lines. Initial
mechanistic studies carried out by our collaborators in Spain indicate that the cell death type for
compound 5 is mainly through caspase-dependent apoptosis but that it triggers caspaseindependent cell death when apoptosis is blocked. These facts along with the lack of interaction
observed for 5 with plasmid (pBR322) and CT DNA points to a mode of action different from
that of cisplatin. Permeability studies of 5 by two different assays: in vitro caco-2 monolayers
and a rat perfusion model, have revealed its high permeability profile (comparable to that of
metoprolol or caffeine) and an estimated oral fraction absorbed of 100% which potentially makes
it a good candidate for oral administration. The results obtained in this chapter support the idea
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that cyclometallated iminophosphorane compounds containing d8 metals (especially cationic
species) are more stable in physiological media and display relevant anticancer properties.

4.7. Experimental section

Materials and methods

All manipulations involving air-free syntheses were performed using standard Schlenk-line
techniques under a nitrogen atmosphere or in a glove-box MBraun MOD System. Solvents were
purified by use of a PureSolv purification unit from Innovative Technology, Inc. The phosphine
substrate PTA and PPh3 were purchased from Sigma-Aldrich, [Mn2(CO)10] and [PtCl2(COD)]
were purchased from Strem chemicals, Na/Hg were purchased from Fisher Scientific and used
without further purification. Compounds [PhCH2Mn(CO)5],68 [Hg(2-C6H4C(O)N=PPh3)Cl],36
[Hg(2-C6H4C(O)N=PTA)Cl],37 and IM ligands Ph3P=N-CO-2-N-C5H4,38 were prepared by
reported methods. The purity of the compounds, based on elemental analysis, is ≥99.5%. NMR
spectra were recorded in a Bruker AV400 (1H NMR at 400 MHz,
NMR at 161.9 MHz,

13

C NMR at 100.6 MHz, 31P

195

Pt NMR at 85.7 Hz). Chemical shifts (δ) are given in ppm using CDCl 3

or DMSO-d6 as solvent, unless otherwise stated. Elemental analyses were performed on a Perkin
Elmer 2400 CHNS/O Analyzer, Series II. Mass spectra HR-ESI (high-resolution electrospray
ionization) or MALDI (matrix-assisted laser desorption/ionization) were performed on an
Agilent Analyzer or a Bruker Analyzer. Conductivity was measured in an OAKTON
pH/conductivity meter in acetone solution (10−3 M). X-ray collection was performed at room
temperature on using graphite-monochromated and 0.5 mm-MonoCap-collimated Mo-K
radiation (λ = 0.71073 Å) with the ω scan method. DNA thermal denaturation experiments were
performed with a Cary 100 Bio UV-visible spectrophotometer. Circular Dichroism spectra were
recorded using a Chirascan CD Spectrometer equipped with a thermostated cuvette holder.
Electrophoresis experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal
electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the
gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity
measurements were carried out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham,
NJ) with right angle detection of fluorescence using a 1 cm path length quartz cuvette.
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Synthesis of 2
[Au(2-C6H4C(O)N=PTA)Cl2]
[Hg(2-C6H4C(O)N=PTA)Cl] (0.15 g, 0.3 mmol), [NMe4][AuCl4] (0.12 g, 0.2 mmol) and
[NMe4]Cl (0.035 g, 0.32 mmol) were stirred at RT in CH2Cl2 (15 mL) for 1 day in a foil-covered
flask. The solvent was removed under reduced pressure. The fraction containing compound 2
was then extracted from the solid residue with CHCl3 (3 x 10 mL) and the resulting yellow
solution filtered through a column of celite. The volume was reduced (< 3 mL) and upon
addition of Et2O (20 mL) a pale yellow solid was precipitated. This solid was finally isolated by
filtration and dried in vacuo.

Yield: 0.15 g (93%). Anal. Calc. for C13H16N4OPCl2Au (543.14): C, 28.75; H, 2.97; N, 10.32.
Found: C, 28.32; H, 3.07; N, 9.93%. ESI-MS: m/z: 507.04 (100%, [M-Cl]+, calc. 507.04).

31

P

{1H} NMR (CDCl3): δ -7.66 (s), (DMSO-d6): -2.68 (s); 1H NMR (CDCl3): δ 4.54 (6H, AB
system, NCH2N), 5.10 (6H, d, 2JPH = 9.1 Hz, PCH2N), 7.34 (1H, d, 3JHH = 7.0 Hz, 6-C6H4), 7.38
(dd, 3JHH = 7.8, 3JHH = 7.8 Hz, 4-C6H4), 7.42 (dd, 3JHH = 7.2, 3JHH = 7.1 Hz, 5-C6H4), 8.04 (d,
3

JHH = 8.1 Hz, 3-C6H4). 13C{1H} δ 55.78 (d, 1JPC = 36.8 Hz, PCH2N), 72.37 (d, 3JPC = 10.8 Hz,

NCH2N), 128.64 (s, 2-C6H4), 129.73 (s, 3-C6H4), 130.74 (s, 5-C6H4), 134.42 (s, 4-C6H4), 143.16
(s, Au-C) ppm. Signals corresponding to NC=O and C1 not observable. IR (cm-1):  352 (Au-Cl),
1299 (N=P) 1654 (C=O). Conductivity: 37.66 μS/cm (acetone) (neutral).

Synthesis of 3
[Pt(2-C6H4C(O)N=PTA)(COD)]2Hg4Cl10
[Hg(2-C6H4C(O)N=PTA)Cl] (0.225 g, 0.44 mmol) and [PtCl2(COD)] (0.165 g, 0.44 mmol)
were refluxed in CH3CN (20 mL) for 2 h giving rise to white solid that was filtrated off and
washed with Et2O (3 x 10 mL), benzene (2 x 5 mL) and hexane (2 x 10 mL). After drying in
vacuo, complex 3 was isolated as a white powder.

Yield: 0.097 g (40%). Anal. Calc. for C42H56Cl10Hg4N8O2P2Pt2 (2313.94): C, 21.80; H, 2.44; N,
4.84. Found: C, 21.72; H, 2.58; N, 4.72. ESI-MS: m/z: 470.1 ([M-COD- Hg4Cl10]+, calc. 470.4),
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578.2 (100%, [M-Hg4Cl10]+, calc. 577.9), 1275.0 (100%, [2M-Hg4Cl6]2+ + CCl3- , calc. 1275.4).
31

P {1H} NMR (CDCl3): δ −7.66 (s), (DMSO-d6): −10.25 (s).

195

Pt{1H} NMR (DMSO-d6): δ -

3652.87 (s). 1H (DMSO-d6): δ 2.30 (8H, s, COD), 4.39 (6H, s, NCH2N), 4.91 (6H, d, 2JPH = 10.3
Hz, PCH2N), 5.51 (4H, s, COD), 7.07 (1H, m, 4-C6H4), 7.16 (1H, m, 5-C6H4), 7.29 (1H, d, 3JHH
= 7.3 Hz, 6-C6H4), 8.15 (1H, d, 3JHH = 8.0 Hz, 3-C6H4).13C{1H}( DMSO-d6): 27.98 (s, COD),
54.27 (d, 1JPC = 39.2 Hz, PCH2N),), 71.30 (d, 3JPC = 10.2 Hz, NCH2N), 124.6 (s, 4-C6H4), 128.1
(s, 6-C6H4), 128.9 (s, COD), 131.9 (s, 5-C6H4), 132.7 (s, 3-C6H4), 135.0 (s, 1-C6H4), 138.0 (d,
2

JCPt = 10.2 Hz, 2-PtC), 182.1 (d, 2JPC = 5.18 Hz, C=O) ppm. IR (cm-1):  1300 (N=P), 1643

(C=O). Conductivity: 129 μS/cm (DMF) (1:2 electrolyte).

Synthesis of 4
[Pt{κ2-C,N-C6H4(PPh2=N(C6H5)(COD)]2(Hg2Cl6)
[Hg{C6H4(PPh2=N(C6H5)}Cl] (0.18 g, 0.3 mmol) and [PtCl2(COD)] (0.11 g, 0.3 mmol) were
refluxed in acetone (30 mL) for 5 d. The solvent was removed under reduced pressure. The final
product was extracted with CH2Cl2 and the resulting solution filtered through a column of celite
giving a light yellow solution. The solution was concentrated (< 3 mL) and upon addition of
Et2O (20 mL), the final product was precipitated as a white solid, isolated by filtration and dried
in vacuo.

Yield: 0.20 g (72%). Anal. Calc. for C64H62N2P2C6lPt2Hg2 · CH2Cl2 (1961.24): C, 38.84; H,
3.21; N, 1.39. Found: C, 38.84; H, 3.42; N, 1.30%. ESI-MS: m/z: 655.18 (100%), [M]+, calc.
655.18). 31P {1H} NMR (CDCl3): δ 64.51 (s), (DMSO-d6): 63.19 (s). 195Pt{1H} NMR (CDCl3): δ
-3622.47 (d, 2JPPt = 404 Hz). 1H NMR (CDCl3): δ 2.66 (8H, m, COD), 5.12-5.30 (4H, m, COD),
6.88 (2H, m, 2-,6-NAr), 7.12 (1H, m, 4-NAr), 7.21 (2H, m, 3-,5-NAr), 7.35 (1H, m, 4-C6H4),
7.56-7.67 (10H, m, o-,m-,p-C6H5), 7.75 (2H, m, 5-C6H4).

13

C{1H} CDCl3): δ 28.24 (s, COD),

31.23 (s. COD), 89.30 (s, COD), 116.12 (s, COD), 124.3 (d, 1JPC = 91.6 Hz, Ci), 127.1 (d, 5JPC =
2.7 Hz, 4-NAr), 127.8 (d, 3JPC = 13.9 Hz, 4-C6H4), 129.5 (d, 3JPC = 2.9, Hz, m-C6H5), 129.7 (s,
3-,5-NAr), 130.1 (d, J = 4.8 Hz, 2-,6-NAr), 132.7 (d, 2JPC = 14.3 Hz, 3-C6H4), 133.3 (m, o-,pC6H5), 134.3 (d, 4JPC = 2.3 Hz, 5-C6H4), 147.8 (s, Pt-C). IR (cm-1):  529 (Pt-N), 1310 (N=P).
Conductivity: 102.3 μS/cm (acetone) (1:1 electrolyte).
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Synthesis of 5
[Pt{κ2-C,N-C6H4(PPh2=N(C6H5)(COD)](PF6)
[Au{C6H4(PPh2=N(C6H5))-2}(PPh3)] (0.28 g, 0.3 mmol) and PtCl2(COD) (0.11 g, 0.3 mmol)
were stirred in CH2Cl2 (20 mL) for 25 min at RT, follow by addition of NH4PF6 (0.049g, 0.3
mmol). The resulting solution was stirred for an additional 1 h. The solution was concentrated
(<3 mL) and dry Et2O (20 mL) was added giving rise to gray precipitate which was stirred for 10
min. The precipitated gray solid was isolated by filtration and washed with water (4 x 2 mL) and
a cold mixture (1:8) of CH2Cl2/Et2O (4 x 5 mL) yielding a white solid that was dried in vacuo.
Yield: 0.14 g (58%). Anal. Calc. for C32H31F6NP2Pt (800.63): C, 48.01; H, 3.90; N, 1.75. Found:
C, 47.74; H, 4.11; N, 1.74%. ESI-MS: m/z: 655.18 (100%), [M]+, calc. 655.18). 31P {1H} NMR
(CDCl3): δ 64.65 (s), (DMSO-d6): 63.19 (s).

195

Pt{1H} NMR (CDCl3): δ -3614.48 (d, 2JPPt =

406.1 Hz). 1H NMR (CDCl3): δ 2.64 (8H, m, COD), 5.20 (4H, m, COD), 6.88 (2H, m, 2-,6NAr), 7.09 (1H, m, 4-NAr), 7.20 (2H, m, 3-,5-NAr), 7.23 (1H, m, 3-C6H4), 7.33 (1H, m, 4C6H4), 7.49-7.66 (10H, m, o-,m-,p-C6H5), 7.72 (2H, m, 5-C6H4); 13C{1H} (CDCl3): δ 28.05 (s,
COD), 31.02 (s. COD), 89.22 (s, COD), 116.49 (s, COD), 124.3 (s, Cipso), 125.2 (s, Cipso), 127.0
(d, 5JPC = 2.9 Hz, 4-NAr), 127.6 (d, 5JPC = 13.9 Hz, 4-C6H4), 129.5 (d, 3JPC = 2.5, Hz, m-C6H5),
129.6 (s, 3-,5-NAr), 130.1 (d, 3JPC = 4.9 Hz, 2-,6-NAr), 132.6 (d, 2JPC = 13.8 Hz, 3-C6H4), 133.3
(m, o-,p-C6H5), 134.2 (d, 4JPC = 2.9 Hz, 5-C6H4), 147.8 (s, Pt-C). IR (cm-1):  566 (Pt-N), 838
(br, PF6-), 1298 (N=P). Conductivity: 106.5 μS/cm (acetone) (1:1 electrolyte).

X-Ray crystallography
A gold block-like crystal with the size of 0.10  0.18  0.18 mm3 was selected for geometry and
intensity data collection with a Bruker SMART APEXII CCD area detector on a D8 goniometer
at 100 K. The temperature during the data collection was controlled with an Oxford Cryosystems
Series 700+ instrument. Preliminary lattice parameters and orientation matrices were obtained
from three sets of frames. Data were collected using graphite-monochromated and 0.5 mmMonoCap-collimated Mo-K radiation (λ = 0.71073 Å) with the ω and φ scan method. Data were
processed with the INTEGRATE program of the APEX2 software for reduction and cell

105

refinement. Multi-scan absorption corrections were applied by using the SCALE program for the
area detector. The structure was solved by the direct method and refined on F2 (SHELXTL)[2].
Non-hydrogen atoms were refined with anisotropic displacement parameters, and hydrogen
atoms were placed in idealized positions (C-H = 0.95-0.99 Å) and included as riding with
Uiso(H) = 1.2 or 1.5 Ueq(non-H).
Cell culture, inhibition of cell growth and cell death analysis
(MTT toxicity assays)
For toxicity assays cells (5 x104 for Jurkat cells and 104 for adherent cell lines) were seeded in
flat-bottom 96-well plates (100 µl/well) in complete medium. Adherent cells were allowed to
attach for 24 h prior to addition of cisplatin or tested compounds. Compounds were added at
different concentrations in triplicate. Cells were incubated with cisplatin or compounds for 24 h
and then cell proliferation was determined by a modification of the MTT-reduction method.
Briefly, 10 µl/well of MTT (5 mg/ml in PBS) was added and plates were incubated for 1-3 h at
37 ºC. Finally, formazan crystal was dissolved by adding 100 µl/well iPrOH (0.05 M HCl) and
gently shaking. The optical density was measured at 570 nm using a 96-well multiscanner
autoreader (ELISA).
Cell death analysis
Apoptosis/necrosis hallmarks of cells treated with compound 5 were analyzed by measuring
mitochondrial

membrane

potential,

plasma

membrane

integrity

and

exposure

of

phosphatidylserine. Cells were treated with different concentrations and at different incubation
times as indicated in figure legends. In some experiments the general caspase inhibitor z-VADfmk was added at 50 µM 1 h before compounds. For mitochondrial membrane potential
determination cells (2.5x105 in 200 µl) after treatment with 5 were incubated at 37ºC for 15
minutes in medium containing 5nM DiOC6(3) (Molecular Probes). Phosphatidylserine exposure
was quantified by labeling cells with AnnexinV-DY634 (Invitrogen) after treatment with 5.
AnnexinV was added at a concentration of 0.5 µg/ml in Annexin Binding Buffer (ABB) and
cells were incubated at room temperature for 15 min. Plasma membrane integrity was evaluated
by staining with 7-Amino-Actinomycin D (7-AAD, Inmunostep). At the end of the treatment
with 5, cells were incubated for 15 min in 200 μl of PBS containing 50 ng/μl 7-AAD. In all
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cases, cells were diluted to 1 ml with ABB or PBS (Phosphate Buffered Saline) to be analyzed
by flow cytometry (FACScan, BD Bioscience, Spain).
Permeability determinations
(Cell culture and transport assays)
Caco-2 cells were grown in Dubelcco’s Modified Eagle’s Media containing L-glutamine, fetal
bovine serum and penicillin-streptomycin. To obtain cells monolayers 250000 cells/cm2 were
seeded on each well with polycarbonate membrane with 4.2 cm2 area. Plates were incubated at
standard conditions of 37ºC temperature, 90% humidity and 5% CO2 until confluence. After 1921 days the integrity of the each cell monolayer was evaluated by measuring the trans-epithelial
electrical resistance (TEER). Values ranging 500-750 Ωcm2 were considered appropriated.
Transport studies were performed using an orbital environmental shaker at constant temperature
(37ºC) and agitation rate (50 rpm). Hank’s balanced salt solution (HBSS) supplemented with
HEPES was used to fill the receiver chamber and to prepare the drug solution placed in the donor
chamber. Four samples of 200 µL each one were taken from the receiver chamber side at
predefined times (15, 30, 60 and 90 minutes) and the same volumen were replaced with fresh
buffer. Moreover, two samples of the donor side were taken at the beginning and the end of the
experiment. Moreover, the amount of compound in cell membranes and inside the cells was
determined at the end of experiments in order to check the mass balance and the percentage of
compound retained in the cell compartment was always less than 5%.
Transport studies were performed in both directions, from apical-to-basal (A-to-B) and from
basal-to-apical (B-to-A) sides. The volume of donor compartment was 2 mL in A-to-B direction
and 3 mL in B-to-A direction.
Analysis of the samples
Samples were analyzed by HPLC using a 5 μm, 4 x 200 mm Novapack C18 column. Samples of
Cisplatin and compound 4 were analyzed with UV detection (λ=240 nm) and the mobile phase
was 95:5, acetonitrile: water, with a flow rate of 1mL/min, and the injected sample volume was
50 μL. Samples of compound 5 were analyzed similarly but using a UV detector at λ=215 nm
and a mobile phase of 80:20 acetonitrile: water.
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Data analysis
The apparent permeability coefficient was calculated following the equation:
C receiver,t =

Qtotal

Vreceiver  Vdonor

1
1 
  P· S· Vreceiver  Vrdonor ·t
·e

(1)


Qtotal
  C receiver,t  1  f  
Vreceiver  Vdonor 


where Creceiver, t is concentration of compound in the receiver chamber at t time, Qtotal is the total
amount of drug in both chambers, Vreceiver and Vdonor are the volumes corresponding to receiver
and donor compartment respectively in each chamber, Creceiver, t-1 is concentration of compound
in receiver chamber at previous time, f is the sample dilution factor due to replaced volume, S is
the surface area of the monolayer, Δt is the time interval and P is the permeability coefficient.
This equation takes into account the continuous change of the donor and receiver concentrations,
i.e. non-sink conditions. However, when the transport rate is low, there are not significantly
changes between the donor and the receiver concentrations with time. In this conditions sink
conditions are assumed and a simpler expression can be used to estimate the permeability
coefficient:
dQ
P 

dt
C·S

(2)

where dQ/dt is the apparent appearance rate of drug in the receiver side calculated using linear
regression of amounts in the receiver chamber versus time, S is the surface area of the monolayer
and C is the drug concentration in the donor chamber.
The permeability coefficient estimations in sink and non-sink conditions were carried out in an
Excel® worksheet.
Studies were performed by triplicate and the data were presented as mean ± SD. Student’s t-test
were performed with SPSS 16.0 (SPSS Inc.) in order to determine statistically significant
differences between A-to-B and B-to-A permeabilities.
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In situ absorption experiments
The absorption experiments were performed using an in situ loop technique described by
Doluisio.52 The study was approved by the Scientific Committee of the Faculty of Pharmacy and
followed the guidelines described in the EC Directive 86/609, the Council of the Europe
Convention ETS 123 and Spanish national laws governing the use of animals in research (Real
Decreto 223/1988, BOE 67, 18-3-98: 8509-8511). Male Wistar rats weighing 280-320 g were
used after 8 h of fasting. Previously to surgical procedure, animals were anesthetized with
Diazepam (Valium, Roche) (1,67 mg/kg), Ketamine (Ketolar; parke-Davis) (50mg/kg) and
Atropine (atropine sulfate; Braun) (1mg/kg). The body temperature was maintained during the
procedure by heating with a lamp. Therefore, a midline abdominal incision were performed and
a loop was isolated from duodenal and ileal region of each rat. The proximal ligatures of the
duodenal and ileal regions were placed approximately 1 cm from the pylorus and 2 cm above the
ileocecal junction. The bile duct was tight up in all experiments. 50 mL of cleaning solution
(Solution A (pH 7,4): 9,2 g NaCl, 0.34 g KCL, 0.19 g CaCl2*H2O and 0.76 g NaH2PO4*2 H2O
per liter) were used to flushed out the content of the loop and then 20 mL volume of solution B
(NaCl g, NaH2PO4*2H2O 1/15M 3.9 mL, Na2HPO4 1/15M 6.1 mL and water up to 1L) were
perfused to condition the intestinal mucosa prior to the experiments. A catheter was tight up at
both intestinal ends and connected to a glass syringe by the use of a stopcock type valve. Under
this set up, the intestinal segment is an isolated compartment and the drug solution can be
perfused. The drug solutions were prepared freshly day at 20 µM using solution B as solvent and
perfused into the loop and then the entire intestine was restored into the abdominal cavity.
Samples of the perfusate were carried out every 5 minutes for 30 minutes.
Permeability Calculations
The apparent first order absorption rate coefficients (kapp) were obtained by non-linear fitting of
a monoexponential equation to the luminal concentrations versus time.
C = C0 · e−kapp·t

(3)

where the C is the drug concentration remaining in the lumen, kapp is the apparent absorption
rate constant, and C0 corresponds to a calculated fraction of the initial perfusion concentration.
Test solutions suffer a slight dilution in the intestinal lumen due to the remaining cleaning
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solution, the adsorption to the membrane, and the loading process in the enterocyte. So, the
intercept, C0, is lower than the perfusion concentration. The quasi-steady-state is achieved in the
membrane when this process is finished. Under these conditions, the disappearance of the
compound from the lumen can be considered as a first order process during the sampling time
interval. For these reasons, only the concentrations obtained after 5 min were used for regression
analysis. In order to obtain good prediction data water reabsorption correction of was introduced
for the concentrations calculations.
The intestinal permeability values were calculated taking into account the relationship between
ka and Peff:
Peff  (ka ·R) / 2

(4)

where R is the radius of the intestinal segment, calculated as area/volume ratio. The effective
intestinal permeabilities (Peff) of the tested compounds (means of at least of three animals) were
used as indexes of the absorption effectiveness.
Interaction of compounds 1-5 and cisplatin with plasmid (pBR322) DNA by
Electrophoresis
(Mobility Shift Assay)

10 µL aliquots of pBR322 plasmid DNA (20 µg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO4,
pH = 7.39) were incubated with different concentrations of the compounds 1-5 (in the range 0.25
and 2.0 metal complex:DNAbp) at 37 oC for 20 h in the dark. Samples of free DNA and
cisplatin-DNA were prepared as controls. After the incubation period, the samples were loaded
onto the 1 % agarose gel. The samples were separated by electrophoresis for 1.5 h at 84 V in
Tris-acetate/EDTA buffer (TAE). Afterwards, the gel was stained for 30 min with a solution of
GelRed Nucleic Acid stain.

Interaction of compounds 3-5 and cisplatin with Calf Thymus DNA by Circular Dichroism
Stock solutions (5 mM) of each complex were freshly prepared in water prior to use. The right
volume of those solutions was added to 3 ml samples of an also freshly prepared solution of CT
DNA (195 µM) in Tris/HCl buffer (5 mM Tris/HCl, 50 mM NaClO4, pH=7.39) to achieve molar
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ratios of 0.1, 0.25, 0.5 and 1.0 drug/DNA. The samples were incubated at 37 ºC for a period of
20 h. All CD spectra of DNA and of the DNA-drug adducts were recorded at 25 ºC over a range
220-330 nm and finally corrected with a blank and noise reduction. The final data is expressed in
molar ellipticity (millidegrees).
Interaction of compounds 1-5 and cisplatin with HSA by Fluorescence Spectroscopy
A solution of each compound (8 mM) in DMSO was prepared and ten aliquots of 2.5 µL were
added successively to a solution of HSA (10 µM) in phosphate buffer (pH = 7.4) to achieve final
metal complex concentrations in the range 10-100 µM. The excitation wavelength was set to 295
nm, and the emission spectra of HSA samples were recorded at room temperature in the range of
300 to 450 nm. The fluorescence intensities of all the metal compounds, the buffer and the
DMSO are negligible under these conditions. The fluorescence was measured 240 s after each
addition of compound solution. The data were analyzed using the classical Stern-Volmer
equation F0/F = 1 + KSV[Q].

Cell culture and XTT assay for RPTC cells
The human Renal Proximal Tubule Cells (RPTC) a non-tumoral human kidney epithelial
cell line (obtained from Lifeline Cell Technology, Frederick, Maryland, USA) were cultured in
Lifeline's RenaLife Medium containing RenaLife LifeFactors with 2.4 mM L-Glutamine, 5
Î¼g/mL rh insulin, 1.0 Î¼M epinephrine, 10 nM triiodothyronine, 0.1 Î¼g/mL hydrocortisone
hemisuccinate, 10 ng/mL rh EGF, 0.5% FBS and 5 Î¼g/m transferrin PS (all from Lifeline Cell
Technology), at 37°C in a humidified atmosphere of 95% of air and 5% CO2 (Brooklyn College,
CUNY, US). For evaluation of cell viability, cells were seeded at a concentration of 5×10^3
cells/well in 90 µl Lifeline's RenaLife complete medium into tissue culture grade 96-well flat
bottom microplates (Thermo Scientific BioLite Microwell Plate, Fisher Scientific, Waltham,
Massachusetts, USA) and grown for 24 h. Solutions of the compounds were prepared by diluting
a freshly prepared stock solution (in H2O) of the corresponding compound in Lifeline's RenaLife
complete medium. Afterwards, the intermediate dilutions of the compounds were added to the
wells (10 µL) to obtain a final concentration ranging from 0.1 to 200 µM, and the cells were
incubated for 24 h. Following 24 h drug exposure, 50 µL of 2,3-Bis-(2-Methoxy-4-Nitro-5Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide (XTT) (Roche Diagnostics, Indianapolis, Indiana,
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USA) labeling mixture per well was added to the cells at a final concentration of 0.3 mg/ml and
incubated for 4 h at 37°C in a humidified atmosphere of 95% of air and 5% CO2. The optical
density of each well (96-well plates) was quantified using EnVision Multilabel Plate Readers
(Perkin

Elmer,

Waltham

Massachusetts,

USA) at 450

nm

wavelength

to

measure

absorbance. The percentage of surviving cells was calculated from the ratio of absorbance of
treated to untreated cells. The IC50 value was calculated as the concentration reducing the
proliferation of the cells by 50% and is presented as a mean (± SE) of at least two independent
experiments each with triplicates.
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4.8. Appendix

Crystallographic data for compounds 2 and 4 including complete drawing of the structure and
table of selected distances and angles for compound 4; stability of compounds 1-5 by

31

P{1H}

spectroscopy in DMSO-d6 solution; selected 1H and 31P{1H} NMR spectra for compounds 1-5 in
DMSO-d6; stability of compounds 4 and 5 in DMSO:PBS (1:99) determined by Uv-Vis.

4.8.1. Crystallographic Data for Compounds 2 and 4.
Table 7. Crystal data for compounds 2 and 4.
Compound

2

4

Formula

C13H16N4OPCl2Au

C66H66Cl10Hg2N2P2Pt2

Formula weight

543.13

2095.01

T [K]

100(2)

100(2)

 (Mo-K) [Å]

0.71073

0.71073

Crystal system

Orthorhombic

Triclinic

Space group

Pbca

P 1

a [Å]

12.8453(8)

11.1159(5)

b [Å]

11.0611(7)

c [Å]

22.6045(14)

14.8021(6)

 [o]

90

92.5060(10)

 [o]

90

99.7520(10)

 [o]

90

115.8280(10)

V [Å3]

3211.7(3)

1715.94(13)

Z

8

1

Dcalcd (g cm-3)

2.247

2.027

 (mm-1)

9.599

9.000

GOF

1.057

1.048

R1 [I > 2(I)]

0.0142

0.0186

wR2 (all data)

0.0317

0.0390
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11.8606(5)

Table 8. Selected Structural Parameters of complex 2 obtained from X-ray single crystal
diffraction studies (see drawing above). Bond lengths are given in [Å] and angles in [º].
Au(1)-Cl(1)
Au(1)-Cl(2)
Au(1)-C(1)

2.3834(5)
2.2798(5)
2.020(2)

N(1)-Au(1)-Cl(2)
N(1)-Au(1)-Cl(1)
Cl(2)-Au(1)-Cl(1)

173.33(5)
97.32(5)
88.62(2)

Au(1)-N(1)

2.0497(18)

P(1)-N(1)-Au(1)

126.07(10)

P(1)-N(1)

1.6658(18)

P(1)-N(1)-C(7)

119.25(15)

N(1)-C(7)
C(7)-O(1)
C(7)-C(6)

1.404(3)
1.213(3)
1.478(3)

N(1)-C(7)-C(6)
N(1)-C(7)-O(1)
C(7)-N(1)-Au(1)

112.16(19)
123.72(19)
114.68(14)

C(6)-C(1)

1.385(3)

C(7)-C(6)-C(1)
C(6)-C(1)-Au(1)

118.0(2)
113.24(16)

C(1)-Au(1)-N(1)
C(1)-Au(1)-Cl(2)

81.68(8)
92.44(6)

N(1)-P(1)-C(10)
N(1)-P(1)-C(8)

113.99(10)
116.45(10)

C(1)-Au(1)-Cl(1)

178.28(6)

N(1)-P(1)-C(13)

117.81(10)
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Table 9. Selected Structural Parameters of complex 4 (see drawing incorporating the anion
above) obtained from X-ray single crystal diffraction studies. Bond lengths are given in [Å] and
angles in [º].
Pt(1)-C(1)
Pt(1)-N(1)

2.039(2)
2.039(2)

N(1)-Pt(1)-C(1)
N(1)-Pt(1)-C(25)

85.31(9)
95.99(9)

Pt(1)-C(30)
Pt(1)-C(29)

2.150(2)
2.160(2)

N(1)-Pt(1)-C(26)
N(1)-Pt(1)-C(29)

91.92(8)
162.15(9)

Pt(1)-C(26)
Pt(1)-C(25)
P(1)-N(1)

2.268(2)
2.287(2)
1.622(2)

N(1)-Pt(1)-C(30)
C(1)-Pt(1)-C(25)
C(1)-Pt(1)-C(26)

160.07(9)
163.39(9)
161.34(9)

P(1)-C(2)
P(1)-C(7)

1.773(2)
1.797(3)

C(1)-Pt(1)-C(29)
C(1)-Pt(1)-C(30)

96.26(10)
92.76(10)

P(1)-C(13)
N(1)-C(19)
C(1)-C(2)

1.797(3)
1.444(3)
1.409(3)

P(1)-N(1)-Pt(1)
C(19)-N(1)-Pt(1)
C(19)-N(1)-P(1)

117.55(11)
125.82(16)
116.21(16)

Hg(1)-Cl(1)
Hg(1)-Cl(2)

2.6117(7)
2.3808(7)

Cl(1)-Hg(1)-Cl(2)
Cl(2)-Hg(1)-Cl(3)

107.66(2)
135.47(3)

Hg(1)-Cl(3)
Hg(1)-Cl(1)#1
Cl(1)-Hg(1)#1

2.3865(7)
2.6665(7)
2.6666(7)

Cl(3)-Hg(1)-Cl(1)
Cl(2)-Hg(1)-Cl(1)#1
Cl(3)-Hg(1)-Cl(1)#1

105.68(2)
106.38(2)
102.92(3)

Cl(1)-Hg(1)-Cl(1)#1
Hg(1)-Cl(1)-Hg(1)#1

88.90(2)
91.10(2)
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4.8.2. Stability of complexes in DMSO-d6 solution overtime assessed by

31

P{1H} NMR

spectroscopy.
Compound

Time (DMSO-d6)
1d

4d

1 w

>99%

1
2

3w

1m

2m

3 ms

90%

55%

36%

2 months

>99%

90%

50%

3 months

>99%

months

3
4
5

>99%

4m

Half life (50%)

>99%

90%

84%

months

96%

94%

77%

months

% of decomposition determined by integration of all the signals present in the 31P{1H} NMR
spectra, the sum being set to 100%.
4.8.3. Selected 1H and 31P{1H} NMR spectra showing the stability of complexes in DMSO-d6
overtime.

Figure 15. 31P{1H} NMR spectrum of compound 1 in DMSO-d6 (δ 33.57 (s) ppm) overtime.
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Figure 16. 31P{1H} NMR spectrum of compound 2 in DMSO-d6 ( -2.66 (s) ppm) overtime.

Figure 17. 31P{1H} NMR spectrum of compound 3 in DMSO-d6 ( -10.26 (s) ppm) overtime
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Figure 18. 1H NMR spectrum of compound 3 in DMSO-d6 overtime.

Figure 19. 31P{1H} NMR spectrum of compound 4 in DMSO-d6 ( -62.57 (s) ppm) overtime.
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Figure 20. 1H NMR spectrum of compound 4 in DMSO-d6 overtime.

Figure 21.

31

P{1H} NMR spectra of compound 5 in DMSO-d6 ( 63.10 (s) and – 148.60 (hept)
ppm) overtime.
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Figure 22. 1H NMR spectrum of compound 5 in DMSO-d6 overtime.
4.8.4. UV-Vis spectra of compounds 4 and 5 in CH2Cl2 and in DMSO, and in 1% DMSOPBS solution overtime.

Figure 23. UV-visible spectrum of compound 4 (4.0 µM) in dichloromethane.
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Figure 24. UV-visible spectrum of compound 4 (50.0 µM) in DMSO recorded overtime.

Figure 25. UV-visible spectrum of compound 4 (15.0 µM) in 1:99 DMSO/PBS-1X (pH 7.4)
recorded overtime, incubation at RT.
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Figure 26. UV-visible spectrum of compound 5 (10.0 µM) in dichloromethane.

Figure 27. UV-visible spectrum of compound 5 (50.0 µM) in DMSO recorded overtime.
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Figure 28. UV-visible spectrum of compound 5 (50.0 µM) in 1:99 DMSO/PBS-1X (pH 7.4)
recorded overtime, incubation at RT.

Figure 29. UV-visible spectrum of iminophosphorane ligand Ph3P=NPh (50.0 µM) in DMSO.
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Figure 30. UV-visible spectrum of iminophosphorane ligand Ph3P=NPh (50.0 µM) in 1:99
DMSO/PBS-1X (pH 7.4).
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CHAPTER V

RUTHENIUM(II) COMPOUNDS WITH N,N- CHELATING AND
C,N- (CYCLOMETALLATED) IMINOPHOSPHORANE LIGANDS.
IN VITRO AND IN VIVO EVALUATION AND PRELIMINARY
MECHANISTIC STUDIES.
_________________________________________________

5.1. Ruthenium(II and III) as potential anticancer agents

As mentioned in chapter I, ruthenium compounds have emerged as promising candidates
for metal based cancer chemotherapeutics.1-5 Like platinum-based drugs, ruthenium compounds
can exchange N- and O-donor molecules with the added advantage of the possibility of forming
octahedral complexes (of interest in reactions with DNA). As described in Chapter I, three
ruthenium(III) coordination complexes have successfully completed phase I clinical trials and
entered phase II (NAMI-A,4,6 KP1019 and KP13394,7,8 ).
More recently, ruthenium (II)-arene complexes (with a piano-stool structure) have also
been described as promising candidates.4,9-18 The two most relevant examples, which have
undergone advanced preclinical studies are RM175, described by Sadler et al. and RAPTA-T
reported by Dyson et al. (Figure 1). RAPTA-T, containing the hydrophilic and monodentante
PTA phosphine ligand, showed to reduce the growth of lung metastases in mice bearing
mammary carcinoma and was able to inhibit highly invasive breast cancer. RM175 demonstrated
to be active in vivo against triple-negative breast cancer cell lines.13,19 Pfeffer-Gaiddon and coworkers reported on C,N-cyclometallated compounds (such as RDC11 in Figure 1) that inhibited
the growth of human cancer xenografts in mice more efficiently than cisplatin.4,10,20-23 Notably, it
did not cause severe side effects in liver, kidneys, neuronal sensory system or blood cells
qualifying as a promising candidate for future clinical trials in cisplatin-resistant cancers.4,20,22
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Figure 1. Selected ruthenium(III) and (II) compounds with important antitumor and/or
antimetastatic properties.4-22,35-37 and refs. therein

Very recently, Dyson et al. showed that RAPTA-C reduces the growth of primary tumors
in preclinical models for ovarian and colorectal carcinomas through an antiangiogenic
mechanism, most likely through binding to the histone protein core in chromatin rather than to
the DNA.24,25 Another recent report by the same group described Ru(II)-arene complex with a
perfluoroalkyl-modified ligand (A, in Figure 1) that displayed antiproliferative activity against
four cancer cell lines in vitro and with no toxic effect to non-tumoral cells. Furthermore, in vivo
studies of A in a xenografted ovarian carcinoma (A2780) grown on the chicken chorioallantoic
membrane model (CAM) led to a 90% reduction in tumor growth, displaying a stronger
antivascular effect than RAPTA-C.24
Dyson et al. also reported on the evaluation of a similar Ru(II)-arene complex, with a
long fluorous chain (B, in Figure 1), which exhibited a synergistic tumor growth reduction in
dual-therapy with local hyperthermia showing tumor growth reduction by 90%. It has been
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shown that combining chemotherapy with regional mild hyperthermia, applying heat locally to
rise the tumor temperature between 40-42ºC, can sensitize tumor tissue to anticancer agents
resulting in improved local control, treatment efficacy and overall survival prolongation.26
The recent strategy to bind a drug of well-known therapeutic value (such as curcumin,
ketoconazole, clotrimazole, hydroxyflavones, hydroxyquinolinones, letrozole, indolobenzazepins
or aspirin) to ruthenium centers has rendered a number of complexes with improved properties
with respect to the parent organic drugs for cancer.e.g.27-34 In this context, ruthenium compounds
resembling staurosporine (like DW1/2 in Figure 1) developed by Meggers and co-workers are
relevant examples of potential chemotherapeutics targeting protein kinases.4,10,35-37
Hartinger et al. explored new routes to develop metallodrugs by coordinating
pharmacophores to metal fragments with established anticancer properties. In their study, oxicam
backbone that is found in the nonsteroidal anti-inflammatory drugs, was incorporated into an
organometallic Ru(II)-arene compound. The most lipophilic compound in this study (C in Figure
1) displayed the most cytotoxicity against human colon carcinoma (HCT116) cell lines in vitro.
Even though the IC50 of the compound was not significantly low, this and other compounds in
this study could be further explored to fully understand their mode of action. In comparison,
other ruthenium compounds complexes, such as NAMI-A and RAPTA derivatives, were
noncytotoxic in vitro but exhibited high activity against metastases in vivo.38
In a recent study done by Süss-Fink and co-workers, dinuclear p-cymene ruthenium
complex was synthesized and evaluated in vitro for its anticancer activity in series of cancer cell
lines (diruthenium-1 in Figure 1). Diruthenium-1 was found to be highly cytotoxic towards
ovarian cancer (A2780) cell lines in vitro, in low nanomolar range (30 nM). The complex was
further studied in vivo in tumor-bearing mice at a dose of 0.6 mg/kg and showed to significantly
prolongated the survival rate of tumor-bearing mice as compared to the untreated control
group.39
Nowadays, there are examples of multinuclear ruthenium compounds,40,41 ruthenium
derivatives which can be activated by light,42 that are thermoresponsive,43 that can be obtained
by a combinatorial approach,44 as well as ruthenium compounds that can be delivered to tumor
sites more efficiently by binding to polymers,45 nanocarriers,46,47 peptides,48,49 or transport
proteins.50 However, there is still a need to find the ultimate target(s) for these ruthenium
compounds as well as to get a better knowledge on the detailed molecular mechanism of action
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in order to develop more powerful and selective chemotherapeutics.4 In addition, more in vivo
data is needed to make more reliable predictions of structure-biological activity correlations.17,19
Within this context, we aimed to explore the potential of IM complexes containing metals
other than d8 transition metals (Au(III), Pd(II) and Pt(II)) as anticancer agents and we focused on
ruthenium(II) compounds. The following chapter reports on the preparation, characterization and
stability

studies

of

organometallic

ruthenium(II)

compounds

containing

different

iminophosphorane ligands. Preliminary biochemical and biochemical studies (in vitro effects on
human cancer cells, type of cell death and permeability studies on selected compounds) were
performed by our collaborators. I studied the interactions of the compounds with plasmid
(pBP322) DNA and of selected compounds on Calf Thymus DNA by different techniques
(melting point, CD circular dichroism). Finally the effects of a water-soluble compound with the
best pharmacological profiles on human cancer xenografts in mice (performed by a PhD student
from our laboratory) will be reported and discussed to put the results into context and discuss the
potential of these ruthenium compounds as cancer chemotherapeutics.

5.2. Synthesis and characterization of ruthenium(II) organometallic complexes containing
iminophosphorane ligands

The synthesis of ruthenium(II) piano-stool complexes containing iminophosphorane
ligands has been described by Urriolabeitia and co-workers.51 We have employed here p-cymene
as the arene group coordinated to the ruthenium centers. Thus, compounds 1-4 can be easily
obtained in high yields by the addition of different IM ligands previously described52-55,56 to [(η6p-cymene)Ru(μ-Cl)Cl]257 (Scheme 1). 4 is an example of a new heterometallic ruthenium
complex containing a ferrocene fragment.
Ruthenium(II) complexes with cyclometallated IM (pincer C,N-) ligands have been
prepared by transmetallation with organomercury derivatives.51 However the nature of the IM
ligand played a crucial role and compounds with semi-stabilized IM ligands containing carbonyl
groups like (2-C6H4)Ph2P=N-CO-Ph could not be obtained due to steric reasons.51
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Scheme 1. Preparation of cationic ruthenium(II) compounds containing IM ligands.

In addition, we also aimed to prepare cycloruthenated compounds in which the aryl group
of the imino fragment is coordinated to the metal center (exo derivatives) as opposed to an aryl
group of the phosphine fragment (endo derivatives) in order to be able to incorporate different
phosphines into the final molecule to tune electronic/steric properties of the resulting complexes.
As described in Chapter IV, cyclometalated iminophosphorane exo derivatives can be prepared
by reaction of the appropriate metal compound with the organomercury derivative Hg(Ph3P=NCO-2-C6H4)Cl.58 As mentioned in the previous chapter, C-H activation at the N-CO-Ph
fragments takes place at a manganese center and by transmetallation of the resulting
136

cyclometalated iminophosphorane manganese compounds to HgCl2, the organomercury
derivatives with PPh3 [Hg(Ph3P=N-CO-2-C6H4)Cl]58 or water soluble phosphine

PTA

[Hg(PTA=N-CO-2-C6H4)Cl] (7) are obtained in high yields. Transmetallation reactions of
[Hg(Ph3P=N-CO-2-C6H4)Cl]58

and

7

with

[(η6-p-cymene)Ru(μ-Cl)Cl]2

afford

new

cyclometallated compounds [(η6-p-cymene)Ru(IM-k-C,N)Cl] (IM = Ph3P=N-CO-2-C6H4 8;
PTA=N-CO-2-C6H4 9) in high yields (Scheme 2).

Scheme 2. Preparation of the new cycloruthenated compounds 8 and 9 containing IM ligands.

All the compounds are obtained as air stable solids in moderate to high yields. Their
structures have been proposed on the basis of microanalytical, spectroscopic (IR and NMR),
conductivity and MS spectrometry data. Some of the compounds are slightly hygroscopic. As
previously proposed by Urriolabeitia and co-workers,51 the IM ligand in compounds 1 and 2 is
bonded as a chelate giving a fac-Cl,N,O arrangement while in compounds 3 and 4 the
arrangement is fac-Cl,N,N. This can be clearly inferred from the IR data. There is a strong
absorption at 1531 cm-1 due to νCO stretch for 1 and 2 shifted to lower frequencies with respect
to that of the free ligand at 1598 cm-1. For 3 and 4 the signal that can be assigned to νPN stretch
is shifted to lower frequency than that of the free ligands (see Experimental Section). As
previously described for compounds containing benzene and some IM ligands,51 the
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P{1H}

NMR signals for 1 and 2 resemble that of the free ligand whereas for 3 and 4 the signals are
strongly shifted to low field with respect to the free ligands, indicating iminic N-bonding. In
addition, the ortho protons of the quinoline (H2) and pyridine (H6) in the 1H NMR spectra for 3
and pyridine (H6) for 4 are shifted downfield supporting the idea of N-coordination. Compound 4
shows fluxional behavior at room temperature (giving rise to broad signals in the 1H NMR
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spectrum in the area of the p-cymene and Cp rings) and its variable temperature NMR spectra are
collected in the Appendix.
The structure of 1 has been determined by an X-ray analysis and it is very similar to that
of previously reported51 [(η6-C6H6)Ru(k-N,O-Ph3P=N-CO-2-N-C5H4)]PF6 with very similar
distances and angles. The molecular structure for the cation of 1 is depicted in Figure 2. Selected
bond lengths and angles for compound 1 are collected in Table 1.

Figure 2. Molecular structure of the cation of compound 1.

Table 1. Selected Structural Parameters of complex 1 obtained from X-ray single crystal
diffraction studies (see drawing above). Bond lengths are given in [Å] and angles in [º].

Ru(1)-O(1)

2.110(3)

Ru(1)-Cl(1)

2.3775(14)

Ru(1)-N(1)
Ru(1)-C(10)
Ru(1)-C(6)

2.095(4)
2.153(5)
2.154(5)

O(1)-C(16)
C(1)-N(2)
C(1)-C(2)

1.266(6)
1.337(7)
1.385(8)

Ru(1)-C(7)

2.171(5)

N(2)-P(1)

1.619(5)

Ru(1)-C(9)

2.187(5)

N(1)-Ru(1)-O(1)

76.68(14)

Ru(1)-C(11)
Ru(1)-C(8)

2.191(5)
2.204(5)

O(1)-Ru(1)-Cl(1)
N(1)-Ru(1)-Cl(1)

83.61(10)
83.13(12)

138

The analysis confirms the piano-stool structure around the ruthenium center as well as the
coordination of the IM ligand through the N and O atoms. Ru-C distances are on average slightly
longer and the O(1)-Ru(1)-N(1) and N(1)-Ru(1)-Cl(1) angles slightly smaller for 1 than for the
compound with (η6-C6H6)51 as expected.
Compounds 8 and 9 are cycloruthenated neutral species with the IM ligand in an exo
disposition [(η6-p-cymene)Ru(IM-k-C,N)] (IM = Ph3P=N-CO-2-C6H4 8; PTA=N-CO-2-C6H4 9).
Their 1H NMR spectra show signals due to η6-arene as well as the C6H4P units. In addition, the
13

C{1H} NMR spectrum shows six well-resolved peaks due to the C6H4P unit. The signals in the
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P{1H} NMR spectra are strongly shifted downfield with respect of those for the free ligand as

reported before for endo cycloruthenated species.51
The cationic compounds with chloride as counterion (2, 3, and 4) are highly soluble in
water (70 to 100 mg/mL). The cycloruthenated derivative 9 with a water-soluble phosphine PTA
(9) is much less soluble in water (1 mg/mL 9). 1, and cyclorutenated 8 and 9 are soluble in
micromolar concentrations in 1:99 DMSO:H2O mixtures. All the complexes but 9 are stable for
weeks in DMSO-d6 solution (see spectra and stability table in the Appendix). The stability of the
water-soluble complexes was studied by
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P{1H} and 1H NMR spectroscopy in D2O. The

spectrum in D2O for compound [(η6-p-cymene)Ru{Cp-P(Ph2)=N-CH2-2-NC5H4}Fe(Cp)}]Cl (4)
does not change for over 3 days but after that time the compound precipitates. The 31P{1H} NMR
spectrum in D2O for 3 (δ= 37.73 ppm) shows an additional signal (δ= 38.34 ppm) that may be
assigned to a hydrolyzed species of the type [(η6-p-cymene)Ru(Ph3P=N-8-C9H6N)(OH2)]2+. The
integration of these signals is ca. 45:55 and the spectrum does not change much over time (days).
In the case of compound 2 (δ in D2O 26.33 ppm) a signal (attributable to [(η6-pcymene)Ru(Ph3P=N-CO-2-N-C5H4)(OH2)]+ is also visible in D2O (δ = 26.65 ppm) along with
another signal (δ = 43.79 ppm), which may correspond to the cyclometalated species [(η6-pcymene)Ru(IM-k-C,N-C6H4(PPh2=N-CO-2-N-C5H4)Cl]

or

[(η6-p-cymene)Ru(IM-k-C,N-

C6H4(PPh2=N-CO-2-N-C5H4)(OH2)]+ and grows overtime. The 1H NMR spectrum of 2 in D2O
after 5 days shows (in addition to those of compound 2) signals due to new species containing
η6-arene as well as the C6H4P unit indicating the cyclometalation of the PPh3 ring. In addition,
the 13C{1H} NMR spectrum shows most of the six peaks due to this C6H4P unit. The doublet that
can be assigned to the C=O peak for these new cyclometalated species appears at 176.06 ppm
(versus 178.08 ppm for 2) an it is closer to the chemical shift observed when C=O is not
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coordinated to the ruthenium center (like in the case of the free ligand which displays a doublet
at 175.34). The MS spectra of 2 in H2O overtime shows a peak at m/z = 617 with a pattern fitting
that of cationic species [(η6-p-cymene)Ru(IM-k-C,N-C6H4(PPh2=N-CO-2-N-C5H4)]+. The
cyclometalation processes at room temperature in DMSO of arylgroups from PPh3 in IM
coordination complexes of Pd and Pt with the Ph3P=N-8-C9H6N IM ligand have been reported
before.55 The half-life for 2 (14.5 mM) in D2O is 2.5 days (although the process slows down for
more concentrated samples). The cyclometalation process for 2 proceeds faster in a 100 mM
NaCl solution in D2O (half-life ca. 10 hours for a concentration of 2 of 14.5 mM) and by
increasing the temperature (60% after 1 hour at 80oC). However, as it will be explained in
section 5.3, the biological activity of compound 2 is very fast (in 8 hours it induces 80% of
apoptosis on Jurkat cells) and thus we believe that the biological activity observed comes mainly
from coordination compound 2 or its hydrolysis product.

5.3. Biological activity in vitro

These studies were performed by Dr. Isabel Marzo, Oscar Gonzalo and Daniel Ramírez de
Mingo at the University of Zaragoza, Spain. The studies on non-carcinogenic RPTC cell lines
were performed by PhD student Benelita T. Elie in our laboratory.

5.3.1. Antiproliferation studies in vitro

The antiproliferative properties of the new ruthenium complexes 1-4, 8 and 9 and of the
starting material [(η6-p-cymene)Ru(μ-Cl)Cl]2 were assayed by monitoring their ability to inhibit
cell growth using the MTT assay (see Experimental Section). Cytotoxic activity of the
compounds was determined in several human cancer cell lines: leukemia Jurkat-T, lung A549,
prostate DU-145, pancreas MiaPaca2, and triple negative breast MDA-MB-231, in comparison
to cisplatin. The results are summarized in Table 2. The starting material [(η6-p-cymene)Ru(μCl)Cl]2 is poorly cytotoxic in all tested cell lines (IC50 >125 µM). The IM ligands coordinated to
the ruthenium centers are known to be poorly cytotoxic (IC50 in different cell lines >100-500
µM).52-55
Compounds with coordinated IM ligands 1-3 and with the IM-PPh3 cyclometalated
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ligand 8 were considerably more cytotoxic than cisplatin in all the cell lines studied. Compounds
1 and 2 (same cation) display almost identical IC50 values but 2 is soluble in H2O. The ruthenium
compound based on an iminophosphorane ligand containing a ferrocenyl phosphine Fe-Ru 4 was
less cytotoxic than cisplatin. The bimetallic compounds Fe-Au and Fe-Pd also showed higher
IC50 values when compared to trimetallic derivatives or compounds with different IM ligands.
The cycloruthenated compound containing a water soluble IM ligand (IM-PTA) was more
cytotoxic than cisplatin for the pancreas MiaPaca2, and triple negative breast MDA-MB-231 cell
lines.
Table 2. IC50 (µM) of metal complexes 1-4, 8-9, [(η6-p-cymene)Ru(μ-Cl)Cl]2a, and cisplatin in
human cell lines.b All compounds were dissolved in 1% of DMSO and diluted with water before
addition to cell culture medium for a 24 h incubation period. Cisplatin was dissolved in H2O.

Jurkat

A549

DU-145

MiaPaca2

MDA-MB-

HEK-293T

231
1

1.1 ± 0.14

9.9 ± 1.9

1.89 ± 0.64

2.4 ± 0.18

4.91± 2.7

2.8 ± 0.2

2

0.78 ± 0.08

9.5 ± 2.1

1.55 ± 0.21

2.9 ± 0.8

2.61 ± 1.2

2.8 ± 0.2

3

0.9 ± 0.32

43.3 ± 8.0

6.6 ± 0.85

7.0 ± 0.4

16.2 ± 0.9

2.2 ± 1.1

4

9.3 ± 0.07

>125

148 ± 33

> 125

> 125

114.5 ± 14.8

8

2.39 ± 0.27

29.9 ± 5.8

14.2 ± 4.2

8.2 ± 0.98

7.1 ± 0.11

4.1 ± 0.06

9

17.7 ± 7.5

>125

125.5 ± 28

54.5 ± 16

75.4 ± 9.8

141.9 ± 13.1

Cisplatin

10.8 ± 1.2

114.2 ± 9.1

112.5±33

76.5 ± 7.4

131.2 ± 18

69.0 ± 6.7

a

IC50 for [(η6-p-cymene)Ru(μ-Cl)Cl]2 >125 µM in all cell lines. bData are expressed as mean ±
SD (n =4).
In order to assess the compounds’ selectivity for cancerous cells with respect to normal
cell lines, they were also screened for their antiproliferative effects on the non-tumorigenic
human embryonic kidney cells HEK293T. In most cases the cytotoxicity is comparable for the
cancerous and HEK293T cells. All compounds are more toxic to leukemia than to HEK293T cell
lines (2 to 8 times) and compounds 1, 2, and 9 are more toxic to the prostate DU-145 cancer cell
line than to HEK cell lines. In addition, 9 is more toxic to the pancreas MiaPaca2 cancer cell line
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and to the breast cancer MDA-MB-231 cell line than to HEK293T although the IC50 for those
cell lines are higher than other compounds in the table.
Importantly as HEK cell lines are immortalized cells that can display a higher sensitivity
to chemicals, we measured the effect of compound 2 on human renal proximal tubular cells
(RPTC). Renal proximal tubular cells in primary culture have been described as an in vitro
model to study nephrotoxicity.59 The IC50 value (XTT assay 24 hours see Experimental Section)
for 2 in this cell line was 13.84±1.46 µM (the value obtained for cisplatin as control was
46.42±2.46 µM similar to a values previously reported60 for 24h in rabbit RPTC). Thus, 2 is
more toxic to all the cancer cell lines studied than to the “healthy” human renal cell line and
markedly more toxic to the leukemia Jurkat-T (17.7-fold), prostate DU145 (9-fold), triple
negative breast cancer MDA-MB-231 (5.3-fold), and pancreas MiaPaca (4.7-fold) cancer cell
lines.
2 with an IC50 of 2.64 µM is 30 times more cytotoxic in MDA-MB-231 breast cancer cell
lines than compound RM175 (Figure 1) with an IC50 of 62 µM under the same conditions (MTT,
24 h incubation). The toxicity of RM175 in HBL100 human epithelial cell lines (IC 50= 54 µM)
was similar to that in breast cancer cell lines.13

5.3.2. Mechanism of cell death

The mechanism of cell death induced by 2 and 3 was explored in Jurkat cells. Nuclei
morphology after 24 h incubation with 1 µM solution of 2 or 3 was analysed by Hoechst
staining. Typical apoptotic features, chromatin condensation and fragmentation, were detected
as shown in Figure 3.

Figure 3. Nuclei morphology after treatment of Jurkat cells with compounds 2 and 3.
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Other apoptotic parameters such as phosphatidylserine exposure and mitochondrial
membrane potential dissipation were analyzed, using fluorescent probes as indicated in the
Experimental Section. Dose-response experiments (Figure 4, right panel) confirmed that 2 is
more cytotoxic than 3, as also indicated by MTT assays. Time-course experiments indicated that
2 induced apoptosis in around 80% of cells after 8 h treatment (Figure 4, left panel). Trypan blue
staining confirmed that cell death was through apoptosis, with very low secondary necrotic cells
at 6 h (data not shown). Phosphatidylserine exposure and loss of transmembrane mitochondrial
potential occurred in the same percentage of cells, although at longer incubation periods, there
was an apparent decrease in the percentage of AnnexinV positive cells that was in fact due to cell
disintegration. Apoptosis induction was slower for 3 with the percentage of both AnnexinV+ and
∆Ψmlow cells gradually increasing during the 24 h period of the experiments (Figure 4, left panel).

Figure 4. Dose-response quantification of PS exposure (A) and time-course analysis of PS
exposure and ∆Ψm loss (B) caused by 2 and 3 in Jurkat cells.

Proteins of the Bcl-2 family are key regulators of apoptosis and the levels of some
members are modified in early phases of the process. Thus, we analyzed the effect of 2 in the
levels of two antiapoptotic proteins of the Bcl-2 family (Bcl-XL and Mcl-1) and three
proapoptotic members (Bim, Puma and Noxa) in Jurkat cells (Appendix Figure 43). Jurkat cells
express very low levels of the other antiapoptotic member (Bcl-2). The main changes observed
after treatment with 2 were a high increase in the levels of the propapoptotic proteins Noxa,
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Puma (isoform b) and Bim (isoform beta). Also a slight decrease in the levels of the
antiapoptotic members Bcl-XL and Mcl-1 was observed in cells treated with 2. The proapoptotic
proteins are damage sensors that induce the activation of Bax and Bak and mitochondrial
permeabilization to release cytochrome c, the key event in the intrinsic pathway of apoptosis.61
Taken together these results point to a classical apoptosis mechanism of cell death. This
was confirmed by the finding that the cytotoxicity of both compounds was caspase-dependent
(Figure 5). The general caspase inhibitor z-VAD-fmk completely abrogated PS exposure but it
only partially reduced ∆Ψm loss (from 80% to 30% for 2 and from 40% to 20% for 3).

Figure 5. Effect of the general caspase inhibitor z-VAD-fmk in apoptotic features induced by 2
and 3.

∆Ψm disruption was not completely inhibited by z-VAD-fmk we hypothesize that 2 and
3 could activate caspase-independent pathways acting on mitochondria. In order to determine
whether caspase inhibition prevented or just delayed cell death, we performed experiments in
which cells were treated with 2 or 3 for 24 h in the presence of z-VAD-fmk and then washed and
further cultured in fresh medium for 24 h. PS exposure was analysed after the first 24 h in the
presence of compound+z-VAD-fmk and 24 h after washing. Only around 20% of cells were
AnnexinV+ after 24 h incubation with 2+z-VAD-fmk and 24 h in fresh medium, while 70% of
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cells treated with 2 alone were apoptotic at the end of the experiments. Thus, these results
indicate that in the case of compound 2, caspase inhibition prevented death commitment in a
very high percentage of cells since only 22% were Annexin V+ 24 hours after washing.
However, in the case of 3, the percentage of AnnexinV+ cells 24 h after washing (32%) equalled
that of cell treated with 3 alone for 24 h (28%), suggesting that in this case caspase inhibition did
not prevent irreversible cell damage leading to cell death. These results suggest that 2 and 3
could be acting through different mechanisms, with 3 causing caspase-independent
premitochondrial damage. These differences in the mechanism of 2 and 3 could explain why 3 is
less selective than 2 for tumor cell lines (Table 2).

Figure 6. Analysis of long-term protection by z-VAD-fmk.

Ruthenium compounds have been reported to induce p53-dependent and –independent
cytotoxicity.12,23 In order to determine whether the cytotoxicity of the compounds here is p53dependent we analyzed the levels of p53 in A549 cells, bearing wt-p53, after a short term
treatment with 2. As shown in Figure 7, treatment with 2 did not induce the stabilization of p53,
and even at 3 and 6 h we observed a slight decline in p53 levels, probably due to cell death and
protein loss. These results differ from that reported with other ruthenium organometallic
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compounds that induce short-term p53 accumulation.12,23 However, although p53 protein is
induced by RM175 in HCT116 (colon carcinoma)12 or RDC-9 in A172 (glioblastoma) and
HCT116,23 genetic inhibition of p53 does not avoid the cytotoxicity of these compounds, clearly
indicating that other p53-independent mechanisms can be activated by ruthenium compounds.
Moreover, Gaiddon et al. have shown that a p53-/- cell line (TK6) exhibits the same sensitivity to
RDC-9 than its p53+/+ parental cell line (NH32).23 Furthermore, compounds 1-3 showed high
toxicity against p53 mutated cell lines (Jurkat, MiaPaca2, DU-145 and MDA-MB-231) as shown
in Table 2. Since the activity of cisplatin has been reported to be p53-dependent, new
organometallic compounds that activate p53-independent pathways could be useful in the
treatment of tumors with alterations in p53, the most frequently mutated gene in human cancer.

Figure 7. p53 protein levels after short-term incubation of A549 cells with 2. B-Actin levels
were determined in the same membranes as a total protein loading control.
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5.4. Reactivity with biomolecules

5.4.1. Interaction with DNA

As described in chapters III and IV, since DNA replication is a key event for cell
division, it is among critically important targets in cancer chemotherapy. Most cytotoxic
platinum drugs form strong covalent bonds with DNA bases.62 However, a variety of platinum
compounds act as DNA intercalators upon coordination to the appropriate ancillary ligands.63
The more thoroughly studied ruthenium antitumor agents (Figure 1) have displayed differences
with respect to their interactions with DNA depending on their structure.4 Thus, while NAMI-A
is known to have fewer and weaker interactions with DNA than cisplatin,4 indazolium
bisindazoletetrachlororuthenate (KP1019) undergoes interactions similar to cisplatin but with a
lower intensity in terms of DNA-DNA and DNA-protein crosslinks.64 Organometallic pianostool ruthenium(II) compounds based on biphenyl rings RM175 interact strongly with DNA
binding to guanines and by intercalation.65,66 Organometallic ruthenium(II) RAPTA derivatives,
characterized by the presence of water-soluble PTA phosphine, exhibit pH-dependent DNA
damage: at the pH typical of hypoxic tumor cells DNA was damaged, whereas at the pH
characteristic of healthy cells little or no damage was detected.67,68 Cycloruthenated compounds
based on pincer C,N ligands (RDC family) displayed a much weaker interaction with plasmid
(pBR322) DNA when compared to cisplatin.69,70 Complexes of the type [Ru(Cp)(2,2bipy)(PR3)][CF3SO3] have shown no observable interaction with DNA.71
In this context, we evaluated the effect of DNA interactions that could, to some extent,
contribute to the observed cytotoxicity of compounds 1-4, 8 and 9, and the apoptotic behaviour
of compounds 2 and 3. We followed the interaction with Calf Thymus DNA (CT DNA) by
circular dichroism (CD), and with plasmid (pBR322) DNA by electrophoresis in agarose gel.
The CD spectral technique is very sensitive to diagnose alterations on the secondary structure of
DNA that result from DNA-drug interactions. A typical CD spectrum of CT DNA shows a
positive band with a maximum at 275 nm due to base stacking, and a negative band with a
minimum at 248 nm due to helipticity, characteristic of the B conformation.72 Therefore, changes
in the CD signals can be assigned to corresponding changes in DNA secondary structure. In
addition, it is known that simple groove binding or electrostatic interaction of small molecules
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cause little or no alteration in any of the CD bands when compared to major perturbations
induced by covalent binding or intercalation.
CD spectra of CT DNA incubated with compounds 1-4 (see Appendix, Figure 44) at
37ºC and pH = 7.30 in Tris/HCl buffer up to molar ratio drug/DNA = 0.5 show no modification
of the DNA bands with respect to untreated CT DNA, indicating that drug-DNA interactions, if
existing, do not induce any observable perturbation on the DNA secondary structure under our
experimental conditions
Higher ratios were also tested, although loss of CD signal was observed due to
precipitation of the DNA induced by 1-4, most likely because of phosphate charge neutralization
by the cationic compounds, which suggests the existence of an electrostatic attraction. DNA
condensation or precipitation by neutralization of backbone charges has been previously
described for other ionic ruthenium drugs73 and confirmed by us for compounds 2 and 3 through
ICP-MS analysis of metal content in the DNA precipitate. In this experiment 500 µM
concentration DNA solutions were treated with 2 equivalents of ruthenium compounds 2 and 3
for 20 hours at 37ºC to promote DNA precipitation. The samples were then centrifuged and the
resulting pellets were analyzed for DNA and metal concentration (see Experimental Section for
more details). Our results show ruthenium content values of 2.60 ± 0.26 mg Ru/mg DNA for
compound 2 and 2.43 ± 0.18 mg Ru/mg DNA for compound 3. This high Ru content in DNA
precipitate, especially when compared to similar Ru compounds interacting with DNA through
covalent interactions29 suggests that the key factor promoting the precipitation of DNA is the
presence of the cationic ruthenium compound.
Attempts to obtain additional evidence of drug-CT DNA interactions were made by
performing thermal denaturation experiments, but resulted in cyclometallation of compounds 1,
2 and hydrolysis of 3 at temperatures above 60ºC, as previously discussed, preventing us from
obtaining reliable information through this technique.
In order to gain further insights on the nature of the compound-DNA interactions, gel
electrophoresis studies were also performed with the ruthenium(II) complexes 1-4, 8 and 9 on
plasmid (pBR322) DNA (Figure 8).
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Figure 8.

Electrophoresis mobility shift assays for cisplatin, [Ru(η6-p-cymene)Cl]2

and

compounds 1-4 and 8, 9. DNA refers to untreated plasmid pBR322. A, B, C and D correspond to
metal/DNAbp ratios of 0.25, 0.5, 1.0 and 2.0 respectively.

For these experiments, cisplatin, all uncoordinated ligands and the starting dimeric
organometallic ruthenium(II) complex [Ru(η6-p-cymene)Cl]2 were also measured as controls.
Plasmid pBR322 presents two main forms, OC (open circular or relaxed) and CCC (covalently
closed circular or supercoiled), which display different electrophoretic mobility. Changes in the
electrophoretic mobility of any of the forms upon incubation of the plasmid with a compound are
usually interpreted as evidence of interaction. Generally, a drug that induces unwinding of the
CCC form will produce a retardation of the electrophoretic mobility, while coiling of the OC
form will result in increased mobility. Figure 8 shows the effect of cisplatin and compounds 1-4,
8 and 9 on DNA pBR322 after incubation at 37ºC for 20 h in Tris/HCl buffer up to drug/DNA
ratio 2.0. As previously reported, cisplatin is able to both increase and decrease the mobility of
the OC and the CCC forms, respectively.74 Interestingly, treatment with increasing amounts of 1
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and 2 induce retardation of the mobility of the CCC form of plasmid DNA, while the rest of the
compounds, the neutral ligands, and the Ru starting dimer do not seem to induce any alteration
on the mobility of the plasmid.
The results of CD, ICP-MS and gel electrophoresis taken together suggest that
compounds 1-4 undergo only electrostatic interactions with DNA. This conclusion is supported
by three main facts: 1) results obtained by CD spectroscopy do not show evidence of CT DNA
modifications of secondary structure, suggesting that drug-DNA interactions, if any, are of weak
nature, but neither covalent nor intercalation; 2) precipitation of CT DNA is observed in CD
experiments at high ratios drug/DNA, and it is further confirmed by ICP-MS analysis of metal
content in DNA precipitates, suggesting backbone charge neutralization, and 3) retardation of the
plasmid DNA electrophoretic mobility is observed also at high drug/DNA ratios for compounds
1 and 2, but only when plasmid DNA is incubated with the cationic metal compounds and not
with the neutral ligands or neutral ruthenium starting material under the same conditions, which
could also be consistent with charge neutralization or DNA precipitation. Loss of migration in
electrophoresis experiments has been previously reported as a consequence of DNA precipitation
for other cationic ruthenium compounds.73 The electrophoretic mobility results also suggest that
the electrostatic interaction between DNA and compounds 1 and 2 is of larger magnitude than
that experienced by 3 and 4, since no mobility retardation is observed for the latter compounds
up to drug/DNA ratio of 2.0. Further evidence of this could be found in the fact that lower
amount of Ru content in DNA is detected for compound 3 when compared to compound 2,
according to ICP-MS results.
Thus, we hypothesize that the anti-tumor properties observed for compounds 1-4, 8 and 9
are due to non-DNA related mechanisms/factors, as previously observed for other
iminophosphorane

complexes

described

before52-55,75,76

compounds.4,5,19 and refs therein
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and

some

other

ruthenium

5.4.2. Lack of inhibition of capthesin B

This assay was performed at Reaction Biology Corporation.

Cathepsin B (cat B) is an abundant and ubiquitously expressed cysteine peptidase of the
papain family, which has turned out to be a prognostic marker for several types of cancers.77
Cathepsin B seems to be involved (along with other cathepsins) in metastasis, angiogenesis, and
tumor progression.78 It has been proposed that cat B may be a possible therapeutic target for the
control of tumor progression.79 RAPTA Ru compounds which inhibit cat B with IC50 in the low
micromolar range can reduce the mass and number of metastases in vivo.80 We therefore, studied
the inhibition of Cat B by compound 2 (see Experimental Section for details). Compound 2 does
not inhibit the enzymatic activity of cat B at concentrations up to 100 µM indicating that this
protease may not be a target for this type of arene-ruthenium(II) derivatives.
5.4.3. Interaction with HSA
Due to the abundance in plasma and relevance to drug binding81 of human serum albumin
(HSA) we studied the interactions of the new ruthenium(II) IM complexes with this protein. The
fluorescence spectra of HSA in the presence of increasing amounts of the compounds 1-5, 8, 9
and cisplatin were recorded in the 300-450 nm range upon excitation of the tryptophan residue at
295 nm. The compounds caused a concentration dependent quenching of fluorescence without
changing the emission maximum or the shape of the peak. All these data indicate an interaction
of the compounds with HSA. The fluorescence data was analyzed by the Stern-Volmer equation.
While a linear Stern-Volmer plot is indicative of a single quenching mechanism, either dynamic
or static, the positive deviation observed in the plots of F0/F versus [Q] of compounds 1-4
(Figure 9) suggests the presence of different binding sites in the protein with different binding
affinities.82 Similar behavior was observed in the case of coordination iminophosphorane
complexes of d8 metals for which concentration dependent fluorescence quenching was
reported.52-55 On the other hand, the Stern-Volmer plot for complexes 8 and 9 shows a linear
relationship, suggesting the existence of a single quenching mechanism, most likely dynamic,
and a single binding affinity. The Stern-Volmer constants for complexes 8 and 9 are 1.81x104
and 3.85x104 M-1, respectively.
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Figure 9. (A) Fluorescence titration curve of HSA with compound 4. Arrow indicates the
increase of quencher concentration. (B) Stern-Volmer plot for HSA fluorescence quenching
observed with compounds 1-4, 8, 9 and cisplatin.

In general, higher quenching by the iminophosphorane complexes was observed
compared to that of cisplatin under the chosen conditions, most likely due to the faster binding of
our compounds with HSA, as compared to cisplatin.
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5.5. Effects on tumor growth in vivo with compound 2

These studies were designed and performed by Benelita T. Elie, and Dr. Maria Contel, at the
laboratory of Dr. Joe W. Ramos (University of Hawaii Cancer Center, Honolulu).

5.5.1. Evaluation of the lethal and maximum tolerated doses

The lethal and maximum tolerated doses of compound 2 were evaluated in C57/Black6
mice (see Experimental Section for details). The lethal dose was determined to be 30 mg/kg/day.
No biological samples were collected from those mice. The MTD was determined to be 10
mg/kg/day, at which the mice showed no visible signs of distress over the 7 days course of
treatment.
Mice lost weight during the trial in a dose dependent manner where mice treated with 5
mg/kg/day, 10 mg/kg/day, or 20 mg/kg/day lost 15%, 19% or 37% body weight respectively,
while vehicle treated mice gained 3% body weight over the 7 days of treatment. Mice treated
with 20 mg/kg/day were euthanized on day 6 of the trial as they had lost too much body weight
and looked in distress.
24 hours after the last dose all the mice used in the MTD study were euthanized and
blood plasma, liver, spleen and kidneys were collected and used for histological analysis.
Necropsy and histology indicate that mice treated at 20 mg/kg/day had discolored livers and
atrophied spleens; at 10 mg/kg/day much less atrophy and minor discoloration was observed,
while in mice treated at 5 mg/kg/day there was no detectable liver discoloration and no
observable change in spleen size.
Therefore, 5 mg/kg/every other day were chosen as the dose of to conduct the subsequent
in vivo trial with compound 2.

5.5.2. Effects of 2 in MDA-MB-231 mouse xenografts

12

female

NOD.CB17-Prkdc

SCID/J

(non-obese

diabetic–severe

combined

immunodeficiency) were selected for the in vivo trial. The mice were inoculated with MDA-MB231 cells (see Experimental Section for details) and treated when the tumors were palpable
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(about 5–6 mm diameter). Each six MDA-MB-231-transplanted animals received compound 2
(5 mg/kg/every other day) or vehicle (0.9% NaCl) intraperitoneally (i.p.). To palliate the weight
loss observed in the MTD study all the mice used in this trial were fed a 46% fat-adjusted diet
(Harlan Teklad, Madison, WI), plus HydroGel™(Harlan Teklad, Madison, WI) and received
subcutaneous injection of 100µl Normal Saline on the off-treatment day.
In the group treated with 2 (see Table 3 and Figure 10) we observed a significant
decrease in tumor size (shrinkage) of 56% from the starting volume between day 1 and day 28 of
treatment (after a total of 14 doses), while in the control vehicle treated group we observed 200%
increase in tumor volume between day 1 and day 28 of treatment. One 2-treated mouse was
removed from the trial because it was not feeding itself and showed other signs of distress, none
of which were observed in the other mice on trial. No significant weight loss in mice treated with
5 mg/kg/every other day was observed. Mice treated with 2 gained an average weight of 2.88%,
while untreated mice gained an average of 18.67% weight (all groups were fed a 46% fatadjusted diet).
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Figure 10. % of reduction of tumor burden in a cohort of 12 female NOD.CB17-Prkdc scid/J
mice inoculated subcutaneously with 5x106 MDA-MB-231 cells. The treatment started when
tumors were palpable (5-6 mm diameter). 6 mice were treated with compound 2 (pink bars), 6
were treated with the vehicle 100 µl Normal Saline (0.9% NaCl) (black bars). 2 was
administered in the amount of 5 mg/kg/every other day.
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Table 3. Effects of 2 on the tumor growth of MDA-MB-231 mammary carcinoma in
NOD.CB17-Prkdc scid/J mice.

Primary Tumor (mm3)

Treatment Group

473.47 ± 45.44

Controls
a

Compound 2 (5 mg/kg/e.o.d x 14)
a

59.58 ± 8.66

e.o.d = every other day. Tumor measured on day 28, after the 14th dose.

The results clearly indicate that compound 2 is extremely efficient in vivo since it not
only inhibits tumor growth but also results in the decrease in the size of the tumors by 56%. It is
interesting to compare these results with those obtained with other arene-ruthenium (II)
derivatives. Compound RM175 was reported to have a final primary tumor growth inhibition of
30% at a dose of 7.5 mg/kg/day in an in vivo trial for breast cancer in mice13 while the
compounds RAPTA-C reduced the growth of lung metastases in CBA mice bearing the MCa
mammary carcinoma in the absence of a corresponding action at the site of primary tumor
growth.15,16 More recently, a ruthenium-arene complex with a perfluoroalkyl-containing amine
ligand demonstrated a 90% reduction in the tumor growth in a xenografted ovarian carcinoma
tumor (A2780) grown in a chorioallantoic membrane (CAM) assay of chicken embryo.18 As
stated above compound 2 is able to decrease tumor size.

5.5.3. Pharmacokinetic study

These studies were performed by Dr. Swayam Prabha and Tanmoy Sadhukha at the University of
Minnesota.

The pharmacokinetic profile of compound 2 in the NOD.CB17-Prkdc scid/J mice used
for the in vivo study described above (Figure 11) is summarized in Table 4. Ruthenium content
was determined using Inductively Coupled Plasma - Mass Spectrometry (ICP-MS). Compound 2
was absorbed quickly into plasma (t1/2 abs = 0.5 h) and the peak plasma concentration was reached
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within 2 h of dosing. The drug was eliminated slowly from the blood compartment with an
elimination half-life (t1/2 e) greater than 12 h. This elimination half-life is similar to that reported
for compounds RAPTA-C,13 NAMI-A83 and KP1019.7
During determination of total area under the concentration – time curve (AUC total) only
7% of the AUC was extrapolated from the last time point suggesting a high confidence in the
AUC, Vapp and apparent clearance (CLapp) determination. Blood concentration, at 6 hours after
the last dose of compound 2, was 4.2 ± 1.3 µg/ml, which is higher (P < 0.1) than the Cmax after
the first dose. This suggests an accumulation of compound 2 after each dose. While it is hard to
make comparisons with other ruthenium compounds for which a PK analysis has been performed
(e.g. RAPTA-C,15 NAMI-A,83 and KP10197) due to the different structures, oxidation states (see
Figure 1) and the amounts employed in these studies (for example 70 mg total of 2 in 14 doses of
5 mg/kg/every other day versus a total of 400 mg or 200 mg for RAPTA-C) there are some
differences that can be pointed out. The Vd (volume of distribution) of 2 when compared to that
of more structurally related arene-ruthenium(II) RAPTA-C derivative is smaller which may be
due to a higher water solubility of 2 or the possibility that it binds strongly to plasma-proteins.
Indeed, we have seen in a qualitative way that compound 2 binds faster to HSA than cisplatin
(section 5.4.3).
Table 4. Pharmacokinetic parameters of compound 2 after first injection in NOD.CB17-Prkdc
SCID/J mice.
Pharmacokinetic parameters

Values

Kabs

1.39 h -1

Ke

0.055 h -1

t1/2 e

12.67 h

t1/2 abs

0.50 h

tmax

2.00 h

Cmax

2.62 µg/ ml

AUCtotal

54.47 µg.h/ml

Vapp

33.57 ml

CLapp

1.84 ml/h

156

Figure 11. Concentration of Compound 2 in plasma at various intervals after the first dose.
At the end of the study, ruthenium content in liver, kidney and tumor was determined
(Figure 12). The level of compound 2 is liver and kidney was less than 5 µg/g tissue weight
while the tumor concentration was about 40 µg/g. The high level in tumor suggests enhanced
tumor accumulation of compound 2 which may explain the high efficacy observed for this
compound in the in vivo studies. The preferential accumulation of some ruthenium complexes in
neoplastic masses in comparison with normal tissue has been reported before by different
researchers.84,85

Figure 12. Compound 2 ruthenium content in tissues at the end of efficacy study. Data
represents mean ± SD. N = 3; * indicates P <0.005.
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5.6. Conclusions

I have sucessfuly synthesized a series of organometallic ruthenium(II) complexes
containing iminophosphorane ligands. The compounds, along with starting material [(η6-pcymene)Ru(μ-Cl)Cl]2, were evaluated against a number of human cancer cell lines in vitro and
most compounds were more cytotoxic to all the cell lines then cisplatin. Only the cationic
compounds (1 and 2) show interaction with plasmid (pBR322) DNA but it seems weak and
electrostatic in nature. Precipitation of Calf Thymus DNA observed in CD experiments at high
ratios drug/DNA, and further confirmed by ICP-MS analysis of metal content in DNA
precipitates, suggesting backbone charge neutralization. Furthermore, higher quenching of HSA
was observed compared to that of cisplatin under the chosen conditions, most likely due to the
faster reactivity of the complexes with HSA, as compared to cisplatin.
From all the iminophosphorane compounds that I prepared, highly water-soluble
ruthenium-arene-iminophosphorane compound (2) was chosen as the best candidate to continue
with advanced pre-clinical studies. This compound is active against a number of cisplatin
resistant cell lines while been less toxic on human renal proximal tubular cell lines. Initial
mechanistic studies indicated that the cell death type for compound 2 is mainly through
canonical or caspase-dependent apoptosis. In addition, cell death seems to be independent of
p53. The interaction of 2 with DNA is weak and electrostatic in nature. All these facts indicate
that 2 has a mode of action different from that of cisplatin which may explain its activity in
cancer cell lines quite resistant to cisplatin such as MDA-MB-231, A549 amd DU-145.
Compound 2 does not inhibit protease cathepsin B in concentrations of 100 µM or lower. The
efficacy of 2 in vivo has been demostrated on xenografted breast carcinoma MDA-MB-231tumors grown on NOD.CB17-Prkdc scid/J mice. An impressive tumor reduction (shrinkage) of
56% was observed after 28 days treatment (14 doses of 5 mg/kg every other day) with low
systemic toxicity. Pharmacokinetic studies showed a quick absorption of 2 in plasma with an
elimination half-life of 12.67 hours (similar to that reported for other ruthenium derivatives).
Importantly, 2 accumulated preferentially in the breast tumor tissues when compared to kidney
and liver, which may explain its high efficacy in vivo. The simple, cheap and accessible synthesis
of compound 2 (by simple coordination of an IM ligand to a well-known organometallic
ruthenium (II) precursor), its high water-solubility and its encouraging preliminary biological
158

activity in vitro and in vivo makes it therefore a good candidate for further evaluation as a
potential chemotherapeutic agent.

5.7. Experimental section

Materials and methods
All manipulations involving air-free syntheses were performed using standard Schlenk-line
techniques under a nitrogen atmosphere or a glove-box MBraun MOD System. Solvents were
purified by use of a PureSolv purification unit from Innovative Technology, Inc. Compounds
[PhCH2Mn(CO)5],86 [(η6-p-cymene)Ru(μ-Cl)Cl]2,57 [Hg(2-C6H4C(O)N=PPh3)Cl],58 and IM
ligands Ph3P=N-CO-2-N-C5H4,56 Ph3P=N-8-C9H6N,55 [Cp-P(Ph2)=N-CH2-2-NC5H4}Fe(Cp)],54
and Ph3P=N-CO-2-C6H456 were prepared by reported methods. The purity of the compounds,
based on elemental analysis, is ≥99.5%. In the case that the compound crystallizes with solvent
the 1H NMR (CDCl3) spectrum is available in the Appendix. Elemental analyses were performed
by Atlantic Microlab Inc. NMR spectra were recorded in a Bruker AV400 ( 1H NMR at 400MHz,
13

C NMR at 100.6 MHz,

31

P NMR at 161.9 MHz). Chemical shifts (δ) are given in ppm using

CDCl3 or DMSO-d6 as solvent, unless otherwise stated. 1H and
31

13

C chemical shifts were

1

measured relative to solvent peaks considering TMS = 0 ppm; P{ H} was externally referenced
to H3PO4 (85%). Infrared spectra (4000-250 cm-1) were recorded on a Nicolet 6700 FT-IR
spectrophotometer from nujol mulls between polyethylene sheets. Mass spectra (electrospray
ionization, ESI) were performed on an Agilent Analyzer, a Bruker Analyzer, or a Waters Q-Tof
Ultima analyzer. Conductivity was measured in an OAKTON pH/conductivity meter in CH3CN
solutions (10-3M). X-ray collection was performed at room temperature on a Kappa CCD
diffractometer using graphite monochromated Mo-Kα radiation (λ=0.71073 Å). Electrophoresis
experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal electrophoresis system
connected to a Bio-Rad Power Pac 300 power supply. Photographs of the gels were taken with
an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity measurements were carried
out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham, NJ) with right angle detection
of fluorescence using a 1 cm path length quartz cuvette. Circular dichroism spectra were
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recorded using a Chirascan CD Spectrometer equipped with a thermostated cuvette holder. The
inhibition of Capthesin B experiments were performed by Reaction Biology Corporation.

Synthesis of 1
[(η6-p-cymene)Ru{(Ph3P=N-CO-2-N-C5H4)-κ-N,O}Cl](PF6)
[(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.15 g, 0.25 mmol) was dissolved in CH3OH (15 mL) and
Ph3P=N(CO)(C5H5-2-N) (0.19 g, 0.5 mmol) was added. To the resulting mixture KPF6 (0.10g,
0.55 mmol) was added. The mixture was stirred for 4 h. The suspension was then filtered and
washed 3 times with Et2O (10mL). The solution was then concentrated and the precipitate was
collected by filtration and dried in vacuo.

Yield: 0.36 g (90%). Anal. Calc. for C34H33N2OP2F6ClRu (798.07): C, 51.17; H, 4.17; N, 3.51.
Found: C, 50.95; H, 4.20; N 3.56 %. ESI-MS: m/z: 653.10 (100%, [M-PF6]+, calc. 653.11). 31P
{1H} NMR (CDCl3): δ 25.72 (s), -148.26 to -140.19 (septet, PF6), (DMSO-d6): 24.27 (s), 152.87 to -130.98 (septet, PF61H NMR (CDCl3): δ 1.10 (6H, dd, J = 6.9, 18.9 Hz, CH3, η6-pcymene), 1.69 (3H, s, CH3, η6-p-cymene), 1.65 (3H, s, CH3, η6-p-cymene), 2.30 (1H, m, CH, η6p-cymene), 5.48-5.59 (4H, m, CH, η6-p-cymene), 7.64-7.78 (16H, m, H5, Hm + Ho + Hp), 8.03
(1H, d, J = 7.7 Hz, H4, C5H4N), 8.35 (1H, d, J = 7.5 Hz, H3, C5H4N), 9.21 (1H, d, J = 5.3 Hz,
H6, C5H4N);

13

C{1H} (CDCl3): δ 18.10 (s, CH3, η6-p-cymene), 21.87 (s, CH3, η6-p-cymene),

22.18 (s, CH3, η6-p-cymene), 30.79 (s, CH, η6-p-cymene), 81.00 (s, CH, η6-p-cymene), 82.09 (d,
CH, J = 8.3 Hz, η6-p-cymene), 82.41 (s, CH, η6-p-cymene), 83.92 (s, C, η6-p-cymene), 124.5 (s,
C2, η6-p-cymene), 125.5 (d, Cipso, J = 100.4 Hz), 127.7 (s, C3, C5H4N), 129.5 (d, Cm, J = 13.0
Hz), 129.8 (s, C5, C5H4N), 133.2 (d, Co, J = 10.4 Hz), 133.8 (s, Cp), 139.3 (s, C4, C5H4N), 153.7
(s, C6) ppm. The signal due to C2 (C5H4N ) and C=O was not observed. IR (cm-1):  524 (Ru-N),
834 (v br, PF6-), 1116 (N=P), 1540 (C=O). Conductivity (acetone): 125.5 μS/cm (1:1
electrolyte).

160

Synthesis of 2
[(η6-p-cymene)Ru{(Ph3P=N-CO-2-N-C5H4)-κ-N,O}Cl]Cl
[(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.15 g, 0.25 mmol) and Ph3P=N(CO)(C5H5-2-N) (0.19 g, 0.5
mmol) were stirred in acetone (20 mL) for 3 h. The brown solution was concentrated and 30 mL
of Et2O added dropwise. The orange solid that formed was collected by filtration and dried in
vacuo.

Yield: 0.33 g (94%). Anal. Calc. for C34H33N2OPCl2Ru·2H2O (724.62): C, 56.36; H, 5.15; N,
3.87. Found: C, 56.41; H, 4.99; N 3.87 %. ESI-MS: m/z: 653.1 (100%, [M-Cl]+, calc. 653.01),
618.1 (100%, [M-2Cl]2+, calc. 618.1), 519.0 (100%, [M-p-cymene-Cl]+, calc. 519.0).

31

P {1H}

NMR (CDCl3): δ 25.18 (s), (DMSO-d6): 28.99 (s); 1H NMR (CDCl3): δ 1.00 (6H, dd, J = 7.0,
24.8, Hz CH3, η6-p-cymene), 2.01 (3H, s, CH3, η6-p-cymene), 2.25 (1H, m, CH, η6-p-cymene),
5.51-5.71 (4H, m, CH, η6-p-cymene), 7.57 (6H, m, Hmeta), 7.68 (9H, m, Hortho + Hpara), 7.87 (1H,
d, J = 6.0 Hz, H5, C5H4N), 8.03 (1H, d, J = 7.7 Hz, H4, C5H4N), 8.32 (1H, d, J = 7.4 Hz, H3,
C5H4N), 9.62 (1H, d, J = 5.0 Hz, H6, C5H4N); 13C{1H} (CDCl3): δ 18.47 (s, CH3, η6-p-cymene),
21.82 (s, CH3, η6-p-cymene), 22.39 (s, CH3, η6-p-cymene), 30.75 (s, CH, η6-p-cymene), 81.20 (s,
CH, η6-p-cymene), 82.60 (d, CH, J = 8.3 Hz, η6-p-cymene), 83.65 (s, CH, η6-p-cymene), 97.87
(s, C, η6-p-cymene), 102.5 (s, C, η6-p-cymene), 125.6 (d, Cipso, J = 101.2 Hz), 127.2 (s, C3,
C5H4N), 129.5 (d, Cm, J = 12.8 Hz), 130.3 (s, C5, C5H4N), 133.3 (d, Co, J = 10.2 Hz), 133.9 (s,
Cp), 139.0 (s, C4, C5H4N), 151.6 (d, C2, J = 24.0 Hz), 156.3 (s, C6), 176.8 (d, C=O, J = 24.14 Hz)
ppm. IR (cm-1):  527 (Ru-N), 1114 (N=P), 1535 (C=O). Conductivity (acetone): 124.20 μS/cm
(1:1 electrolyte). Solubility: 145.3 mM or 100 mg/mL (H2O). pH (5 x 10-5M in H2O): 5.76.

Synthesis of 3
[(η6-p-cymene)Ru{(Ph3P=N-8-C9H6N)-κ-N,N}Cl]Cl
[(η6- p-cymene)Ru(μ-Cl)Cl]2 (0.092 g, 0.15 mmol) was dissolved in CH2Cl2 (15 mL) and
Ph3P=N-8-C9H6N (0.12 g, 0.3 mmol) was added. The mixture was stirred for 3h. The solution
was concentrated to 2 mL and 20 mL of Et2O added to precipitate an orange solid, which was
filtered and dried in vacuo.
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Yield: 0.18 g (84%). Anal. Calc. for C37H35N2PCl2Ru.2.5H2O (755.68): C, 58.81; H, 5.34; N,
3.71. Found: C, 58.95; H, 4.81; N 3.82 %. ESI-MS: m/z: 675.13 (100%, [M-Cl]+, calc. 675.13),
540.0 (100%, [M-p-cymene-Cl]+, calc. 541.02).

31

P {1H} NMR (CDCl3),: δ 37.68 (s), (DMSO-

d6): 37.84 (s); 1H NMR (CDCl3): δ 0.73 (3H, d, J = 6.7 Hz, CH3, η6-p-cymene), 1.01 (3H, d, J =
6.6 Hz, CH3, η6-p-cymene), 1.98 (3H, s, CH3, η6-p-cymene), 2.44 (2H, m, CH, η6-p-cymene),
5.43 (2H, s, CH, η6-p-cymene), 5.72 (2H, s, CH, η6-p-cymene), 6.40 (1H, d, J = 8.0 Hz, H7,
C9H6N), 6.91 (1H, d, J = 8.1 Hz, H7, C9H6N), 7.15 (1H, d, J = 8.1 Hz, H7, C9H6N), 7.66 (9H,
m, Hm + Hp), 7.68 (1H, s, H3, C9H6N ), 8.00 (6H, m, Ho), 8.21 (1H, d, J = 8.4 Hz, H4, C9H6N),
), 8.21 (1H, s, H2, C9H6N). 13C{1H} (CDCl3): δ 19.20 (s, CH3, η6-p-cymene), 21.02 (s, CH3, η6p-cymene), 22.96 (s, CH3, η6-p-cymene), 31.62 (s, CH, η6-p-cymene), 118.4 (s, C5, η6-pcymene), 121.7 (d, C7, J = 10.3 Hz, η6-p-cymene), 124.6 (s, C3, η6-p-cymene), 125.8 (s, C6),
129.4 (s, C8), 129.6 (d, Cm, J = 12.7 Hz), 130.0 (s, Cipso), 134.1 (s, Cp), 134.9 (d, Co, J = 9.8 Hz),
138.4 (d, C4), 144.7 (s, C9H6N), 144.9 (s, C9H6N), 149.2 (s, C=NP) ppm. Signals due to the
quaternary C atoms were not observed. IR (cm-1):  519 (Ru-N), 1268 (N=P). Conductivity
(acetone): 125.60 μS/cm (1:1 electrolyte). Solubility: 112.6 mM or 80 mg/mL (H2O).

Synthesis of 4
[(η6-p-cymene)Ru([{Cp-P(Ph2)=N-CH2-2-NC5H4}Fe(Cp)]-κ-N,N)Cl]Cl
To a solution of [(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.16 g, 0.26 mmol) in CH2Cl2 (10 mL), [{CpP(Ph2)=N-CH2-2-NC5H4}Fe(Cp)] (0.25 g, 0.52 mmol) in CH2Cl2 (10 mL) was added and stirred
for 40 min. The solvent removed to dryness under reduced pressure. The solid was dissolved in
CH2Cl2 and 25 mL of Et2O were added. The solid formed was then filtered and dried in vacuo.

Yield: 0.30 g (81%). Anal. Calc. for C38H39N2FePCl2Ru·3.5H2O (845.59): C, 53.98; H, 5.48; N,
3.31. Found: C, 54.02; H, 5.30; N 3.47 %. ESI-MS: m/z: 747.0 (100%, [M-Cl]+, calc. 747.1),
613.0 (100%, [M-p-cymene-Cl], calc. 612.98). 31P {1H} NMR (CDCl3): δ 46.40 (s), (DMSO-d6):
45.99 (s), (D2O): 46.95 (s); 1H NMR (CDCl3): δ 0.99 (3H, d, J = 5.4 Hz, CH3, η6-p-cymene),
1.23 (3H, m, CH3 + CH2, η6-p-cymene, NCH2C), 2.03 (3H, s, CH3, η6-p-cymene), 3.51 (1H, m,
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CH, η6-p-cymene), 3.98 (5H, s, C5H5), 4.42-4.78(6H, m, CH2 + C5H4), 4.79 (2H, m, Cp), 5.175.62 (4H, m, CH, η6-p-cymene), 7.45-7.68 (10H, m, Hm+o+p), 7.83 (1H, d, J = 7.4 Hz, H5,
C5H4N), 7.98 (2H, d, J = 7.7 Hz, H3 + 4, C5H4N), 9.09 (1H, d, J = 4.7Hz, H6, C5H4N); 13C{1H}
(CDCl3): δ 18.91 (s, CH3, η6-p-cymene), 21.99 (d, CH3 + CH3, η6-p-cymene), 23.25 (s, CH3, η6p-cymene), 31.30 (s, CH, η6-p-cymene), 70.55 (s, Cp), 72.24 (d, J = 9.9 Hz, Cp), 73.73 (d, J =
9.9 Hz ,Cp), 75.03 (m, Cp), 83.29 (d, CH, J = 14.4 Hz, η6-p-cymene), 85.98 (d, 2CH, J = 8.3 Hz,
η6-p-cymene), 87.09 (s, CH, η6-p-cymene), 99.99 (s, C, η6-p-cymene), 103.8 (s, C, η6-p-cymene),
124.9 (s, Ph), 128.4-128.8 (m, Ph), 130.2 (s, Cipso), 133.0-133.3 (s, Ph), 133.9-134.0 (d, C3 + C4,
J = 10.1 Hz, C5H4N), 138.8 (s, C4, C5H4N), 155.1 (s, C2, C5H4N), 164.1 (s, C6) ppm. . IR (cm-1):
 488 (Ru-N), 1116 (N=P). Conductivity (MeCN): 130.37 μS/cm (1:1 electrolyte). Solubility:
89.5 mM or 70 mg/mL (H2O).
Synthesis of 5
[PTA=N-C(O)-2-C6H5]
PTA (0.34 g, 2.18 mmol) and benzamide (0.264 g, 2.18 mmol) were placed in a Schlenk flask
under nitrogen. Dry, degassed THF (10 mL) was added and to this solution, tBuDAD (N,Nbis(tert-butyl)1,4-diazabutadiene) (0.503g, 2.18 mmol) in dry and degassed THF (4 mL) was
added dropwise at 0 °C. The reaction was left stirring at RT for 2.5 h. After this period, the
solvent was removed to dryness under reduced pressure. The white residue was washed three
times with Et2O (15 mL) giving a white solid that was filtered and dried in vacuo.
Yield: 0.53 g (88%). Anal. Calc. for C13H17N4OP (276.11): C, 56.52; H, 6.20; N, 20.28. Found:
C, 55.55; H, 6.16; N 20.69 %. ESI-MS: m/z: 277.12.0 (99.6%, [M]+, calc. 276.11).

31

P{1H}

NMR (CDCl3): δ −30.8 (s); 1H NMR (CDCl3): δ 4.32-4.63 (12H, m, PTA), 7.38 (2H, t, J = 7.6
Hz, H3 + H5, C6H5), 7.44 (1H, t, J = 7.1 Hz, H4 , C6H5), 8.07 (2H, d, J = 7.5 Hz, H2 + H6,
C6H5);

13

C{1H} NMR (CDCl3): δ 55.10 (d, J = 47.2 Hz, PTA), 72.60 (d, J = 8.9 Hz, PTA),

128.08 (s, C3 + C5, C6H4), 129.21 (s,C2 + C6, C6H4), 131.47 (s, C4), 136.74 (d, J = 17.7 Hz, C1),
179.28 (s, J = 9.6 Hz, C=O). Conductivity (acetone): 2.08 μS/cm (neutral).
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Synthesis of 6
[(CO)4Mn(2-C6H4C(O)N=PTA)]
PhCH2Mn(CO)5 (0.43 g, 1.5 mmol) and PTA=NC(O)Ph (5) (0.41 g, 1.5 mmol) were refluxed in
n-hexane (45 mL) for 4h. The hot solution was filtered and the yellow filtrate reduced in volume
until signs of crystallization became evident. Storage at -20 ºC gave yellow crystals of
(CO)4Mn(2-C6H4C(O)N=PTA).
Yield: 0.59 g (90%). Anal. Calc. for C17H16N4O4PMn (442.02): C, 46.07; H, 3.65; N, 12.67.
Found: C, 45.69; H, 3.56; N 12.72%. ESI-MS: m/z: 443.03 (100%, [M], calc. 443.03), 415.04
(100%, [M-CO], calc. 415.04), 386.01 (100%, [M-2CO], calc. 387.04), 331.05 (100%, [M-4CO],
calc. 331.05).

31

P {1H} NMR (CDCl3): δ −15.27 (s); 1H NMR (CDCl3): δ 4.32-4.58 (12H, m,

PTA), 7.16 (1H, t, J = 7.5, 14.8 Hz, H4, C6H4), 7.38 (1H, t, J = 7.5, 14.5 Hz, H3 , C6H4), 7.68
(1H, d, J = 7.6 Hz, H2, C6H4), 7.93 (1H, d, J = 7.4 Hz, H5, C6H4); 13C{1H} (CDCl3): δ 53.30 (d,
J = 43.3 Hz, PTA) ppm. 72.54 (d, J = 9.8 Hz, PTA), 124.02 (s, C4, C6H4), 128.60 (s, C2, C6H4),
132.55 (s, C3, C6H4), 139.93 (s, C1), 141.25 (s, C5, C6H4), 171.36 (s, C=O), 185.71 (s, C=O),
213.66 (s, C=O), 215.97 (s, C=O) ppm. Conductivity (acetone): 1.11 μS/cm (neutral).

Synthesis of 7
[Hg(2-C6H4C(O)N=PTA)Cl]
(CO)4Mn(2-C6H4C(O)N=PTA) (6) (0.44 g, 1.0 mmol) and HgCl2 (0.54 g, 2.0 mmol) were
refluxed in CH3OH (55 mL) for 5 h during which time the solution turned yellow and a white
solid formed. The mixture was cooled in an ice-water bath and subsequently filtered. The white
solid formed was washed well with cold methanol. The solid was redissolved in CH2Cl2 (<200
mL) and filtered through celite. The resulting clear solution was reduced in volume (<3 mL) and
Et2O was added dropwise until the solution became cloudy. Storage at -20 ºC gave white crystals
of 7, which were filtered off, dried and used without further purification.

Yield: 0.33 g (65%). Anal. Calc. for C13H16N4OPClHg·0.5CH2Cl2 (553.78): C, 29.28; H, 3.09;
N, 10.112. Found: C, 29.08; H, 3.02; N, 9.75 %. ESI-MS: m/z: 513.05 (100%, [M+H]+, calc.
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513.05), 535.03 (100%, [M+Na]+, calc. 535.04).

31

P {1H} NMR (CDCl3): δ −25.68 (s, 2JHg-P =

27.4 Hz). 1H NMR (CDCl3): δ 4.40 (12H, m, PTA), 7.39 (2H, t, J = 7.6 Hz, H2 + H4, C6H4), 7.51
(1H,
13

t,

J

=

7.5

Hz,

H3,

C6H4),

8.23

(1H,

d,

J

=

8.1

Hz,

H5,

C6H4);

1

C{ H} (CDCl3): δ 52.71 (d, J = 45.9 Hz, PTA), 72.76 (d, J = 9.5 Hz, PTA), 128.33 (s, C4,

C6H4) 129.84 (s, C5, C6H4), 131.98 (s, C3, C6H4), 136.31 (s, C2, C6H4), signals corresponding to
NC=O ,C1and C6 were not observable. Conductivity (acetone): 0.73 μS/cm (neutral) μS/cm.

Synthesis of 8
6

[(η -p-cymene)Ru((Ph3P=N-CO-2-C6H4)-κ-C,N)Cl]
[Hg(2-C6H4C(O)N=PPh3)Cl] (0.12 g, 0.2 mmol) and [(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.13 g, 0.22
mmol) were refluxed in CH3CN (20 mL) for 7 days after which a yellow precipitate formed. The
pale yellow solid was filtered off and discarded and the orange solution was concentrated to
dryness. The solid was dissolved in CH2Cl2 and filtered through celite. The solvent was removed
under reduced pressure to a minimum, followed by addition of Et2O (~20 mL). The orange solid
was filtered off and dried in vacuo.

Yield: 0.049 g (37%). Anal. Calc. for C35H33NOPClRu·2H2O (687.18): C, 61.18; H, 5.43; N,
2.04. Found: C, 60.97; H, 5.05; N 2.35 %. ESI-MS: m/z: 616.13 (100%, [M-Cl]+, calc. 616.13).
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P {1H} NMR (CDCl3): δ 20.63 (s), (DMSO-d6): 21.15 (s); 1H NMR (CDCl3): δ 1.31 (6H, d, J =

6.9 Hz, CH3, η6-p-cymene), 2.18 (3H, s, CH3, η6-p-cymene), 2.95 (1H, sept, J = 6.9 Hz, CH, η6p-cymene), 5.37 (2H, d, J = 6.0 Hz, CH, η6-p-cymene), 5.49 (2H, d, J = 6.0 Hz, CH, η6-pcymene), 7.42-7.48 (2H, m, H3 + H4), 7.49 -7.53 (6H, m, Hm), 7.56 -7.61 (3H, m, Hp), 7.84-7.89
(6H, m, Ho ), 8.36-8.37 (2H, dd, J = 1.4, 8.0 Hz, H2 + H5); 13C{1H} (CDCl3): δ 19.02 (s, CH3, η6p-cymene), 22.21 (s, 2CH3, η6-p-cymene), 30.68 (s, CH, η6-p-cymene), 80.58 (s, CH, η6-pcymene), 81.32 (s, CH, η6-p-cymene), 96.77 (s, C, η6-p-cymene), 101.25 (s, C, η6-p-cymene),
127.65 (s, C3 + C4), 127.92 (s, C6), 128.62-128.74 (d, Cm, J = 12.4 Hz), 128.91 (s, Cipso,), 129.51129.53 (d, J = 3.02 Hz, C2 + C5), 130.67 (s, C3 + C4), 132.19-132.22- (d, Cp, J = 2.9 Hz), 133.13133.24 (d, Co, J = 9.6 Hz), 138.51-138.72 (d, J = 20.6 Hz, C-Ru), 176.26 (s, C=O) ppm. IR (cm1

):  517 (Ru-N), 1162 (N=P), 1593 (C=O). Conductivity (acetone): 3.76 (neutral) μS/cm.
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Synthesis of 9
[(η6-p-cymene)Ru{(PTA=N-CO-2-C6H4)-κ-C,N}Cl]
[Hg(2-C6H4C(O)N=PTA)Cl] (7) (0.1 g, 0.2 mmol) and [(η6-p-cymene)Ru(μ-Cl)Cl]2 (0.13 g, 0.2
mmol) were refluxed in CH2Cl2 (20 mL) for 3 days. Subsequently, the solvent was removed to
dryness and the yellow solid obtained was dissolved in CHCl3 and filtered through celite. The
solvent was removed under reduced pressure to a minimum, followed by addition of Et2O. The
yellow solid obtained was collected by filtration and dried in vacuo.

Yield: 0.14 g (66%). Anal. Calc. for C23H30N4OPClRu (546.01): C, 50.59; H, 5.54; N, 10.26.
Found: C, 50.32; H, 5.20; N 10.53 %. ESI-MS: m/z: 546.0 (100%, [M-Cl]+, calc. 546.06), 412.0
(100%, [M-p-cymene]-, calc. 412.0).

31

P {1H} NMR) (CDCl3): δ -16.3 (s), (DMSO-d6): -11.98

(s); 1H NMR (DMSO-d6): δ 0.61 (3H, d, J = 6.7 Hz, CH3, η6-p-cymene), δ 0.99 (3H, d, J = 6.8
Hz, CH3, η6-p-cymene), 2.34 (3H, s, CH3, η6-p-cymene), 2.24 (1H, sept, J = 7.1 Hz, CH, η6-pcymene), 4.47-4.67 (12h, m PTA), 5.81 (d, 2H, CH, η6-p-cymene), 6.06 (d, 1H, J = 6.5 Hz, CH,
η6-p-cymene), 6.74 (d, 1H, J = 6.9 Hz, CH, η6-p-cymene), 7.11 (t, 1H, J = 7.7 Hz , H4), 7.31 (t,
1H, J = 7.5 Hz, H3), 7.37 (d, 1H, J = 7.5 Hz, H5), 7.81 (d, 1H, J = 7.5 Hz, H2); 13C{1H} (DMSOd6): δ 18.70 (s, CH3, η6-p-cymene), 19.97 (s, CH3, η6-p-cymene), 24.13 (s, CH3, η6-p-cymene),
31.00 (s, CH, η6-p-cymene), 51.82 (s, PTA), 52.22 (s, PTA), 71.50 (d, J = 40.5 Hz, PTA), 86.72
(s, CH, η6-p-cymene), 87.22 (s, CH, η6-p-cymene), 95.97 (s, CH, η6-p-cymene), 100.6 (s, C, η6p-cymene), 127.65 (s, C4), 128.6 (s, C5), 128.6 (s, Cipso,), 132.6 (s, C3), 138.6-138.7 (d, J = 20.6
Hz, C-Ru), 141.1 (s, C2), 183.9 (s, C=O) ppm. IR (cm-1):  562 (Ru-N), 1314 (N=P), 1582
(C=O). Conductivity (acetone): 25.4 (neutral) μS/cm. Solubility: 0.79 mM or 0.43 mg/mL (H2O).

X-Ray crystallography
Single crystals of 1 (see details in Table 5 in Appendix) were mounted on a glass fiber in a
random orientation. Data collection was performed at RT on a Kappa CCD diffractometer using
graphite monochromated Mo-Kα radiation (λ=0.71073 Å). Space group assignments were based
on systematic absences, E statistics and successful refinement of the structures. The structures
were solved by direct methods with the aid of successive difference Fourier maps and were
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refined using the SHELXTL 6.1 software package. All non-hydrogen atoms were refined
anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding
model. Details of the crystallographic data are given in Table S1 (SI). These data can be obtained
free

of

charge

from

The

Cambridge

Crystallographic

Data

Center

via

www.ccdc.cam.ac.uk/data_request/cif. (CCDC 1008354) or in the supporting information.
Crystals of 1 (xxx prisms with approximate dimensions 0.26 x 0.24 x 0.21 mm) were obtained
from a solution of 1 in CH2Cl2 by slow diffusion of Et2O at RT.

Cell culture, inhibition of cell growth and cell death analysis
Cell culture
The human T-cell leukemia Jurkat (clone E6.1) and the prostate carcinoma DU-145 were
routinely cultured in RPMI 1640 medium supplemented with 5% fetal calf serum (FCS), Lglutamine and penicillin/streptomycin. A549 (lung carcinoma), MiaPaca2 (pancreatic
carcinoma), MDA-MB-231 (Triple negative breast carcinoma) and 293T (non-tumoral
embryonic kidney cells) were cultured in DMEM medium supplemented with 10% FCS, Lglutamine and penicillin/streptomycin. Media for A549 cells were also supplemented with 2,2
g/l Na2CO3, 100 µg/ml pyruvate and 5 ml non-essential amino acids (Invitrogen). All these
media will be referred as ‘complete medium’ hereinafter. Cell cultures were maintained in a
humidified atmosphere of 95% air / 5% CO2 at 37 ºC.
MTT toxicity assays
For toxicity assays cells (5 x104 for Jurkat cells and 104 for adherent cell lines) were seeded in
flat-bottom 96-well plates (100 µl/well) in complete medium. Adherent cells were allowed to
attach for 24 h prior to addition of cisplatin or tested compounds. Compounds were added at
different concentrations in triplicate. Cells were incubated with cisplatin or compounds for 24 h
and then cell proliferation was determined by a modification of the MTT-reduction method.
Briefly, 10 µl/well of MTT (5 mg/ml in PBS) was added and plates were incubated for 1-3 h at
37 ºC. Finally, formazan crystal was dissolved by adding 100 µl/well iPrOH (0.05 M HCl) and
gently shaking. The optical density was measured at 570 nm using a 96-well multiscanner

167

autoreader (ELISA). In some experiments total cell number and cell viability were determined by
the Trypan-blue exclusion test.
Cell culture and XTT assay for RPTC cells
The human Renal Proximal Tubule Cells (RPTC) a non-tumoral human kidney epithelial cell
line (obtained from Lifeline Cell Technology, Frederick, Maryland, USA) were cultured in
Lifeline's RenaLife Medium containing RenaLife LifeFactors with 2.4 mM L-Glutamine, 5
Î¼g/mL rh insulin, 1.0 Î¼M epinephrine, 10 nM triiodothyronine, 0.1 Î¼g/mL hydrocortisone
hemisuccinate, 10 ng/mL rh EGF, 0.5% FBS and 5 Î¼g/m transferrin PS (all from Lifeline Cell
Technology), at 37°C in a humidified atmosphere of 95% of air and 5% CO2 (University of
Hawaii Cancer Center, Honolulu, Hawaii, USA). For evaluation of cell viability, cells were
seeded at a concentration of 5×10^3 cells/well in 90 µl Lifeline's RenaLife complete
medium into tissue culture grade 96-well flat bottom microplates (Thermo Scientific BioLite
Microwell Plate, Fisher Scientific, Waltham, Massachusetts, USA) and grown for 24 h. Solutions
of the compounds were prepared by diluting a freshly prepared stock solution (in H 2O) of the
corresponding compound in Lifeline's RenaLife complete medium. Afterwards, the intermediate
dilutions of the compounds were added to the wells (10 µL) to obtain a final concentration
ranging from 0.1 to 200 µM, and the cells were incubated for 24 h. Following 24 h drug
exposure, 50 µL

of

2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-

Carboxanilide (XTT) (Roche Diagnostics, Indianapolis, Indiana, USA) labeling mixture per
well was added to the cells at a final concentration of 0.3 mg/ml and incubated for 4 h at 37°C in
a humidified atmosphere of 95% of air and 5% CO2. The optical density of each well (96-well
plates) was quantified using EnVision Multilabel Plate Readers (Perkin Elmer, Waltham
Massachusetts, USA) at 450 nm wavelength to measure absorbance. The percentage of surviving
cells was calculated from the ratio of absorbance of treated to untreated cells. The IC 50 value was
calculated as the concentration reducing the proliferation of the cells by 50% and is presented as
a mean (± SE) of at least two independent experiments each with triplicates.
Cell death analysis
Apoptosis/necrosis hallmarks of cells treated with compounds 2 and 3 were analyzed by
measuring mitochondrial membrane potential and/or exposure of phosphatidylserine. Cells were
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treated with different concentrations and at different incubation times as indicated in figure
legends. In some experiments the general caspase inhibitor z-VAD-fmk was added at 50 µM 1 h
before compounds. For mitochondrial membrane potential determination cells (2.5x105 in 200
µl) after treatment with compounds were incubated at 37ºC for 15 min. in ABB (140 mM NaCl,
2.5 mM CaCl2, 10 mM Hepes/NaOH, pH 7,4) containing 60 mM tetramethylrhodamine ethyl
ester (TMRE, Molecular Probes). Phosphatidylserine exposure was quantified by labeling cells
with AnnexinV-PE or AnnexinV-DY636 (Invitrogen) after treatment with compounds.
AnnexinV was added at a concentration of 0.5 µg/mL and cells were incubated at room
temperature for 15 min. In all cases, cells were diluted to 1 ml with ABB to be analyzed by flow
cytometry (FACScan, BD Bioscience, Spain).
Intracellular ROS quantification
Oxidative stress induced by compounds 2 and 3 was analyzed by intracellular staining with the
fluorescent probe 2-hydroxiethidium (2-HE, Molecular Probes). After 16 h of culture in the
presence of compounds 1-3, cells were incubated with 2 µM 2-HE at 37ºC for 15 min. Red
fluorescence produced by reduction of 2-HE to ethidium was quantified in a flow cytometer.
Effect of 2 in the levels of proteins of the Bcl-2 family
Jurkat cells (5x105 cells/ml) were treated with 2 (1 µM) for 6 h. At the end of incubations total
protein extracts from 2x106 cells were prepared in lysis buffer and samples (50 micrograms/lane)
were resolved by SDS-PAGE and transferred onto nitrocellulose membranes. Then, levels of
some members of the Bcl-2 family of proteins were analyzed by Western Blot using specific
antibodies: Bcl-XL (Cell Signalling, cat 2764), Bcl-2 (Abcam, Cat AB692), Mcl-1 (Santa Cruz
Biotech, cat. SC819), Bim (Calbiochem, cat. 202000), Puma (Cell Signaling, Cat. 4976) and
Noxa (Abcam, Cat. 114C307). After incubation with primary antibodies, membranes were
incubated with appropriate secondary antibodies conjugated with HRP. Finally, membranes
were revealed using a chemiluminiscence substrate (Pierce).
Inhibition of cathepsin B
Cathepsin B, purified from human liver (Accession # P07858) and substrate Peptide sequence:
Z-FR-AMC [AMC=7-amino-4-methylcoumarin] were dissolved on a buffer: 25 mM MES pH 6,
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50 mM NaCl, 0.005% Brij35, 5 mM DTT and 1% DMSO with a final concentration of 10 μM.
The enzyme solution was delivered into the reaction well. 2 (1% DMSO solution) was delivered
into the enzyme mixture by Acoustic technology (Echo550; nanoliter range), incubate for 10
min. at room temp. The substrate solution was delivered into the reaction well to initiate the
reaction. The enzyme activity was monitored (Ex/Em = 355/460 nm) as a time-course
measurement of the increase in fluorescence signal from fluorescently-labeled peptide substrate
for 120 min. at room temperature. The data was analyzed data by taking slope (signal/time) of
linear portion of measurement. The slope is calculated by using Excel, and curve fits are
performed using Prism software.
Interaction of compounds 1-4, 8, 9, [(η6-p-cymene)Ru(μ-Cl)Cl]2 and cisplatin with plasmid
(pBR322) DNA by Electrophoresis
(Mobility Shift Assay)
10 µL aliquots of pBR322 plasmid DNA (20 µg/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO4,
pH = 7.39) were incubated with different concentrations of the compounds (1-4, 8, 9, [(η6-pcymene)Ru(μ-Cl)Cl]2) (in the range 0.25 and 2.0 metal complex:DNAbp) at 37 oC for 20 h in the
dark. Samples of free DNA and cisplatin-DNA were prepared as controls. After the incubation
period, the samples were loaded onto the 1 % agarose gel. The samples were separated by
electrophoresis for 1.5 h at 84 V in Tris-acetate/EDTA buffer (TAE). Afterwards, the gel was
stained for 30 min. with a solution of GelRed Nucleic Acid stain.

Interaction of compounds 1-4 with Calf Thymus DNA by Circular Dichroism
Stock solutions (5 mM) of each complex were freshly prepared in water prior to use. The right
volume of those solutions was added to 3 ml samples of an also freshly prepared solution of CT
DNA (48 µM) in Tris/HCl buffer (5 mM Tris/HCl, 50 mM NaClO4, pH=7.39) to achieve molar
ratios of 0.1, 0.25, 0.5, 1.0 and 2.0 drug/DNA. The samples were incubated at 37ºC for a period
of 20 h. All CD spectra of DNA and of the DNA-drug adducts were recorded at 25ºC over a
range 220-420 nm and finally corrected with a blank and noise reduction. The final data is
expressed in molar ellipticity (millidegrees).
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DNA precipitation with compounds 2 and 3 and quantification of ruthenium by ICP-MS
Stock solutions of compounds 2 and 3 (4 mM in water) and CT DNA (11.56 mM in 5 mM
Tris/HCl, 50 mM NaClO4, pH=7.39) were freshly prepared prior to use. 216 µl of DNA stock
solution were diluted in 3.53 mL of buffer and 1.25 mL of compound stock solution were then
added to achieve 5 mL final volume at concentrations of 500 µM in DNA and 1 mM in metal
compound. Each sample was incubated at 37ºC for a period of 20 h, then cooled down to room
temperature and centrifuged at 3000 rpm for 15 min. and at 4000 rpm for extra 40 min. The
supernatant was separated and analyzed for CT DNA concentration by CD spectroscopy. The
resulting pellet was washed twice with ice-cold ethanol (1 mL), centrifuged at RT for 1 min. at
4000 rpm, dried under high vacuum and analyzed for Ru content by ICP-MS. The total amount
of DNA in each sample was 0.92 mg. Every experiment was run in duplicate.
Interaction of compounds 1-4, 8, 9, and cisplatin with HSA by Fluorescence Spectroscopy
A solution of each compound (8 mM) in DMSO was prepared and ten aliquots of 2.5 µL were
added successively to a solution of HSA (10 µM) in phosphate buffer (pH = 7.4) to achieve final
metal complex concentrations in the range 10-100 µM. The excitation wavelength was set to 295
nm, and the emission spectra of HSA samples were recorded at room temperature in the range of
300 to 450 nm. The fluorescence intensities of all the metal compounds, the buffer and the
DMSO are negligible under these conditions. The fluorescence was measured 240 s. after each
addition of compound solution. The data were analyzed using the classical Stern-Volmer
equation F0/F = 1 + KSV[Q].
In vivo tests
All animal experiments were performed according to the University of Hawaii Cancer Center
regulations and by approval of the responsible authorities (UH IACUC number: A3423-01).
Determination of lethal dose (LD) and maximum tolerated dose (MTD) of 2 in mice
14 female C57/Black 6 from Jackson Laboratory (Bar Harbor, ME and Sacramento, CA, USA)
ages 8 to 14 weeks and weighing 18–26 g were used for these experiments. Mice were
randomized to treatment groups based on their age to ensure equivalent distribution between the
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groups. At trial end-point the mice were sacrificed and liver, spleen, kidney and blood plasma
were collected, and then processed for further analysis. Gross and microscopic evaluations of
liver, spleen and kidney were conducted. The weight of 2 treated mice compared and that of
vehicle-treated mice as measured twice weekly.
The lethal dose (LD) was determined by injecting once mouse i.p. once 5 mg/kg/day, 10
mg/kg/day, 20 mg/kg/day, 30 mg/kg/day, or 50 mg/kg/day, and one vehicle control with 100µl
Normal Saline (0.9% NaCl)). The dose that killed the mice within 24 hours was set to be lethal
dose. The lethal dose was confirmed by administering that dose to a second mouse. The
maximum tolerated dose (MTD) was determined by injecting two mice with 5 mg/kg/day, 10
mg/kg/day, or 20 mg/kg/day over 6 days, or 20 mg/kg/every other day over 6 days and one
vehicle control mouse with 100µl Normal Saline (0.9% NaCl). The MTD was confirmed by
administering the determined dose to 3 mice over 7 days and three vehicle control mice with
100µl Normal Saline (0.9% NaCl).
Study of the effects of 2 in MDA-MB-231 xenografts in mice
12 female NOD.CB17-Prkdc scid/J (non-obese diabetic–severe combined immunodeficiency)
from Jackson Laboratory (Bar Harbor, ME and Sacramento, CA, USA) for the xenograft
experiment (ages 8 to 12 weeks and weighing 19–24 g, were used. Each mouse received 5x106
tumor cells subcutaneously without anesthesia. Exponentially growing oestrogen-receptor alphanegative MDA-MB-231 human breast cancer cells were suspended in 1:1 ratio 50 μl phosphatebuffered saline (PBS; pH 7.4) plus 50 μl of matrigel (BD Biosciences, San Jose, CA, USA) were
injected subcutaneously on both left and right flank of each mice’. The diameter of the tumors
was measured once weekly using an electronic digital caliper and the tumor volume (TV) was
calculated according to the empirical equation TV = (a)(b2) x π/6 where a = longest dimension; b
= largest dimension orthogonal to a. The median volumes of each group were normalized to the
initial tumor volume resulting in the relative tumor volume. Each six MDA-MB-231transplanted animals received compound 2 (5 mg/kg/every other day) or vehicle (0.9% NaCl)
intraperitoneally (i.p.) Treatment started when tumors were palpable (about 5–6 mm diameter).
To palliate the weight loss observed in the MTD study the mice were fed a 46% fat-adjusted diet
(Harlan Teklad, Madison, WI), plus HydroGel™ (Harlan Teklad, Madison, WI) and received
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subcutaneous injection of 100µl Normal Saline (0.9% NaCl) to improve hydration. Mice were
randomized to treatment groups based on their starting tumor burden at 12 weeks of age to
ensure equivalent distribution between the two groups. At trial end-point the mice were
sacrificed and tumors measured again after excision and then processed for further analysis.
Histological as well as biochemical evaluations of blood, liver, intestine, kidney, and lung were
conducted. Tumor volumes were graphed for (2) treated mice compared to vehicle-treated mice,
based on weekly external digital caliper measurements.
Pharmacokinetic study: determination of ruthenium content in the organs, entire blood,
and plasma
Female NOD.CB17-Prkdc scid/J bearing subcutaneous MDA-MB-231 tumors and treated with
compound 2 (5 mg/kg/every other day) intraperitoneally were used for pharmacokinetic
evaluation of the drug in blood and other tissues. Blood was collected retroorbitally using
heparin coated glass capillary into heparinized blood collection vials on ice at time intervals of
30 min, 2 h, 6 h, 24 h and 48 h. after the first dose. The blood samples were centrifuged at 2800
rpm at 4°C for 15 min. and the supernatant plasma was transferred into 1.5 mL micro-centrifuge
tubes and maintained at -80 °C until analysis.
Ruthenium content was determined using Inductively Coupled Plasma - Mass Spectrometry
(ICP-MS). Fifty microliter of plasma was transferred into a glass vial and 1 mL of concentrated
acid mix (comprising of 75% of 16 N nitric acid and 25% of 12 N hydrochloric acid) was added.
The mixture was heated at 90 °C for 5 h. After cooling, the samples were diluted with water, 40
ppb of Indium internal standard was added and analyzed in a Thermo Scientific XSERIES 2
ICP-MS with ESI PC3 Peltier cooled spray chamber with SC-FAST injection loop and SC-4
autosampler. All the elements were analyzed using He/H2 collision-reaction mode. Plasma from
control mice was spiked with the test compound to determine the extraction efficiency.
At the end of the study, liver, kidney and tumor of the animals were harvested, weighed and
transferred into glass vials. One ml of water was added to each samples and subjected to
ultrasonic tissue disruption at 15W power for 1 min. The tissue homogenates were frozen at -80
°C for 2 h and lyophilized. The lyophilized product was heated at 90 °C with the concentrated
acid mix (described above) for 5 h, cooled, diluted with water and analyzed for ruthenium by
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ICP-MS. Pharmacokinetic estimates were obtained from the plasma concentration–time profiles
by noncompartmental analysis using Phoenix WinNonlin 6.1 (Mountain View, California).
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5.8. Appendix

5.8.1. Crystallographic Data for Compound 1.

Table 5. Crystal Data and Structure Refinement for compound 1.
Formula

C34H33ClF6N2OP2Ru

Fw

798.08

T [K]

293 (2)

λ (MoKα)[Å]

0.71073

crystal system

Monoclinic

space group

C2/c

a [Å]

37.8820(15)

b [Å]

10.8170(5)

c [Å]

17.8540(4)

α [o]

90

β [o]

108.766(2)

γ [o]

90

V [Å]3

6927.1(4)

Z

8

Dcalcd (g cm-3)

1.531

µ (mm-1)

0.685

GOF

0.951

R1[I > 2σ]

0.0551

wR2(all data)

0.1658
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5.8.2. 1H NMR spectra of compounds 2-4, 7 and 8.

Figure 13. 1H NMR spectra of compound 2 in CDCl3.

Figure 14. 1H NMR spectra of compound 3 in CDCl3.
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Figure 15. 1H NMR spectra of compound 4 in CDCl3.

Figure 16. Variable temperature 1H NMR spectra of compound 4 in CDCl3 (magnification zone
6.1-3.6 ppm).
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Figure 17. Variable temperature 1H spectra of compound 4 in CDCl3 (magnification zone 2.90.1 ppm).

Figure 18. Variable temperature 31P{1H} NMR NMR spectra of compound 4 in CDCl3 ( 46.45
(s) ppm).
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Figure 19. 1H NMR spectra of compound 7 in CDCl3.

Figure 20. 1H NMR spectra of compound 8 in CDCl3.
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5.8.3. Stability of compounds 1-4, 8 and 9 in DMSO-d6 and D2O solution overtime assessed
by 31P{1H} NMR spectroscopy.a

Compound

Time (DMSO-d6)
2.5 h

1d

6d

1w

2w

3w

1m

1.5 m

Half life
(50%)

>99%

1

>99%

2

91%

months

87%

months
>99%

3
4
>99%

8
9

>99%

85%

58%

25%

50%

27%

months

>99%

months

0%

~ 9 days

6%

~ 1 week

a) % of decomposition determined by integration of all the signals present in the 31P{1H}
NMR spectra, the sum being set to 100%.

Compound

Time (D2O)
3d

Half life (50%)

1

insoluble

2

2.5 days

3

b

4

99%

c

a) % of decomposition determined by integration of all the signals
present in the 31P{1H} NMR spectra, the sum being set to 100%.
b) Compound hydrolyzes when dissolved in water (45:55 ratio).
c) Compound precipitates after 3 days.
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5.8.4. 31P{1H} NMR spectra showing the stability of compounds 1-4, 8 and 9 in DMSO-d6
overtime.

Figure 21. 31P{1H} NMR spectra of compound 1 in DMSO-d6 ( 24.27 (s) and – 144.20 (h)
ppm) overtime.

Figure 22. 31P{1H} NMR spectra of compound 2 in DMSO-d6 ( 24.26 (s) ppm) overtime.
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Figure 23. 31P{1H} NMR spectra of compound 3 in DMSO-d6 ( 37.84 (s) ppm) overtime.

Figure 24. 31P{1H} NMR spectra of compound 4 in DMSO-d6 ( 45.99 (s) ppm) overtime.
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Figure 25. 31P{1H} NMR spectra of compound 8 in DMSO-d6 ( 21.09 (s) ppm) overtime.

Figure 26.

31

P{1H} NMR spectra of compound 9 in DMSO-d6 ( -11.85 (s) ppm) overtime.
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5.8.5. 31P{1H}, 1H NMR and 13C NMR spectra of compounds 2, 3 and 4 in D2O overtime.

Figure 27. 31P{1H} NMR spectra of compound 2 in D2O ( 26.37 (s) ppm) overtime.

Figure 28. 1H NMR spectra of compound 2 in D2O at t = 0 and after 5 days.
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Figure 29. 13C NMR spectra of compound 2 in D2O at t = 0 and after 5 days.

Figure 30. 13C NMR spectra of compound 2 in D2O at t = 0 and after 5 days.
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Figure 31. 31P{1H} NMR spectra of compound 3 in D2O ( 37.79 (s) ppm) overtime.

Figure 32. 1H NMR spectra of compound 3 in D2O overtime.
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Figure 33. 1H NMR spectra of compound 3 in D2O overtime.

Figure 34. 31P{1H} NMR spectra of compound 4 in D2O ( 46.95 (s) ppm) overtime
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5.8.6. 31P{1H} NMR spectra of compounds 2 in a 100 mM NaCl/D2O solution overtime.

Figure 35. 31P{1H} NMR spectra of compound 2 in 100mM NaCl/D2O ( 26.21 (s) ppm)
overtime.
5.8.7. 31P{1H} and 1H NMR spectra of compounds 2 and 3 in a D2O solution at 80oC during
1 h.

Figure 36. 31P{1H} NMR spectra of compound 2 in D2O ( 26.48 (s) ppm) after heating at 80oC
for one hour.
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Figure 37. 31P{1H} NMR spectra of compound 3 in D2O ( 37.84 (s) ppm) after heating at 80oC
for one hour.
5.8.8. Mass spectra (ESI+) of compound 2 in H2O solution overtime (5 days).

Figure 38. MS ESI+ of compound 2 in H2O solution at t = 0.
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Figure 39. Magnification of [m/z] from 600 to 665 of compound 2 in H2O solution at t = 0.

Figure 40. MS ESI+ of compound 2 in H2O solution at t = 5 days.
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Figure 41. Magnification of [m/z] from 600 to 665 of compound 2 in H2O solution at t = 5 days.

Exact Mass: 617.13
+

Found: 617.13 [M-Cl]
(1.19%)

Figure 42. Magnification of peak at [m/z]: 617.1 corresponding to species [(η6-pcymene)Ru(IM-k-C,N-C6H4(PPh2=N-CO-2-N-C5H4)]+ in the MS ESI+ spectrum of compound 2
in H2O solution at t= 5 days. Insert: theoretical isotopic distribution.
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5.8.9. Study of the effect of 2 in the levels of proteins of the Bcl-2 family.

Figure 43. Effect of 2 in the levels of proteins of the Bcl-2 family. Jurkat cells were left
untreated (control) or incubated for 6 h with compound 2 (1 µM). At the end of incubations total
protein extracts were prepared as described in the Experimental section and analyzed by Western
Blot with specific antibodies as indicated.

Blots are representative of three independent

experiments.
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5.8.10. Experiments to assess the interaction of compounds 2-4 with CT DNA by circular
dichroism.
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Figure 44. CD spectra of CT DNA (48 µM) and CT DNA incubated with 0.1, 0.25 and 0.5
equivalents of compounds 1 (A), 2 (B), 3 (C) and 4 (D) for 20 h at 37 °C.
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CHAPTER VI

CONCLUSIONS AND FUTURE DIRECTIONS
_________________________________________________
• A series of organometallic and coordination gold(III), platinum(II), palladium(II) and
ruthenium(II)

compounds

with

water-soluble,

ferrocene-based

and

luminescent

iminophosphorane ligands have been successfully synthesized and characterized. A synthetic
method for the preparation of cyclometalated exo derivatives of different metals is described.
A mercury-free transmetallation with organogold(I) derivatives has been employed for the
preparation of endo cycloplatinated compounds.
• In the cases of d8 transition metal complexes it was demonstrated that cyclometallated
complexes are more stable in physiological media than coordination compounds. Both,
coordination and cyclometalated IM ruthenium(II) complexes are quite stable in physiological
media or water.
• The compounds exhibit important cytotoxic effects in vitro in the low or sub-micromolar
range in selected human cancer cell lines and in most cases are markedly more cytotoxic than
cisplatin, while being less toxic on ”healthy” cell lines.
• Studies of the interactions of the compounds with plasmid (pBR322) DNA and/or Calf
Thymus DNA indicated in most cases no interaction, or a weak interaction electrostatic in
nature. In specific cases we were able to demonstrate the formation of left-handed helix of Zform DNA through strong electrostatic interactions (for a cyclometalated exo-Pt(II) complex
(3)) or backbone charge neutralization, further confirmed by ICP-MS analysis of metal
content in DNA precipitates for ruthenium(II) complexes.
• Most of the complexes displayed a concentration dependent fluorescence quenching of HSA,
indicating faster binding compared to cisplatin.
• Studies of intracellular distribution on human ovarian cancer (A2780) cells with selected
compounds (e.g. 3, and 7, Chapter I) using fluorescence microscopy failed.
• Initial mechanistic studies for selected compounds indicated that the cell death type is
different than that of cisplatin (e.g. ruthenium(II) compounds cell death is mainly through
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caspase-dependent apoptosis, not dependent on p53 while for apoptotic cycloplatinated
compound 5, caspase-independent cell death is triggered when apoptosis is blocked).
• Permeability studies for a selected cycloplatinated compound (5) revealed its high
permeability profile and an estimated oral fraction absorbed of 100% which potentially makes
it a good candidate for oral administration.
• The efficacy of the highly water-soluble Ru(II) complex (2) in vivo on xenografted breast
carcinoma MDA-MB-231-tumors grown on NOD.CB17-Prkdc scid/J mice demostrated a
tumor reduction (shrinkage) of 56% after 28 days treatment with low systemic toxicity, and
accumulation of the complex preferentially in the breast tumor tissues when compared to
kidney and liver. These results make compound 2 the most promising organometallic pcymene ruthenium(II) anticancer agent described so far and a potential candidate for
subsequent more elaborated preclinical studies.
• Overall, our results support the idea that non-toxic iminophosphorane molecules are excellent
ligands for the synthesis of organometallic compounds of d6 and d8 metals (especially cationic
species) with relevant anticancer properties, high permeability and, in some cases, watersolubility.
Future directions

The results obtained in chapter III will guide us to design new iminophosphoranes
complexes with better luminescence properties in cells in vitro. We will need to design
compounds with a better stability in biological media and to increase the fluorescence detection
limits. A possible direction involves the synthesis of cyclometalated compounds incorporating
modified luminescent iminophosphorane ligands based on susbtitutions on the 8-aminoquinoline
scaffold (methyl or fluorine groups).
The results obtained in chapter IV have made us select endo cycloplatinated compound 5
as a candidate for further in vivo and mechanistic evaluation. The promising water-soluble
ruthenium(II) complex (2) will be further evaluated in vivo on different tumors such as prostate,
colon and pancreas. More detailed mechanistic studies are underway after its evaluation on the
NCI 60-cell panel.
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